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Abstract 
 
Background: 
Beta-lactams are often used empirically in the intensive care unit (ICU), as they possess a 
wide spectrum of antibacterial activity.  Most agents in this class are renally excreted, such 
that clinicians regularly modify dosing in the setting of kidney dysfunction.  Rising plasma 
creatinine concentrations, or declining mathematical estimates of glomerular filtration, are 
commonly used for this purpose.  Outside of this scenario, a ‘one dose fits all’ approach is 
typically employed, largely based on research from non-critically ill cohorts. 
 
However, previous pharmacokinetic studies have demonstrated that many critically ill 
patients manifest significantly elevated beta-lactam clearance, often in parallel with 
augmented creatinine clearance (CLCR).  This in turn promotes sub-therapeutic 
concentrations for lengthy periods, potentially leading to treatment failure or the selection 
of resistant organisms.  Currently little data are available that examine the epidemiology of 
this phenomenon, as augmented renal clearance (ARC) is poorly visible to the clinician. 
 
The aims of this research were therefore to; a) examine the relationship between elevated 
CLCR and plasma beta-lactam concentrations; b) explore the potential cardiovascular 
mechanisms promoting ARC; c) determine the prevalence of ARC in a heterogonous 
cohort of recently admitted patients with normal plasma creatinine (CR) concentrations; 
and d) evaluate the utility of mathematical estimates of glomerular filtration (GFR) in this 
setting.   
 
Methods: 
Relevant literature was reviewed concerning changes in renal function and beta-lactam 
pharmacokinetics in the critically ill.  Four major clinical studies were performed; a) an 
analysis of plasma beta-lactam trough concentrations and CLCR measures in select 
critically ill patients, b) a comparison of cardiac output and CLCR in trauma and septic 
patients, c) a multicentre study of the prevalence of ARC in a cohort of recently admitted 
patients with normal plasma CR concentrations, and d) a comparison of mathematical 
estimates of GFR with measured CLCR in this setting.  Data were collected prospectively, 
with a timed urinary CLCR employed as the primary measure of renal function.  
Demographic, anthropometric, therapeutic, illness-severity and outcome data were 
 iii 
recorded concurrently.  Ethical approval was obtained for all clinical investigations 
(GC2008/054, HREC 2007/188, HREC/09/QRBW/192). 
 
Results: 
Fifty-two concurrent trough beta-lactam concentrations and CLCR measures were utilised 
in the first study.  Piperacillin was the most frequent beta-lactam prescribed (48%), while 
empirical cover and Staphylococcus spp. were the most common indications for therapy 
(62%). In only 58% (n=30) was the trough drug concentration ≥ the minimum inhibitory 
concentration (MIC), falling to 31% (n=16) when using 4 x MIC as the target.  CLCR values 
≥ 130ml/min/1.73m2 were associated with trough concentrations < MIC in 82% (p<0.001), 
and < 4 x MIC in 72% (p<0.001). CLCR remained a significant predictor of sub-therapeutic 
concentrations in multivariate analysis. 
 
Seventy-one patients contributed data to the second study (sepsis n=43, multitrauma 
n=28).  Overall, 57.7% of the cohort manifested ARC, although there was a greater 
prevalence in trauma (85.7 versus 39.5%, p<0.001). An improved correlation between 
cardiac index (CI) and CLCR was seen in septic (r=0.508, p=0.001), as compared to 
trauma (r=-0.012, p=0.951) patients.  Those manifesting ARC were younger (p<0.001), 
male (p=0.012), with lower acute physiology and chronic health evaluation (APACHE) II 
(p=0.008) and modified sequential organ failure assessment (SOFA) scores (p=0.013), 
and higher cardiac indices (p=0.013).  In multivariate analysis, age ≤ 50 years, trauma, 
and a modified SOFA score ≤ 4, were identified as significant risk factors.  As a combined 
score, these parameters had greater utility in identifying ARC, compared with CI 
assessment alone. 
     
Two-hundred and eighty-one patients were recruited into the multicentre study, 
contributing 1660 individual CLCR measures.  The mean (95% CI) age was 54.4 (52.5-
56.4) years, APACHE II score 16 (15.2-16.7), and ICU mortality 8.5%.  Overall, 65.1% 
manifested ARC on at-least one occasion during the first seven study days; the majority 
(74%) of whom did so on ≥ 50% of their CLCR measures.  Utilising a mixed effects model, 
the presence of ARC on study day 1, strongly predicted (p=0.019) sustained elevation of 
CLCR in these patients over the first week in ICU.  
  
One hundred and ten patients (n = 110) were included in the final analysis examining the 
utility of mathematical estimates of glomerular filtration. 63.6% were male, the mean age 
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was 50.9 (16.9) years, 57.3% received invasive mechanical ventilation, and 30% required 
vasopressor support. The mean CLCR was 125 (45.1) ml/min/1.73m2, compared to a 
Chronic Kidney Disease-Epidemiology Collaboration estimated glomerular filtration rate 
(CKD-EPI eGFR) of 101 (23.7) ml/min/1.73 m2 (p<0.001). Moderate correlation was 
evident (r=0.72), although there was significant bias and imprecision (24.4 +/− 32.5 
ml/min/1.73 m2). In those patients with a CKD-EPI eGFR between 60–119 ml/min/1.73 m2 
(n = 77), 41.6% displayed ARC (CLCR ≥ 130 ml/min/1.73 m2), while 7.8% had a CLCR < 60 
ml/min/1.73 m2. 
 
Conclusions: 
Data from these investigations highlight the following key findings; i) ARC is strongly 
associated with sub-therapeutic beta-lactam concentrations; ii) younger patients admitted 
post trauma appear to be at greatest risk, likely a reflection of available organ reserve and 
systemic inflammation; iii) ARC is highly prevalent in recently admitted patients with 
normal plasma CR concentrations; and iv) mathematical estimates perform poorly in 
comparison to measured CLCR in this setting. 
 v 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly-authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the General Award Rules of The University of Queensland, 
immediately made available for research and study in accordance with the Copyright Act 
1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
 
Andrew Alexander Udy 
July 2014 
 vi 
Publications During Candidature 
 
Book Chapters 
A. Udy and J. Lipman. Chapter 12 - Importance of High Creatinine Clearance for 
Antibacterial Treatment in Sepsis. In: Sepsis Management PIRO and MODS. Rello J, 
Lipman J, Lisboa T (Eds.) 2011, Springer-Verlag, Berlin Heidelberg. 
 
A. Udy, JA. Roberts, J. Lipman. Augmented Renal Clearance (ARC) – un-ravelling the 
mystery of elevated antibiotic clearance. In: Yearbook of Intensive Care and Emergency 
Medicine. Vincent JL (Ed). 2010, Springer, Heidelberg. 
 
Journal Articles, Abstracts and Letters 
Roberts JA, Udy AA, Bulitta JB, Stuart J, Jarrett P, Starr T, Lassig-Smith M, Roberts NA, 
Dunlop R, Hayashi Y, Wallis SC, Lipman J. Doripenem population pharmacokinetics and 
dosing requirements for critically ill patients receiving continuous venovenous 
hemodiafiltration. Journal of Antimicrobial Agents, 2014; doi: pii: dku177. 
 
Jamal J-A, Mat-Nor M-B, Mohamad-Nor F-S, Udy AA, Lipman J, Roberts JA. A national 
survey of renal replacement therapy prescribing practice for acute kidney injury in 
Malaysian intensive care units. Nephrology, 2014; doi: 10.1111/nep.12276. 
 
Jamal J-A, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement 
therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the 
critically ill: An analysis of published literature and dosing regimens. Critical Care 
Medicine, 2014; 42(7): 1640-1650. 
 
Udy AA, Morton FJA, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J, Dunlop R, 
Starr T, Boots RJ, Lipman J. A comparison of CKD-EPI estimated glomerular filtration rate 
and measured creatinine clearance in recently admitted critically ill patients with normal 
plasma creatinine concentrations. BMC Nephrology, 2013; 14: 250. 
 
Udy AA, Baptista JP, Lim NL, Joynt G, Jarrett P, Wockner L, Boots RJ, Lipman J.  
Augmented Renal Clearance in ICU: Results of a multicenter observational study of renal 
function in critically ill patients with normal plasma creatinine concentrations. Critical Care 
Medicine, 2014; 42(3): 520-527. 
 vii 
Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic 
principles. Intensive Care Medicine, 2013; 39(12): 2070-2082. 
 
Sturgess DJ, Parmar D, Dulhunty J, Hegde R, Jarrett P, Udy A. An evaluation of plasma 
B-type natriuretic peptide as a marker of left ventricular diastolic dysfunction in non-cardiac 
critical care. Anaesthesia and Intensive Care, 2013; 41(5): 591-595. 
 
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, 
Eastwood GM, Myburgh J, Paterson DL, Starr T, Udy AA, Paul SK, Lipman J and the 
ANZICS Clinical Trials Group and ASID Clinical Research Network.  A protocol for a 
multicentre randomised controlled trial of continuous beta-lactam infusion compared with 
intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II 
study. Critical Care and Resuscitation, 2013; 15(3): 179-185. 
 
Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic 
and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk 
patients. Critical Care, 2013; 17(1): R35. 
 
Udy AA, Roberts JA, Lipman J. How should we dose antibiotics for pneumonia in the ICU. 
Current Opinion in Infectious Diseases, 2013; 26(2): 189-195. 
 
Lonsdale DO, Udy A, Roberts JA, Lipman J. Antibacterial therapeutic drug monitoring in 
cerebrospinal fluid: Difficulty in achieving adequate drug concentrations. Journal of 
Neurosurgery 2012; 118(2): 297-301. 
 
Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA. β-
Lactam therapeutic drug monitoring in the critically ill: Optimising drug exposure in patients 
with fluctuating renal function, and hypoalbuminaemia.  International Journal of 
Antimicrobial Agents 2013; 41(2): 162-166. 
 
Van der Merwe F, Wallis S, Udy A. Understanding the impact of critical illness on drug 
pharmacokinetics - scientifically robust study design. Journal of Clinical Toxicology 
2012; S4:002. doi:10.4172/2161-0495.S4-002. 
 
 viii 
Udy A, Altukroni M, Jarrett P, Roberts JA, Lipman J. A comparison of pulse contour wave 
analysis and ultrasonic cardiac output monitoring in the critically ill. Anaesthesia and 
Intensive Care 2012; 40(4): 631-637. 
 
Udy A, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What’s behind the failure of 
emerging antibiotics in the critically ill? Understanding the impact of altered 
pharmacokinetics and augmented renal clearance. International Journal of 
Antimicrobial Agents 2012; 39(6): 455-457. 
 
Udy A, Varghese J, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts 
JA. Sub-therapeutic initial β-lactam concentrations in select critically ill patients: 
association between augmented renal clearance and low trough drug concentrations. 
Chest 2012; 142(1): 30-39. 
 
Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, 
consequent interventions and resultant clinical scenarios in the intensive care unit? The 
antibiotic story.  Anaesthesia and Intensive Care 2011; 39(6): 999-1000. 
 
Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using 
estimations of glomerular filtration rate in an intensive care population. Internal Medicine 
Journal 2011; 41(7): 537-543. 
 
Udy A, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill 
patients. Nature Reviews-Nephrology 2011; 7(9): 539-543. 
 
Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J.  Augmented 
renal clearance (ARC) in critically ill patients with SIRS and sepsis - Are estimates of renal 
function accurate? Critical Care 2011; 15(3): R139. 
 
Hosein S, Udy A, Lipman J. Physiological changes in the critically ill patient with sepsis. 
Current Pharmaceutical Biotechnology 2011; 12(12): 1991-1995. 
 
Udy A, Putt MT, Boots RJ, Lipman J. ARC - Augmented Renal Clearance. Current 
Pharmaceutical Biotechnology 2011; 12(12): 2020-2029. 
 
 ix 
Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in 
critically ill patients – robust methods for improved continuous infusion regimens. 
Antimicrobial Agents and Chemotherapy 2011; 55(6): 2704-2709. 
 
Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, 
Kruger P, Lipman J. Antibiotic dosing in the ‘at-risk’ critically ill patient: Linking 
pathophysiology with pharmacokinetic/pharmacodynamics in sepsis and trauma patients. 
BMC Anesthesiology 2011; 11(5). 
 
Udy A, Boots RJ, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented 
Creatinine Clearance in Traumatic Brain Injury. Anesthesia and Analgesia 2010; 111(6): 
1505-1510. 
 
Udy A, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented Renal Clearance 
(ARC) in the Intensive Care Unit - An illustrative Case Series. International Journal of 
Antimicrobial Agents 2010; 35(6): 606-608. 
 
Udy A, Roberts JA, Boots RJ, Paterson DL, Lipman J. ARC - Augmented Renal 
Clearance: Implications for Antibiotic Dosing in the Critically Ill. Clinical 
Pharmacokinetics 2010; 49(1): 1-16. 
 
Udy A, Roberts JA, Boots R, Lipman J. You only find what you look for: the importance of 
high creatinine clearance in the critically ill. Anaesthesia and Intensive Care 2009; 37(1): 
11-13. 
 
Conference Presentations 
Not adjusting drug doses in critical illness, what’s the risk? – Annual Scientific 
Meeting, College of Intensive Care Medicine, Brisbane, Australia, June 2014.   
 
Implications of augmented renal clearance on antibiotic therapy in ICU patients – Clinical 
Infectious Diseases Forum, Pfizer Inc, Sydney, Australia, July 2013. 
 
Augmented renal clearance (ARC) is common in multi-trauma patients without renal 
impairment. Australian and New Zealand Intensive Care Society (ANZICS) Annual 
Scientific Meeting, Adelaide, Australia, October 2012. 
 x 
Sepsis Management: Antibacterial dosing in the ICU - Sedation and Analgesia Therapy, 
and Organ Function Protection Training Course, 1st Affiliated Hospital of Kunming Medical 
College, Kunming, China, August 2012. 
 
Antimicrobial prescription in the ICU – physiologically sound dosing – 1st Annual 
Congress of the Faculty of Consulting Physicians of South Africa, Cape Town, Republic of 
South Africa, May 2012. 
 
Antimicrobial Dosing in the Critically Ill – Society of Hospital Pharmacists of Australia, 
Continuing Education Session, Brisbane, Australia, October 2010. 
 
Augmented renal clearance (ARC) in critically ill patients with SIRS and sepsis: are 
estimates of renal function accurate? Royal Brisbane and Women’s Hospital 
Healthcare Symposium, Brisbane, Australia, October 2010. 
 
Augmented Renal Clearance (ARC) in Traumatic Brain Injury. Annual Scientific 
Meeting, College of Intensive Care Medicine, Sydney, Australia, June 2010.  
 
The Critical Care Patient – Society of Hospital Pharmacists of Australia, Infectious 
Diseases Symposium, Brisbane, Australia, August 2009. 
 
Conference Posters / Abstracts 
The Influence of Augmented Renal Clearance on Plasma Concentrations in Critically 
Ill Patients Receiving Beta-lactam Therapy. 11th Congress of the World Federation of 
Societies of Intensive and Critical Care Medicine (WFSICCM) – “Critical Care for All – 
Providing More for Less”, Durban, Republic of South Africa 2013. 
 
Augmented Renal Clearance: A Common and Sustained Finding in Patients without 
Renal Impairment during the First Seven Days in ICU. 11th Congress of the World 
Federation of Societies of Intensive and Critical Care Medicine (WFSICCM) – “Critical 
Care for All – Providing More for Less”, Durban, Republic of South Africa 2013. 
 
Minimally Invasive Cardiac Output Monitoring is Useful in Identifying Septic 
Critically Ill Patients with Augmented Renal Clearance (ARC). Australian and New 
 xi 
Zealand Intensive Care Society (ANZICS) Annual Scientific Meeting, Adelaide, Australia 
2012. 
 
Augmented renal clearance (ARC) in critically ill patients with SIRS and sepsis: Are 
estimates of renal function accurate? Royal Brisbane and Women’s Hospital 
Healthcare Symposium, Brisbane, Australia 2010. 
 
Augmented Renal Clearance (ARC) in Traumatic Brain Injury. Annual Scientific 
Meeting, College of Intensive Care Medicine, Sydney, Australia 2010.  
 
Augmented Renal Clearance (ARC) in Traumatic Brain Injury. 30th International 
Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium 2010. 
 
Augmented Renal Clearance (ARC) in Traumatic Brain Injury. Royal Brisbane and 
Women’s Hospital Healthcare Symposium, Brisbane, Australia 2009. 
 
 
 xii 
Publications Included in this Thesis 
 
Udy A, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill 
patients. Nature Reviews-Nephrology 2011; 7(9): 539-543 –incorporated into Chapter 2. 
 
Contributor Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript and figures (85%) 
Roberts JA Prepared & edited the manuscript (10%) 
Lipman J Prepared & edited the manuscript (5%) 
 
Udy A, Putt MT, Boots RJ, Lipman J. ARC - Augmented Renal Clearance. Current 
Pharmaceutical Biotechnology 2011; 12(12): 2020-2029 – incorporated into Chapter 2. 
 
Contributor Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript and figures (85%) 
Putt MT Prepared & edited the manuscript (5%) 
Boots RJ Prepared & edited the manuscript (5%) 
Lipman J Prepared & edited the manuscript (5%) 
 
Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic 
principles. Intensive Care Medicine, 2013; 39(12): 2070-2082 – incorporated into 
Chapter 2 and Chapter 3. 
 
Contributor Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript and figures (80%) 
Roberts JA Prepared & edited the manuscript (15%) 
Lipman J Prepared & edited the manuscript (5%) 
 
Udy A, Roberts JA, Boots RJ, Paterson DL, Lipman J. ARC - Augmented Renal 
Clearance: Implications for Antibiotic Dosing in the Critically Ill. Clinical 
Pharmacokinetics 2010; 49(1): 1-16 – incorporated into Chapter 3. 
 
 xiii 
Contributor(s) Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript (75%) 
Roberts JA Prepared & edited the manuscript (10%) 
Boots RJ, Paterson DL, & Lipman J Prepared & edited the manuscript (5% each) 
 
Udy A, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What’s behind the failure of 
emerging antibiotics in the critically ill? Understanding the impact of altered 
pharmacokinetics and augmented renal clearance. International Journal of 
Antimicrobial Agents 2012; 39(6): 455-457 – incorporated into Chapter 3. 
 
Contributor(s) Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript (80%) 
Roberts JA, De Waele JJ, Paterson 
DL, & Lipman J 
Prepared & edited the manuscript (5% each) 
 
A. Udy and J. Lipman. Chapter 12 - Importance of High Creatinine Clearance for 
Antibacterial Treatment in Sepsis. In: Sepsis Management PIRO and MODS. Rello J, 
Lipman J, Lisboa T (Eds.) 2011, Springer-Verlag, Berlin Heidelberg – incorporated into 
Chapter 3. 
 
Contributor(s) Statement of contribution 
Udy A (Candidate) Literature search and data synthesis (100%) 
Prepared the manuscript (90%) 
Lipman J Prepared & edited the manuscript (10%) 
 
Udy A, Varghese J, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts 
JA. Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: 
association between augmented renal clearance and low trough drug concentrations. 
Chest 2012; 142(1): 30-39 – incorporated as Chapter 4. 
 
Contributor Statement of contribution 
Udy A (Candidate) Study design & methodology (15%) 
 xiv 
Collated study data (30%) 
Performed the statistical analysis (90%) 
Prepared the manuscript (80%) 
Varghese J Study design & methodology (15%) 
Collated study data (50%) 
Performed the statistical analysis (10%) 
Prepared & edited the manuscript (5%) 
Altukroni M Collated study data (20%) 
Briscoe S & McWhinney B Performed the laboratory analysis (45% each) 
Ungerer J Performed the laboratory analysis (10%) 
Lipman J Prepared & edited the manuscript (5%) 
Roberts JA Study design & methodology (70%) 
Prepared & edited the manuscript (10%) 
 
Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic 
and traumatized patients with normal plasma creatinine concentrations: Identifying at-risk 
patients. Critical Care, 2013; 17(1): R35 – incorporated as Chapter 5. 
 
Contributor Statement of contribution 
Udy AA (Candidate) Study design & methodology (20%) 
Collected study data (90%) 
Performed the statistical analysis (80%) 
Prepared the manuscript (75%) 
Roberts JA Study design & methodology (70%) 
Collected data (10%) 
Prepared & edited the manuscript (10%) 
Shorr AF Performed the statistical analysis (20%) 
Prepared & edited the manuscript (5%) 
Boots RJ Prepared & edited the manuscript (5%) 
Lipman J Study design & methodology (10%) 
Prepared & edited the manuscript (5%) 
 
Udy AA, Baptista JP, Lim NL, Joynt G, Jarrett P, Wockner L, Boots RJ, Lipman J.  
Augmented Renal Clearance in the ICU: Results of a multicenter observational study of 
 xv 
renal function in critically ill patients with normal plasma creatinine concentrations. Critical 
Care Medicine, 2014; 42(3): 520-527. – incorporated as Chapter 6. 
 
Contributor Statement of contribution 
Udy AA (Candidate) Study design & methodology (90%) 
Collected study data (40%) 
Performed the statistical analysis (80%) 
Prepared the manuscript (75%) 
Baptista JP, Lim NL, & Joynt G Collected study data (15% each) 
Prepared & edited the manuscript (5% each) 
Jarrett P Collected study data (15%) 
Wockner L Performed the statistical analysis (20%) 
Boots RJ Prepared & edited the manuscript (5%) 
Lipman J Study design & methodology (10%) 
Prepared & edited the manuscript (5%) 
 
Udy AA, Morton FJA, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J, Dunlop R, 
Starr T, Boots RJ, Lipman J. A comparison of CKD-EPI estimated glomerular filtration rate 
and measured creatinine clearance in recently admitted critically ill patients with normal 
plasma creatinine concentrations. BMC Nephrology, 2013; 14: 250 – incorporated as 
Chapter 7. 
 
Contributor Statement of contribution 
Udy AA (Candidate) Study design & methodology (100%) 
Collected study data (65%) 
Performed the statistical analysis (100%) 
Prepared the manuscript (90%) 
Morton FJA, Nguyen-Pham S, Jarrett 
P, Lassig-Smith M, Stuart J, Dunlop R 
& Starr T 
Collected study data (5% each) 
Boots RJ & Lipman J Prepared & edited the manuscript (5% each) 
 
 
 xvi 
Contributions by Others to the Thesis  
 
Professor Jeffrey Lipman (The University of Queensland) and Associate Professor Robert 
Boots (The University of Queensland) contributed significantly to the design, methodology, 
implementation, and interpretation of the studies presented. Professor Lipman conceived 
the central premise of these works, after decades working and researching in this area.  
His expert advice, mentorship and guidance were fundamental to completing the Higher 
Research Degree Candidature.  Associate Professor Boots provided crucial revisions to 
many aspects, substantially improving the overall quality of the thesis. 
 
Professor Jason Roberts (The University of Queensland) contributed significantly to this 
body of work.  He provided expert advice in study design and interpretation, in addition to 
crucial revisions to many of the manuscripts presented herein.  Dr. Steven Wallis (The 
University of Queensland) developed many of the assays used in laboratory analysis, 
allowing the timely completion of key works. 
 
Statement of Parts of the Thesis Submitted to Qualify for the Award of Another 
Degree 
 
None. 
 
 
 xvii 
Acknowledgements 
 
My foremost acknowledgement is to Professor Jeffrey Lipman, my Principle Supervisor.  
His vision, and enthusiasm were key motivators in my decision to commence this 
Candidature.  Over this period, he has been tireless in his support, providing me with 
numerous opportunities to collaborate, present, and publish.  He has been a tremendous 
role model, exemplifying all of the key qualities of an outstanding clinical researcher.  As 
my clinical supervisor, he has established a vocational environment that is responsive to 
the demands of clinical research, while ensuring ongoing personal and professional 
development.  In the same vein, the support of Associate Professor Boots as my 
Associate Supervisor has been invaluable in completing this Higher Research Degree. 
 
Professor Jason Roberts has been an integral part of this process. He devoted substantial 
time and energy to assisting with study design, methodology, and data interpretation.  His 
support, guidance, expert advice, and friendship have been crucial through out.  It will 
always remain immensely gratifying and humbling to work with such a dedicated clinician-
scientist.  Paul Jarrett, Melissa Lassig-Smith, Janine Stuart, Therese Starr, Renae Deans 
and Rachel Dunlop (RBWH ICU Research Office), were central in obtaining governance 
and ethical approval, as well as assisting in bedside data collection.  Their ongoing 
patience, humour, friendship, and professionalism over numerous years were fundamental 
to completing this work. 
 
Without financial support from the Royal Brisbane and Women’s Hospital Foundation, 
completing this research would have been significantly more difficult.  Encouragement and 
friendship from all of my colleagues at the Royal Brisbane and Women’s Hospital Intensive 
Care Unit are gratefully acknowledged.  The flexibility to complete this thesis while working 
as a full-time clinician is testimony to their support. 
 
My final acknowledgements are to my family and close friends.  Dr. Stephen O’Donoghue 
as a friend and colleague has shared much of this journey, always with humour, and 
perspective.  My parents, David and Mary took the first steps with me on this road, 
providing ongoing unconditional love and support.  My brother, Christopher, has been an 
endless source of encouragement, always a willing listener and sounding board. Finally, to 
my fiancé Kelly, you have been unbelievably supportive, understanding, and caring. 
 
 xviii 
Keywords 
 
critical care medicine, infectious diseases, pharmacology, renal function 
  
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
ANZSRC Code: 110310 Intensive Care 70% 
ANZSRC Code: 110309 Infectious Diseases 10% 
ANZSRC Code: 111502 Clinical Pharmacology and Therapeutics 20% 
 
Fields of Research (FoR) Classification 
 
FoR code: 1103 Clinical Sciences 70% 
FoR code: 1115 Pharmacology and Pharmaceutical Sciences 30% 
 xix 
Table of Contents 
 
Abstract ii 
Declaration by the Author v 
Publications During Candidature vi 
Publications Included in this Thesis xii 
Contributions by Others to the Thesis xvi 
Statement of Parts of the Thesis Submitted to Qualify for the Award of 
Another Degree 
 
xvi 
Acknowledgements xvii 
Keywords xviii 
Australian and New Zealand Standard Research Classifications (ANZSRC) xviii 
Table of Contents xix 
List of Figures xxii 
List of Tables xxiii 
List of Abbreviations xxiv 
PART ONE – Introduction 1 
Chapter 1 Overview 2 
1.1 Introduction 2 
1.2 Aims 3 
1.3 Thesis Outline 3 
Chapter 2 – ARC: Definition, Mechanisms and Risk Factors 7 
2.1 Chapter Overview 7 
2.2 Introduction 7 
2.3 Defining ARC 8 
2.4 Identifying ARC using Established Measures of Renal Function in the 
Critically Ill 
 
9 
2.5 Mechanisms Underlying ARC 10 
2.6 Patients At Risk of ARC 13 
2.7 Conclusions 18 
Chapter 3 – ARC and Beta-lactam PK-PD in the Critically Ill 19 
3.1 Chapter Overview 19 
3.2 Introduction 19 
3.3 Basic Pharmacological Principles 20 
 xx 
3.4 Beta-lactam PK-PD Targets 23 
3.5 Beta-lactam CL in Critical Illness 23 
3.6 Linking ARC, Beta-lactam PK-PD Target Attainment and Clinical 
Outcomes 
 
28 
3.7 Implications of ARC for Dosing Beta-lactams in the Critically Ill 30 
3.8 Conclusions 31 
PART TWO – Clinical Studies 32 
Chapter 4 – Sub-therapeutic Initial Beta-lactam Concentrations in Select 
Critically Ill Patients: Association Between ARC and Low Trough Drug 
Concentrations 
 
 
33 
4.1 Chapter Overview 33 
4.2 Introduction 33 
4.3 Materials and Methods 34 
4.4 Results 37 
4.5 Discussion 48 
4.6 Conclusions 51 
Chapter 5 – ARC in Septic and Traumatized Patients with Normal Plasma 
Creatinine Concentrations: Identifying At-risk Patients 
 
52 
5.1 Chapter Overview 52 
5.2 Introduction 52 
5.3 Materials and Methods 54 
5.4 Results 56 
5.5 Discussion 67 
5.6 Conclusions 70 
Chapter 6 – ARC in the ICU: Results of a Multicentre Observational Study of 
Renal Function in Critically Ill Patients with Normal Plasma Creatinine 
Concentrations 
 
 
71 
6.1 Chapter Overview 71 
6.2 Introduction 71 
6.3 Materials and Methods 72 
6.4 Results 74 
6.5 Discussion 85 
6.6 Limitations 87 
6.7 Conclusions 88 
 xxi 
Chapter 7 – A Comparison of CKD-EPI Estimated Glomerular Filtration Rate 
and Measured Creatinine Clearance in Recently Admitted Critically Ill 
Patients with Normal Plasma Creatinine Concentrations 
 
 
89 
7.1 Chapter Overview 89 
7.2 Background 89 
7.3 Methods 90 
7.4 Results 92 
7.5 Discussion 101 
7.6 Conclusion 103 
PART THREE - Discussion 104 
Chapter 8 – Discussion, Implications, and Overall Findings 105 
8.1 Discussion 105 
8.2 Limitations 107 
8.3 Key Findings 110 
8.4 Future Directions 110 
References 112 
Appendix A – Supplemental Digital Content for Chapter 6. 131 
 
 
 xxii 
List of Figures 
 
Figure 1.1 Schematic Outline of Clinical Studies Included in the Thesis 4 
Figure 2.1 Mechanisms Relating to ARC in the Critically Ill 12 
Figure 3.1 PK-PD Indices for Different Antibacterial Classes 22 
Figure 4.1 Trough Drug Concentrations / MIC Ratio (Log10 scale) as a 
Function of CLCR 
 
43 
Figure 4.2 Receiver Operating Characteristic (ROC) Curve for CLCR vs 
Trough Concentrations ≥ 16mg/l in 25 Patients Receiving Piperacillin 
 
47 
Figure 5.1 Box Plot of CI (L/min/m2) and CLCR (ml/min/1.73m2) in Trauma and 
Septic Patients 
 
59 
Figure 5.2 Correlation of CI (L/min/m2) and CLCR (ml/min/1.73m2) 60 
Figure 5.3 Box Plot of Age (years), CI (L/min/m2), CLCR (ml/min/1.73m2) and 
Modified SOFA Score in Patients With and Without ARC 
 
63 
Figure 5.4 Proportion of Patients Manifesting ARC with Increasing ARC Risk 
Scores 
 
65 
Figure 5.5 Receiver Operating Characteristic (ROC) curve of CI (L/min/m2) 
and ARC Risk Score in Predicting ARC 
 
66 
Figure 6.1 Daily Prevalence of ARC to Study Day 7 77 
Figure 6.2 Daily CLCR Measures by Admission Type to Study Day 7 81 
Figure 6.3 Mixed Effects Model Comparing Those With and Without ARC on 
Study Day 1 
 
84 
Figure 7.1 Scatter Graphs of CLCR Versus Mathematical Estimates in All 
Patients 
96 
Figure 7.2 Bland-Altman Plots of CLCR Versus Mathematical Estimates in All 
Patients 
97 
Figure 7.3 Comparison of CLCR with Mathematical Estimates Over Different 
Ranges 
 
100 
 
 
 
 xxiii 
List of Tables 
 
Table 1.1 Thesis Outline, Aims/Hypotheses, and References 5 
Table 2.1 Patients At Risk for ARC 14 
Table 3.1 Studies of Beta-lactam Antibacterial Agents in Healthy Volunteers 
and the Critically ill 
 
24 
Table 4.1 Demographic Data for Those Patients (n=48) Receiving Beta-
lactam Therapeutic Drug Monitoring in the Intensive Care Unit 
 
38 
Table 4.2 Comparison of Demographic, Therapeutic and Infection Related 
Variables Between Those with Unbound Trough Concentrations < MIC, and ≥ 
MIC 
 
 
40 
Table 4.3 Comparison of Demographic, Therapeutic and Infection Related 
Variables Between Those with Unbound Trough Concentrations < 4 x MIC, 
and ≥ 4 x MIC 
 
 
41 
Table 4.4 Results of Single Step Forced Entry Logistic Regression Modelling, 
Using a Target Concentration ≥ MIC and ≥ 4 x MIC 
 
45 
Table 5.1 Laboratory, Demographic, and Illness-severity Data of All Patients 
(n=71) 
 
57 
Table 5.2 Demographic, Diagnostic and Treatment-related Data in Those 
With and Without ARC 
62 
Table 6.1 Demographic, Admission, and Illness severity Data 75 
Table 6.2 Demographic, Therapeutic, and Illness severity Data in Those With 
and Without ARC at Any Time During the First Seven Study Days 
 
79 
Table 6.3 Comparison of Demographics, Anthropometric Measures, Illness 
severity, and Interventions Between Admission Types 
 
82 
Table 7.1 Demographic, Illness severity and Treatment Data 93 
Table 7.2 Comparison, Correlation, Bias and Precision Between Measured 8-
hr CLCR and Mathematical Estimates in All Patients, and Each Diagnostic 
Sub-group 
 
 
95 
Table 7.3 Correlation, Bias and Precision Across Different Ranges of CLCR 99 
 
 xxiv 
List of Abbreviations 
 
95% CI – 95% Confidence Interval 
AKI – Acute Kidney Injury 
APACHE – Acute Physiology and Chronic Health Evaluation 
ARC – Augmented Renal Clearance 
AUC – Area Under the Curve 
BMI – Body Mass Index 
BSA – Body Surface Area 
CG CLCR – Cockcroft-Gault Calculated Creatinine Clearance 
CI – Cardiac Index 
CKD – Chronic Kidney Disease 
CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration 
CL - Clearance 
CLCR – Creatinine Clearance 
CLR – Renal Clearance 
Cmax – Maximum plasma concentration 
Cmin – Minimum plasma concentration 
CO – Cardiac Output 
CR – Creatinine 
CV – Coefficient of Variance 
CVP – Central Venous Pressure 
eGFR – Estimated Glomerular Filtration Rate 
EUCAST – European Committee of Antimicrobial Susceptibility Testing 
fT>MIC – Time above MIC, as a fraction of the Dosing Interval 
GFR – Glomerular Filtration Rate 
HIV – Human Immunodeficiency Virus 
HPLC – High Performance Liquid Chromatography 
HR – Heart Rate 
ICU – Intensive Care Unit 
IDC – Indwelling Urinary Catheter 
IDMS – Isotope Dilution Mass Spectrometry 
IQR – Interquartile Range 
LOS – Length of Stay 
MAP – Mean Arterial Pressure 
 xxv 
ME – Microbiologically Evaluable 
MDRD – Modification of Diet in Renal Disease 
MIC – Minimum Inhibitory Concentration 
MITT – Microbiological Intention to Treat 
MODS – Multiple Organ Dysfunction Syndrome 
NP – Nosocomial Pneumonia 
OR – Odds Ratio 
PAC – Pulmonary Artery Catheter 
PK – Pharmacokinetics 
PD – Pharmacodynamics 
ROC – Receiver Operating Characteristic 
RR – Respiratory Rate 
RRT – Renal Replacement Therapy 
SAPS II – Simplified Acute Physiology Score 
SD – Standard Deviation 
SIRS – Systemic Inflammatory Response Syndrome 
SOFA – Sequential Organ Failure Assessment 
T1/2 – Half-life 
TBI – Traumatic Brain Injury 
TDM – Therapeutic Drug Monitoring 
WCC – White Cell Count 
VAP – Ventilator Associated Pneumonia 
Vd – Volume of Distribution 
 
 
 1 
 
 
 
 
 
 
 
 
 
 
 
PART ONE - INTRODUCTION
 2 
Chapter 1 
 
Overview 
 
1.1 Introduction 
 
Intensive care and hospital mortality rates for severe sepsis continue to be unacceptably 
high (1).  Consensus guidelines on management have been published (2, 3), in an attempt 
to improve outcomes.  A cornerstone of good clinical practice remains the timely 
application of antimicrobial agents (4-7), of both an appropriate dose and spectrum. 
Unfortunately, while drug development has largely stagnated, commonly encountered 
bacterial pathogens are continuing to evolve new resistance patterns, challenging the 
prescriber to improve antibacterial application (8).  Tailoring antibacterial therapy to the 
patients’ physiology therefore seems inherently logical (9). 
 
Traditional antibacterial pharmaceutical research has largely focused on studies in healthy 
volunteers or hospitalised patients (10).  Empirical dosing regimens in the critically ill, often 
extrapolated from such work, are mostly flawed.  They fail to consider the distinctive 
demographic and physiology of this group (11), in particular the substantial changes in 
organ function that can be recognised.  This will result in significant changes in key 
pharmacokinetic (PK) parameters, such as renal (CLR) and total body clearance (CL) (12).  
This is turn may promote sub-therapeutic drug concentrations for lengthy periods of the 
dosing interval, treatment failure, and / or the development of antibacterial resistance (9). 
 
The critically ill represent a unique population of hospitalised patients, manifesting 
physiology that is infrequently seen in a ward or outpatient setting, and often requiring 
invasive support to maintain homeostasis.  A common feature is that of the systemic 
inflammatory response syndrome (SIRS), an innate humoral-based response to cellular 
inflammation and trauma (13-15).  In the presence of either presumed or proven infection, 
this is then termed sepsis (16), while the development of end organ dysfunction and 
hypotension resistant to fluid resuscitation can be regarded as severe sepsis and septic 
shock respectively (16).  Inadequately treated this can lead to multiple organ dysfunction 
(MODS) including the development of acute kidney injury (AKI)  (17).  In this setting, 
consideration of antibacterial dose reduction may be necessary, and is often the primary 
focus for clinicians.     
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However, the converse, escalating antibacterial doses in patients demonstrating supra-
normal renal drug elimination or augmented renal clearance (ARC) is rarely considered in 
clinical practice (12).  This is likely due to a lack of appreciation of this phenomenon, the 
poor sensitivity of standard diagnostic tests to identify ARC, and a paucity of clinical end-
points to titrate antibacterial drug prescription against.  To date, there has been scarce 
research in this area, limiting the conclusions that can be drawn from existing data. Both 
the underlying disease and the nature and frequency of invasive therapies provided in the 
ICU, are likely to contribute to this process.  For prescribers, an appreciation of ARC and 
its implications for beta-lactam antibacterial drug exposure in this setting is essential. 
 
1.2 Aims  
 
The broad aims of this research were to: 
 
a) Examine the relationship between plasma beta-lactam concentrations and ARC in 
critically ill patients receiving standard doses 
b) Explore the potential cardiovascular mechanisms promoting ARC in septic and 
traumatised patients admitted to the intensive care unit (ICU) 
c) Determine the prevalence of ARC in a heterogonous population of recently admitted 
critically ill patients with normal plasma creatinine (CR) concentrations 
d) Compare mathematical estimates of glomerular filtration and measured creatinine 
clearance (CLCR) in critically ill patients without overt renal impairment 
e) Review the implications of ARC for adequate beta-lactam exposure and future 
dosing strategies in the critically ill  
 
1.3 Thesis Outline 
 
Figure 1.1 outlines the framework of the thesis in relation to the clinical studies 
undertaken.  Specific aims and hypotheses along with the relevant references to published 
work are provided in Table 1.1. 
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Figure 1.1 Schematic Outline of Clinical Studies Included in this Thesis 
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Caption: Schematic outline of the major clinical studies undertaken during the Higher 
Research Degree Candidature.  
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Table 1.1 Thesis Outline, Aims/Hypotheses, and References 
 
Chapter  Title Specific Aim/Hypothesis References 
PART ONE – Introduction 
2 ARC: Definition, Mechanisms and Risk 
Factors 
- Udy A, Roberts JA, Lipman J. Implications of 
augmented renal clearance in critically ill patients. 
Nature Reviews-Nephrology 2011; 7(9): 539-43 
 
Udy A, Putt MT, Boots RJ, Lipman J. ARC - 
Augmented Renal Clearance. Current 
Pharmaceutical Biotechnology 2011; 12(12): 2020-
9 
 
Udy AA, Roberts JA, Lipman J. Clinical implications 
of antibiotic pharmacokinetic principles. Intensive 
Care Medicine, 2013; 39(12): 2070-82 
3 ARC and Beta-lactam PK-PD in the 
Critically Ill 
ARC has significant 
implications for effective 
beta-lactam dosing in the 
critically ill and may require 
novel dosing strategies 
Udy A, Roberts JA, Boots RJ, Paterson DL, Lipman 
J. ARC - Augmented Renal Clearance: Implications 
for Antibiotic Dosing in the Critically Ill. Clinical 
Pharmacokinetics 2010; 49(1): 1-16 
 
Udy A, Roberts JA, De Waele JJ, Paterson DL, 
Lipman J. What’s behind the failure of emerging 
antibiotics in the critically ill? Understanding the 
impact of altered pharmacokinetics and augmented 
renal clearance. International Journal of 
Antimicrobial Agents 2012; 39(6): 455-7 
 
A. Udy and J. Lipman. Chapter 12 - Importance of 
High Creatinine Clearance for Antibacterial 
Treatment in Sepsis. In: Sepsis Management PIRO 
and MODS. Rello J, Lipman J, Lisboa T (Eds.) 
2011, Springer-Verlag, Berlin Heidelberg 
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   Udy AA, Roberts JA, Lipman J. Clinical implications 
of antibiotic pharmacokinetic principles. Intensive 
Care Medicine, 2013; 39(12): 2070-82 
PART TWO – Clinical Studies 
4 Sub-therapeutic Beta-lactam 
Concentrations in Select Critically Ill 
Patients: Association Between ARC 
and Low Trough Drug Concentrations 
Augmented CLCR is strongly 
associated with sub-optimal 
beta-lactam plasma 
concentrations 
Udy A, Varghese J, Altukroni M, Briscoe S, 
McWhinney B, Ungerer J, Lipman J, Roberts JA. 
Sub-therapeutic initial beta-lactam concentrations 
in select critically ill patients: association between 
augmented renal clearance and low trough drug 
concentrations. Chest 2012; 142(1): 30-39 
5 ARC in Septic and Traumatized 
Patients with Normal Plasma 
Creatinine Concentrations: Identifying 
At-risk Patients 
Elevated CLCR is correlated 
with higher cardiac indices, 
and provides a useful method 
of identifying patients at risk 
of ARC 
Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman 
J. Augmented renal clearance in septic and 
traumatized patients with normal plasma creatinine 
concentrations: Identifying at-risk patients. Critical 
Care, 2013; 17(1): R35 
6 ARC in the ICU: Results of a 
Multicentre Observational Study of 
Renal Function in Critically Ill Patients 
with Normal Plasma Creatinine 
Concentrations 
ARC is prevalent amongst 
patients with normal plasma 
CR concentrations recently 
admitted to critical care units 
Udy AA, Baptista JP, Lim NL, Joynt G, Jarrett P, 
Wockner L, Boots RJ, Lipman J.  Augmented 
Renal Clearance in the ICU: Results of a 
multicenter observational study of renal function in 
critically ill patients with normal plasma creatinine 
concentrations. Critical Care Medicine, 2014; 42(3): 
520-527 
7 A Comparison of CKD-EPI Estimated 
Glomerular Filtration Rate and 
Measured Creatinine Clearance in 
Recently Admitted Critically Ill Patients 
with Normal Plasma Creatinine 
Concentrations 
Mathematical estimates 
perform poorly in comparison 
to CLCR measures in critically 
ill patients with normal 
plasma CR concentrations 
Udy AA, Morton FJA, Nguyen-Pham S, Jarrett P, 
Lassig-Smith M, Stuart J, Dunlop R, Starr T, Boots 
RJ, Lipman J. A comparison of CKD-EPI estimated 
glomerular filtration rate and measured creatinine 
clearance in recently admitted critically ill patients 
with normal plasma creatinine concentrations. BMC 
Nephrology, 2013; 14: 250 
PART THREE - Discussion 
8 Discussion and Overall Findings 
 
- - 
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Chapter 2 
 
ARC: Definition, Mechanisms and Risk Factors 
 
2.1 Chapter Overview 
 
This chapter provides a comprehensive review of the likely mechanisms and risk factors 
underpinning ARC in the critically ill.  As this represents a new concept in critical care 
pharmacology, a simple definition is proposed, with the aim of promoting future research in 
this area.   
 
A combination of text, figures, and tables from previously published manuscripts (as 
outlined in Chapter 1) form the majority of this chapter.  Where appropriate, additional data 
have been included if they were published subsequent to these manuscripts, and further 
inform the thesis.  The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
  
2.2 Introduction 
 
The critically ill represent a unique patient population, unlike that encountered in either the 
outpatient or general ward setting.  Their physiology is significantly disturbed (18), both as 
a consequence of the underlying disease process, and also as a result of invasive 
procedures and interventions (2, 3).  In this setting, interpretation of standard diagnostic 
tests, and the application of conventional therapies, are often flawed, as they fail to 
consider the unique characteristics of this group.  One such area is the assessment of 
renal function, and the application to antibacterial drug prescription in the ICU. 
 
To a large extent, clinical and biochemical assessment of renal function in this setting is 
focused on identifying kidney injury, with a view to correcting potential causes, avoiding 
complications, and monitoring the need for renal replacement therapy (RRT).  Although 
newer biomarkers are being investigated, plasma CR concentrations continue to be used 
widely as an indicator of the glomerular filtration rate (GFR), arguably the most important 
index of renal function (19).  In this respect, elevated plasma CR concentrations are 
routinely interpreted as representing renal dysfunction, and prompt dose reduction of 
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renally eliminated drugs.  However, the converse, escalating dosing in response to 
augmented elimination, is seldom considered in clinical practice. 
 
This is largely a reflection of the poor utility of plasma CR concentrations when reported in 
the reference range, and the lack of objective feedback to allow optimisation of 
antibacterial drug dosing.  This chapter explores the biological rationale and mechanisms 
underlying ARC in the critically ill, based on existing literature.  The difficulty with 
interpreting standard tests of renal function is reviewed, along with those patients at 
greatest risk for ARC. 
  
2.3 Defining ARC 
 
ARC can be defined as the enhanced renal elimination of circulating solute (such as 
nitrogenous waste products or pharmaceuticals), and is quantified as the volume of 
plasma cleared of a given substance by the kidneys per unit time.  In terms of the 
mechanisms involved, three important processes occur in the kidney - namely glomerular 
filtration, tubular re-absorption and tubular secretion.  The relative contribution from each 
process will vary depending upon the solute in question, but the most widely accepted 
descriptor of renal function in both health and disease is the GFR (19).  This defines the 
volume of plasma filtered by the kidney per unit time, and normal values are approximately 
130 ml/min/1.73m2 and 120 ml/min/1.73m2 in young men and women respectively (19). 
 
Defining ARC in terms of glomerular filtration is convenient, as it is both measurable and 
repeatable, such that trends can be followed over time, and in response to specific 
interventions.  However, using the GFR for this purpose is complicated, as there is no 
consensus on the most accurate technique to quantify this at the bedside, nor what are the 
accepted normal values for any given population.  In addition, the GFR provides no 
specific information on tubular function, which may be a key consideration for certain 
pharmaceuticals (20).  Specifically, while data concerning such changes in critical illness 
are currently lacking, evidence for altered tubular drug handling has been reported outside 
of the ICU, such as in HIV infection (21), and may contribute significantly to altered renal 
drug elimination (22). 
 
Despite these limitations, defining ARC in terms of an elevated GFR is attractive, 
particularly as previous authors have identified this as a key PK covariate in predicting 
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drug CL for renally eliminated agents (23-38).  Any 'cut-off' would ideally be intimately 
related to a measure of drug CL or plasma concentrations, such that values above this 
figure would pre-dispose to inadequate drug exposure.  Unfortunately, such data are not 
widely available.  Importantly, any specific definition of ARC will only act as a pointer to 
potential sub-therapeutic drug exposure, prompting either implementation of therapeutic 
drug monitoring (TDM) or empirical application of higher dosing in those agents with a 
favourable therapeutic index.   
 
2.4 Identifying ARC using Established Measures of Renal Function in the Critically Ill  
 
Some form of estimate of renal function is routinely required by clinicians, both to guide 
and optimise ongoing therapy, and as a means of documenting and following deteriorating 
organ function.  Clinical features, such as oliguria (urine output < 0.5 ml/kg/hr), and 
biochemical indices (such as plasma CR concentrations) are routinely used for such 
purposes.  However, in these circumstances, the focus is on identifying renal impairment, 
as opposed to augmented function. 
 
The most widely employed biochemical index of renal function is the plasma CR 
concentration.  Creatinine is an amino-acid derivative (molecular mass 113 D) produced in 
the liver and muscle that is freely filtered by the glomerulus, and secreted by proximal 
tubular cells.  Importantly, plasma concentrations will only rise once 60% of renal function 
is lost, and values within the 'normal' range, provide little if any information in the intensive 
care environment (39), particularly in relation to augmented function.  Other indirect 
markers of renal function (such as blood urea nitrogen) or indeed newer indicators of 
kidney injury (such as Cystatin C) suffer from the same limitations.  Gold-standard 
measures of GFR (such as inulin or iohexol CL, and radionucleotide studies) will provide 
the most accurate information, but are largely unavailable in a critical care setting.   
 
In order to provide more useful information for prescribers and to improve the early 
identification of chronic kidney disease (CKD), mathematical estimates of glomerular 
filtration have been developed using simple laboratory and demographic measures.  The 
Cockcroft-Gault equation was first published in 1973, and calculates an estimated CLCR 
(CG CLCR) using age, sex, weight and the plasma CR value (40).  It has been widely 
adopted in pharmaceutical research.  The newer modification of diet in renal disease 
(MDRD) formula was developed in a cohort of ambulatory patients with CKD, and both a 
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four and six variable equation have been employed (41).  More recently the CKD 
Epidemiology Collaboration (CKD-EPI) equation has also entered clinical practice (42). 
 
These mathematical estimates of GFR suffer from significant limitations in the critical care 
environment.  In particular, while they may provide more information that plasma CR 
concentrations alone (43), neither equation was designed for use in this setting, and 
ongoing research confirms that they are less accurate, particularly with burns (44), trauma 
(45), in general critical care practice (46-48) and at higher filtration rates (49-51).  In order 
to better model the dynamic nature of CR values in the critically ill, Jellife has proposed an 
estimate of CLCR using two separate measurements (52).  Although of significant merit, 
such equations still ignore the substantial underlying pathophysiology seen in critical 
illness, and suffer from the limitations of relying of plasma CR values alone (53). 
 
A potentially more accurate, and easily accessible estimate of GFR is a measured CLCR 
(54).  Although less readily obtainable in the ambulatory patient, urinary catheterisation is 
frequent in the critically ill, making a timed urinary collection relatively easy.  The duration 
of collection can be anywhere from 2 to 24hours (43, 55-59), with reasonable correlation 
between results (43).  Eight-hour collections appear to provide the best balance between 
accuracy and feasibility (45), and can usually be reported daily, allowing the clinician to 
monitor trends and tailor therapy accordingly.  The use of measured CLCR in the ICU is 
also underscored by studies demonstrating a significant correlation with drug CL (26, 60, 
61), allowing this to be employed as a surrogate of renal drug elimination. 
 
2.5 Mechanisms Underlying ARC 
 
Patients requiring ICU admission often demonstrate SIRS that is largely driven by the 
underlying disease.  A major component of this, particularly that seen with sepsis, is the 
development of a vasodilated or hyperdynamic cardiovascular state (62), characterised by 
a high cardiac output (CO) and increased major organ blood flow (63).  How this alters 
renal function, and as a consequence renal drug elimination remains a matter of ongoing 
research.  Many parallels can be drawn with pregnancy, where similar cardiovascular 
changes are encountered (64), along with markedly augmented renal blood flow (RBF) 
and glomerular filtration (65).  As a consequence, increased renal drug CL, and reduction 
in the terminal elimination half-life, has been documented for many agents during 
pregnancy (66).  
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Leading international guidelines also recommend aggressive intravascular fluid loading 
and cardiovascular support in the early phases of sepsis management (2, 3, 67), which are 
likely to further exacerbate such changes.  In this respect, evidence from large animal 
models demonstrate an increase in urine output and CLCR with crystalloid administration 
(68), in addition to an increase in CO, RBF, and CLCR  (69, 70) following initiation of 
vasopressor support.  As such, in the absence of AKI (where dose reduction would be 
appropriate), the use of aggressive resuscitative strategies in the critically ill may 
potentially augment renal drug delivery and elimination (71). 
 
In addition to the disease process and interventions provided, the native renal response to 
catabolism and inflammation may also influence renal drug handling.  This concept stems 
from early research demonstrating an increase in GFR following the administration of a 
high protein diet or infusion of amino acids (72).  This surge in filtration has been termed 
the 'renal reserve', and suggests the normal human kidney is not working at full capacity 
under basal conditions.  At times of biological stress, it is conceivable that this may 
promote higher filtration rates than otherwise would be observed (73).  Importantly, this 
‘reserve’ appears to decline with age, and in proportion to the baseline GFR (19).  The 
implications in critical illness are currently poorly understood.  Figure 2.1 graphically 
summarises the mechanisms likely to underpin ARC in the critically ill. 
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Figure 2.1 Mechanisms Relating to ARC in the Critically Ill 
 
 
 
 
Caption: Mechanisms driving ARC in the critically ill; including the underlying systemic 
inflammatory state (leading to increased organ blood flow), administration of 
intravenous resuscitation fluids and vasoactive medications, and the recruitment of 
renal reserve. 
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The interaction between physiological reserve (most marked in younger patients), and 
systemic inflammation, is likely to be an important driver of this process.  This was recently 
substantiated by Shimamoto et al., in which an increasing number of SIRS criteria were 
strongly associated with higher drug CL, and consequently lower plasma concentrations, 
in non-ventilated critically ill patients receiving standard doses of vancomycin (74).  
 
2.6 Patients At Risk of ARC  
 
Although a relatively new concept in critical care, some data exists that may guide 
identification of those patients at risk of ARC.  Table 2.1 summarises risk factors 
associated with either elevated CLCR or augmented drug CL from existing literature.  
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Table 2.1 Patients At Risk for ARC  
 
Risk Factor Key References 
Younger Age  
Systemic Inflammation 
Sepsis  
Trauma and Surgery  
Traumatic Brain Injury  
Burns  
Haematological Malignancy  
Ventilator Associated Pneumonia 
(59, 75) 
(74) 
(31, 32, 76-83) 
(30, 45, 84-88) 
(89-92) 
(44, 93) 
(94-100) 
(101) 
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In a single centre study of 4hr CLCR in a cohort of general ICU patients, Fuster-Lluch et al. 
demonstrated an incidence of  'glomerular hyperfiltration' (CLCR > 120ml/min/1.73m2) of 
17.9% on the day of admission (59).  The prevalence peaked on day 5, and elevated CLCR 
were more common in younger trauma and post-operative patients, with lower illness 
severity scores, higher urine outputs and diastolic blood pressure (59).  Furthermore, 
increased CL of cefpirome (32), ceftriaxone (102), ceftazidime (76), piperacillin (77), 
ertapenem (25, 78, 103), vancomycin (79), teicoplanin (24), ciprofloxacin (80), levofloxacin 
(81), linezolid (82), and aminoglycosides (83), have been demonstrated in PK studies of 
general ICU patients. More recently, Claus and colleagues reported a > 50% incidence of 
at least one episode of ARC (CLCR > 130 ml/min/1.73m2) in a mixed cohort of medical and 
surgical patients receiving antimicrobial therapy in the ICU.  Male gender and younger age 
were independently associated with ARC status (104). 
 
2.6.1 Trauma and Surgery 
Emergency post-operative and multitrauma victims frequently receive large quantities of 
fluid and blood products, in addition to undergoing often-repetitive surgical intervention.  
As such, they are at high risk of manifesting ARC, due to the underlying inflammatory state 
(13), coupled with fluid and vasoactive drug administration.  The work by Brown et al. 
approximately thirty years ago still provides perhaps the best illustration of this 
phenomenon, with CLCR reaching a peak of 190 ml/min/1.73m2 in trauma patients on the 
4th post-operative day (84).  In addition, in those where CO was measured by trans-
pulmonary thermodilution, a modest correlation was demonstrated with CLCR, although 
septic patients and those receiving vasoactive medications were excluded (84).   
 
In their work exploring the accuracy of shorter duration CLCR collections, Cherry and 
colleagues observed a similar result, with significantly elevated CLCR across all time points 
in trauma versus non-trauma patients (45).  More recently Minville and colleagues also 
demonstrated a significant association between elevated 24-hour CLCR (> 120 
ml/min/1.73m2) and admission post multitrauma.  In multivariate logistic regression, age 
and trauma status were the only independent factors correlated with CLCR (88).   
 
In respect to antibacterial studies, Hanes et al. have reported increased CL of ceftazidime 
in trauma patients (85), while Toschlog and colleagues in a prospective study of once daily 
dosing of gentamicin demonstrated rapid drug elimination in over 50% of the trauma 
cohort, closely correlated with age and estimated CLCR (87).   In comparison, work by 
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Jacolot and colleagues investigating the use of cefpirome in traumatised patients with 
SIRS, failed to demonstrate any significant alterations in key PK parameters when 
compared with matched healthy controls (105).  This is despite estimated CLCR values 
being elevated in the trauma group (median = 147ml/min), although this was not of 
statistical significance.   Of note, the mean length of stay (LOS) prior to antibiotic 
administration was 9 days, patients requiring vasopressors were excluded, and no 
haemodynamic data were reported (105).   
 
In the surgical ICU, Shikuma et al. have demonstrated markedly elevated CL of piperacillin 
in a young cohort of critically ill patients with sepsis (86).  In addition, wide inter-patient 
variation in key PK parameters was reported, as well as a moderate correlation between 
drug elimination and estimated CLCR (86).  Li et al. investigating the use of piperacillin for 
complicated intra-abdominal infection reported similar data.  In this multicentre randomised 
clinical trial, a population PK model demonstrated drug CL greater than that reported in 
healthy volunteers, and identified CLCR as a key covariate in predicting antibacterial PK 
(30). 
 
2.6.2 Neurosurgery 
Traumatic brain injury (TBI) and sub-arachnoid haemorrhage are two further sub-groups of 
critically ill patients likely to manifest ARC.  This is a reflection of the injury process and 
patient demographic, as well as the treatment provided.  Brain injury can occur in the 
setting of a global inflammatory process, such as that associated with multitrauma, or as 
an isolated insult (106).  Importantly younger patients with relatively limited co-morbidity 
tend to be over-represented (in TBI), and ICU management largely focuses on the 
restoration of a normal haemodynamic profile. This commonly involves the use of 
resuscitation fluids and vasoactive medications, particularly in the defence of an adequate 
cerebral perfusion pressure (CPP) (107, 108).  To add to this, concentrated saline 
solutions, or osmotic diuretics are often prescribed to reduce cerebral free water in the 
setting of refractory intracranial hypertension (109).  Data confirms that CLCR can be 
markedly elevated from baseline in this setting (Mean maximum CLCR = 179 
ml/min/1.73m2), with measures continuing to be significantly elevated, even following 
withdrawal of brain specific therapy (CLCR = 150 ml/min/1.73m2) (92). Induced 
hypertension and hypervolaemia are also commonly employed in attempts to prevent 
delayed cerebral ischaemia following sub-arachnoid haemorrhage (110), and although 
unproven, may also promote ARC in this population. 
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2.6.3 Burns 
Major burn injury represents a significant risk factor for ARC.  The nature of the insult 
results in a biphasic haemodynamic response (111), with the early phase being 
characterised by relative hypovolaemia, due to ongoing leak of protein rich fluid across the 
capillary membrane (112).  Aggressive fluid loading is the hallmark of emergency 
management, with many patients receiving large quantities of crystalloid resuscitation 
(113). AKI has been reported to occur in a significant number of burns patients, and is 
often multifactorial in aetiology (114).     
 
The second phase is then characterised by marked hypercatabolism and inflammation 
lasting several days to weeks, and is further complicated by multiple visits to the operating 
theatre for ongoing debridement and grafting.  At this time, CO and RBF can be markedly 
elevated leading to significantly augmented CL (93).  This was demonstrated by Conil and 
colleagues, where 15 of 36 burns patients had a mean 24hr CLCR of 174 ml/min in the 
second to third week post injury (44). 
 
Not surprisingly, the CL of renally eliminated antibacterial agents would be expected to be 
high.  Indeed, research has confirmed that cefepime (115), ceftazidime (116, 117), 
piperacillin (118), ticarcillin (119), imipenem (120), vancomycin (35, 121), tobramycin (93), 
amikacin (122), daptomycin (123) and ciprofloxacin (124) elimination is increased in this 
setting. 
  
2.6.4 Additional Risk Factors 
Two additional groups likely to manifest ARC are those with cystic fibrosis and 
haematological malignancy.  Although data concerning changes in GFR with cystic fibrosis 
are conflicting (125), investigators have demonstrated augmented drug elimination in 
correlation with elevated inulin CL (126), and CLCR (127) in this setting.  Similarly changes 
in tubular drug handling have been demonstrated (128), and may help to explain some of 
the augmented drug CL observed. 
 
Haematological malignancy or more specifically febrile neutropaenia appears to be 
another group where ARC is common (96).  These patients routinely receive broad-
spectrum empirical antibacterial therapy on admission to the ICU, and it is in this context 
that augmented renal drug CL have been noted (129).  In particular, Pea et al. observed a 
 18 
moderate inverse linear relationship between trough levels and estimated CLCR in patients 
receiving high dose teicoplanin as empirical treatment for febrile neutropaenia (94).  
Significantly, higher dosing regimes than those currently recommended were required to 
achieve adequate concentrations (94).  Similarly, augmented CL and/or higher dosing 
requirements have been demonstrated with ceftazidime (95), imipenem (96), amikacin 
(97), gentamicin (98), daptomycin (99), and vancomycin (100) in this setting.  The 
mechanisms underlying this phenomenon are likely to involve SIRS, in addition to 
recruitment of 'renal reserve'. 
 
2.7 Conclusions 
 
ARC can be defined as the enhanced renal elimination of circulating solute, and is most 
conveniently considered in terms of an elevated GFR.  An assessment of renal status is 
common in daily critical care practice, although is generally aimed at identifying kidney 
injury, rather than assessing renal function.  Plasma CR concentrations are used widely for 
this purpose, although provide little value when reported in the normal reference range.  
Mathematical estimates of GFR are also likely to be of limited utility, given they were 
derived from non-critically ill cohorts.  A measured urinary CLCR provides the most 
pragmatic estimate of renal function currently available. Systemic inflammation, fluid 
loading and vasoactive drug administration are hallmarks of critical illness, likely 
contributing to ARC in many patients. Sub-groups at greatest risk include younger patients 
admitted post major trauma or surgery, those suffering TBI or burns injury, and in the 
setting of febrile neutropaenia.  Augmented major organ blood flow and recruitment of 
renal reserve may be implicated.  With the knowledge that sub-optimal application of 
antibacterial agents may promote increased morbidity, a greater understanding of the 
impact of ARC on drug exposure and clinical outcomes is required.   
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Chapter Three 
 
ARC and Beta-lactam PK-PD in the Critically Ill 
 
3.1 Chapter Overview 
 
This chapter synthesises existing data concerning ARC and altered beta-lactam 
pharmacokinetics-pharmacodynamics (PK-PD) in the critically ill.  The rationale for specific 
drug exposure targets is reviewed, along with the potential impact of ARC on PK-PD and 
clinical endpoints.    
 
A combination of text, figures, and tables from previously published manuscripts (as 
outlined in Chapter 1) form the majority of this chapter.  Where appropriate, additional data 
have been included if they were published subsequent to these manuscripts, and further 
inform the thesis.  The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
 
3.2 Introduction 
 
ARC in patients without organ dysfunction is being increasingly described in subsets of 
critically ill patients (12, 26, 56, 59, 61, 84, 89-91, 93, 130).  In the context of antibacterial 
therapy, ARC will promote rapid renal drug elimination and sub-therapeutic concentrations, 
potentially leading to treatment failure or the selection of resistant microorganisms (12, 
131).  This has significant implications in patients with sepsis, whereby the consequences 
of inappropriate antibacterial therapy may be catastrophic (4-7).  
 
The prescription of antibacterial agents in critically ill patients remains complex.  Inter-
patient variability is significant, with fluid shifts, altered capillary permeability, impaired 
vascular tone, organ dysfunction and multi-organ failure, all distorting the PK profile of 
many routinely prescribed agents (10).  To date, ARC has been rarely considered in this 
context.  However, the implications for beta-lactam PK are substantial, and require 
considerable review, as these agents are commonly used empirically in the ICU (132).  
This chapter outlines existing literature concerning beta-lactam elimination, and specifically 
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how this is altered in a critical care setting.  In addition, the link between ARC, sub-
therapeutic drug exposure, and clinical outcomes is explored. 
 
3.3 Basic Pharmacological Principles 
 
Clinical pharmacology is concerned with optimising the effects of pharmaceuticals on the 
body, such that a specific effect is achieved, while avoiding toxicity and side effects.  Two 
major disciplines key to the application of this process, are that of pharmacokinetics (PK) 
and pharmacodynamics (PD).  PK is primarily interested in the changes in drug 
concentration (ideally at the effect site) over time, and is graphically represented by a 
concentration time curve (See Figure 3.1).  Typically this involves considering the 
absorption, distribution, metabolism and elimination of pharmaceuticals from the body.  A 
variety of PK parameters can be employed to define this process for different agents, 
examples of which are defined below: 
• Volume of distribution (Vd) = Hypothetical volume of fluid that the total amount of 
administered drug distributes into, generating a concentration equal to that 
measured in plasma.  
• Clearance (CL) = Volume of plasma effectively cleared of the drug per unit time.  
Total drug CL is the combination of the clearances for each eliminating organ or 
tissue. 
• Plasma half-life (T1/2) = Time required for the plasma concentration to fall by one 
half. 
• Cmax  = The maximum concentration measured after one dose.  Ideally at the effect 
site, although commonly measured in plasma. 
• Cmin = The minimum concentration during a dosing period.  Commonly determined 
in plasma prior to the next dose. 
•  Area under the curve (AUC) = The area under the concentration–time curve.  
Typically estimated from time zero to infinity using plasma concentrations.  
The distribution of any given antibacterial agent will vary significantly depending upon its 
inherent pharmacochemical properties (such as molecular weight, and electrochemical 
charge) and its degree of plasma protein binding.   Those agents with a higher affinity for 
lipids (lipophilic) will tend towards a higher Vd and longer elimination times, with extensive 
distribution into tissues and the intracellular space.  In contrast, hydrophilic agents will 
primarily be limited to the extracellular space, favouring a lower Vd and more rapid 
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elimination.  Those agents that are highly bound (to albumin or alpha-1 acid glycoprotein) 
may have very limited distribution (primarily in plasma) and a longer duration of action.  
Importantly, it is the free (or unbound) fraction that is pharmacologically active, and this will 
be influenced by plasma protein concentrations and binding competition from other agents.  
 
PD in contrast involves the study of the effects of the drug, and is typically represented by 
a dose response curve.  In terms of antibacterial agents, this refers to the ability of the 
agent to kill or inhibit the growth of an infecting organism following a given dose.  
Significantly, there is an important inter-play between the PK properties of these agents 
and their efficacy, which is referred to as the PK-PD characteristics.  The PK-PD 
parameters of note for antibacterial agents are summarised below and in Figure 3.1:  
• fT≥MIC = Fraction of the dosing interval for which the concentration of the 
antibacterial agent remains at or above the minimum inhibitory concentration (MIC) 
for bacterial growth 
• Cmax/MIC = Ratio of the maximum antibacterial concentration (Cmax) to the MIC of 
the infecting organism 
• AUC0–24/MIC = Ratio of the area under the concentration time curve during a 24-
hour time period, to the MIC of the infecting organism. 
Antibacterial agents can subsequently be classified on the basis of these PK-PD 
characteristics.  Concentration-dependant killing (as is the case with aminoglycosides) 
relies on achieving a high Cmax/MIC ratio at the site of infection (133, 134).  In comparison, 
time-dependent agents (such as beta-lactams) require an extended fT≥MIC (135).  Some 
agents, such as the glycopeptides and fluoroquinolones demonstrate both time and 
concentration dependent features, such that achieving an adequate AUC0–24/MIC ratio has 
been associated with successful bacterial kill (136, 137). 
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Figure 3.1 PK-PD Indices for Different Antibacterial Classes 
 
 
 
Caption:  Graphical depiction of Antibacterial PK-PD Indices.  Time-dependent agents (such as 
the beta-lactams) require a suffient period where the drug concentration is at or above the MIC of 
the infecting pathogen.  AUC – area under the curve, Cmax – maximum plasma concentration, Cmin 
– minimum plasma concentration, MIC – minimum inhibitory concentration, T > MIC – time above 
MIC  
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3.4 Beta-lactam PK-PD Targets 
 
The beta-lactam group demonstrate time-dependent killing, such that fT≥MIC, is the best 
predictor of efficacy (138).  Although optimum beta-lactam exposure in clinical practice is 
currently debated, in the absence of any significant post-antibiotic effect (PAE), dosing 
schedules should ideally aim to achieve sufficient drug concentrations for prolonged 
periods of the dosing interval (90-100% fT≥MIC) (139).  In addition, trough concentrations 4-
5 times the MIC are favoured, as bacterial killing is maximised (140, 141).  The 
carbapenems (meropenem, imipenem, panipenem, ertapenem, doripenem, and 
biapenem) are a newer class of beta-lactams that also demonstrate time-dependent killing 
(142).  However, In vitro models have suggested that the carbapenem PAE enables these 
agents to require less fT≥MIC (143) for bacteriostatic activity (20% fT≥MIC) and bactericidal 
activity (40% fT≥MIC) (144). Given the PK-PD profile for this class of agents, rapid renal 
drug elimination in the setting of ARC is highly disadvantageous, leading to potentially sub-
therapeutic levels for large portions of the dosing interval (25). 
 
3.5 Beta-lactam CL in Critical Illness 
 
The majority of agents in this class are renally eliminated (through a mixture of glomerular 
filtration and tubular secretion), and a number of studies have been published using 
different dosing regimens in the critically ill (Table 3.1).  A correlation between CLCR and 
drug CL has been reported for a number of agents (23, 28-33, 102, 117, 145-150).  Work 
by Conil and colleagues also highlight the importance of renal function as a key covariate 
in piperacillin elimination, with a strong inverse relationship between measured CLCR and 
trough concentrations (26).  In addition, as illustrated in Table 3.1, increased beta-lactam 
drug CL and significant inter-individual variability has been widely reported in the critically 
ill (25, 32, 86, 102, 103, 151, 152).  
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Table 3.1 Studies of Beta-lactam Antibacterial Agents in Healthy Volunteers and the Critically Ill 
 
Agent CL in Healthy 
Volunteers 
(ml/min)* 
CL and CLCR in the 
Critically Ill (ml/min)* 
Number and 
Population of 
Patients 
Dose Inter-patient 
Variability? 
Increased 
CL? 
Ref 
Cefepime  CL = 138 (22) 
n=7 
Dose: 2 g IV (153) 
 
CL = 127 (33) 
CLCR = 130.6 (32) 
 
n=13, Sepsis 
 
 2 g IV 
12hrly  
 
  (31) 
  CL = 137.3 (45%)+  
CLCR = 123.2 (54.6) 
n=55, ICU patients 
 
2 g IV 
12hrly or 4 
g IV CI 
 
!
 
 (152) 
  CL = 119.1 (59.6) 
CLCR = 133.5 (67.4) 
 
n=13, Burns 
 
2 g IV 8hrly !
 
 (117) 
 
  CL = 125 (51) 
CLCR = 54.6 (7.7) 
 
n=7, Sepsis 
 
2 g IV !
 
 (154) 
 
Cefpirome  CL = 101.7 (85-
146.7)** 
n=9 
Dose: 2 g IV (105) 
 
CL = 158 (88-228)** 
CLCR = 146.4 (72-252)** 
n=12, Sepsis 
 
2 g IV 
12hlry 
 
!
 
!
 
(32) 
 
  CL = 126.7 (71.7-248.3)**  
CLCR = 147 (82-190)** 
 
n = 9, Trauma and 
Sepsis 
2 g IV 
12hrly 
!
 
 (105) 
 
  CL = 75 (11) 
CLCR = 69.6 (21.2) 
 
n=12, sepsis 2 g IV   (145) 
Ceftriaxone CL = 19.8 (2.5) 
n=12 
Dose: 2 g IV(155) 
 
CL = 41 (12) 
CLCR = 114 (39) 
 
 
n=9, Critically Ill, 
normal renal function 
 
2 g IV Daily  !
 
(102) 
 
  CL = 26.3 (4.9) /1.73m2 
CLCR = 93.7 (20.3) /1.73m2 
 
n=7, ICU patients 
normal renal function 
 
2 g IV Daily  !
 
(156) 
  CL = 18 (5.5) 
CLCR = 112 (29) 
 
n=3, Critically Ill, 
normal renal function 
1.5 g IV   (148) 
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Ceftazidime CL = 116.5 (8.8) 
n=12 males 
Dose: 1 g IV(157) 
 
CL = 124.9 (62.6) 
CLCR = 119.2 (53.4) 
 
n=17, Burns 
 
1 g IV 4hrly !
 
!
 
(117) 
 
 CL = 97 (6.5) 
n=12 females 
Dose: 1 g IV(157) 
 
CL = 99 (28.1) 
CLCR = 102.8 (28.5) 
 
n=8, Sepsis 
 
2 g IV 8hrly !
 
 (33) 
 
  CL = 164.5 (62.3)  
CLCR IB = 96.8 (21.6) 
CLCR CI = 96.8 (23.3) 
 
n=31, Trauma 
 
2 g IV 8hrly 
or 
60mg/kg/d 
CI 
!
 
!
 
(85) 
(assuming 
weight = 
70kg) 
 
  CL = 151 (79.8) 
CLCR = 61.1 (24.9) 
 
n=15, Critically Ill 
 
2 g IV 8hlry   !
 
!
 
(76) 
 
  CL = 67.67 (5.83-185.5) ** 
 
n=21, Melioidosis 120mg/kg/d 
8hrly IB or 
CI 
 
!
 
 (23) 
(assuming 
weight = 
70kg) 
 
  CL IB = 85 (38.3-148.3) *** 
CL CI = 68.3 (23.3-
148.3)*** 
CLCR IB = 106 (59-160)*** 
CLCR CI = 93 (36-215)*** 
 
n=18, Abdominal 
Sepsis 
4.5 g IV CI 
or 1.5 g IV 
8hrly 
 
!
 
 (158)  
Piperacillin CL = 188 
Dose: 4 g 8hrly (159) 
 
CL = 396 (286) 
CLCR = 116.5 (55.8) 
n=11, Critically Ill 
 
2.5 to 4 g 
IV 
!
 
!
 
(86) 
 
  CL= 1150 (1001 - 3530) $ 
CLCR IB = 199 (91-233) $ 
CLCR CI = 166 (103-237) $ 
n=13, Critically Ill 4g IV 6 or 
8hrly as IB 
or CI (333 -
500mg/hr) 
 
!
 
!
 
(77) 
  CLCR = 65 (6-216)** n=70, Critically Ill 4 g IV 6 or 
8hrly 
!
 
!
 
(26) 
  CL = 230 (34.6%) + 
CLCR = 89 (22-150)** 
 
n=52, Abdominal 
Sepsis 
 
3 g IV 6hlrly 
or 12 g IV 
CI 
 
 !
 
(30) 
 
 26 
Meropenem CL = 254 (16) 
n=6 
Dose: 1 g IV(160) 
 
CL = 191 (52.2) 
CLCR = 61.2 (37.9)  
 
n=10, Sepsis 
 
1 g IV !
 
 (151) 
 
  CL = 155.8 (40.6) 
CLCR = 71.1 (15) 
 
n=8, Sepsis (CLCR > 
50ml/min) 
1 g IV 8hrly !
 
 (146) 
  CL = 112 (70) 
CLCR = 52 (51) 
 
n=6, Septic Shock 
 
1 g IV !
 
 (161) 
 
  CL = 170 (65) 
CLCR = 50 (21.4) 
 
n=11, Surgical 
infections 
1 g IV 8hrly !
 
 (147) 
  CL IB = 156.67 (20) 
CL CI = 128.33 (23.3) 
CLCR = 83.7 (53.1) 
 
n=15, Critically Ill 2 g IV 8hrly 
or 3 g IV CI 
  (162) 
  CL = 226.7 (23.3) 
CLCR CI = 93 (69-161) $ 
CLCR IB = 106 (98-127) $ 
 
n=10, Sepsis 
 
1g IV 8hrly 
or 3g IV CI 
!
 

 
(163) 
Imipenem CL = 186 (16) /1.73m2 
n=8 
Dose: 1 g + 1 g 
cilastatin IV (164) 
 
CL = 116.4 (42.3) 
CLCR = 76.2 (33.67) 
 
n=10, Sepsis 
 
1 g + 1 g 
cilastatin IV 
!
 
 (151) 
 
  CL = 105 (13.3) 
CLCR = 34.3 (10.3) 
n=6, Critically Ill 
 
500mg + 
500mg 
cilastin IV 
6-8hrly 
 
  (165) 
 
  CL = 205 (70) 
CLCR CI = 122 (33) 
CLCR IB = 128 (35) 
n=20, Nosocomial 
Pneumonia 
 
1 g + 1 g 
cilastatin IV 
8hrly or  2 g 
+ 2 g 
cilastatin CI 
   
!
 
!
 
(166) 
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Ertapenem  CL = 29.5 (3.4)  
n=16 
Dose: 1 g IV (167) 
 
CL = 200.5 (306.9) 
CLCR = 96.8 (43.3)  
 
n=8, Severe Sepsis 
 
Dose: 1 g 
IV daily 
!
 
!
 
(103) 
  CL = 73.3 (63.3-81.7)$ 
CLCR = 74 (66-109)$ 
 
n=15, VAP 1 g IV daily  !
 
(78) 
 
  CL = 43.2 (23.7) 
CLCR = 93.8 (52.4) 
 
n=17, VAP 
 
1 g IV daily  !
 
(25) 
 
 
* mean (SD), ** median (range), *** mean (range), $ median (IQR), + mean (inter-individual variability) 
CLCR – Creatinine Clearance, IV – Intravenous, CLR – Renal Clearance, CL – Total (Body) Clearance, ARC – Augmented Renal 
Clearance, IB – Intermittent Bolus, CI – Continuous Infusion, VAP = Ventilator Associated Pneumonia 
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Although for some agents the mean PK data reported may not be greatly different from 
studies in healthy volunteers (Table 3.1), the significant inter-patient variability often 
observed indicates that summary statistics are not always accurate in describing this 
phenomenon.  In addition, as many critically ill patients will manifest AKI and renal 
dysfunction, studies of small numbers in a heterogonous critically ill population will be 
underpowered to detect ARC.  In those patients with ‘normal’ plasma CR concentrations, 
ARC is likely to be significantly more common (77, 163).  Importantly these data provide a 
robust collection of PK-PD work that highlights the strong influence of altered renal 
function on beta-lactam PK, such that in the setting of ARC, pre-defined targets for optimal 
drug exposure are less likely to be achieved. 
 
3.6 Linking ARC, Beta-lactam PK-PD Target Attainment and Clinical Outcomes 
 
Limited data exists that explores the impact of ARC on beta-lactam PK-PD target 
attainment and clinical outcomes. Conil et al. examined Cmin in seventy critically ill patients 
receiving standard doses of piperacillin.  In patients with higher CLCR (≥ 50 ml/min), Cmin 
levels were unlikely to reach the break point for commonly encountered pathogens, 
particularly those with reduced susceptibility (26). However no difference in clinical 
outcomes was observed.   McKinnon and colleagues evaluated the relationship between 
fT≥MIC and clinical and microbiological outcomes in patients with bacteraemia and sepsis 
treated with cefepime or ceftazidime (168).  Significantly greater clinical cure and 
bacteriological eradication than was seen in circumstances where 100% fT≥MIC was 
achieved.   
 
More recently, a large multi-national point prevalence study of antibacterial levels in critical 
illness has demonstrated that treatment failure was three times more likely, when fT≥MIC 
was < 50% in those receiving beta-lactams (169).  In addition, higher beta-lactam 
concentration to MIC ratios at both 50% and 100% of the dosing interval were associated 
with a greater probability of a positive clinical outcome in multivariate analysis.  Using CG 
CLCR, ARC (CG CLCR ≥ 130ml/min) was strongly associated with lower drug 
concentrations (< MIC) at both time points (170).   
 
In this context, it is noteworthy to consider the recent premature conclusion to the industry 
sponsored clinical trial (ClinicalTrials.gov Identifier: NCT00589693) examining the use of 
doripenem (DORIBAX®, Johnson & Johnson, Raritan, NJ 08869) in the treatment of 
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ventilator-associated pneumonia (VAP).   Specifically, this phase III, prospective, 
multicentre, randomized, double blind study, aimed to assess the safety and efficacy of a 
fixed 7-day course of doripenem (1g, 4-hour infusion, q8hrly) compared with a fixed 10-day 
course of imipenem-cilastatin (1g, 1-hour infusion, q8hrly) as treatment for adult subjects 
hospitalized for at least 5 days, and diagnosed with VAP.  The primary objective was to 
demonstrate the non-inferiority of doripenem in a microbiological intention to treat (MITT) 
and microbiologically evaluable (ME) population. 
 
When terminated, 274 of the planned 524 subjects were randomised, with interim data 
analyses showing greater mortality, and lower clinical cure rates in those receiving 
doripenem.  Although issues regarding diagnosis, patient selection, causative pathogen 
and ancillary interventions, separate to simple under-dosing, may confound this result 
(171), marked differences in clinical cure rates (favouring imipenem-cilastatin) were 
observed in patients with a CG CLCR ≥ 150ml/min (172).  Of note, separate PK-PD 
modelling has suggested that significantly higher daily doripenem doses (up to 2 g 8-
hourly) might have been required for adequate drug exposure in these patients (173). 
 
This result follows that of a separate industry sponsored clinical trial (ClinicalTrials.gov 
Identifier: NCT00229008) examining the efficacy and safety of a new extended spectrum 
cephalosporin; ceftobiprole, in nosocomial pneumonia (NP).  Specifically, this phase III, 
multicentre, double-blind study, randomized 781 patients to receive either ceftobiprole 
(500mg, 2-hr infusion, q8hrly) and placebo (0.9% NaCl, 1-hr infusion, q12hrly) or 
ceftazidime (2g, 2-hr infusion, q8hrly) and linezolid (600mg, 1-hr infusion, q12hrly) for 7-14 
days, for the treatment of NP or VAP.  Clinical cure rate at 7-14 days after the last dose of 
study drug was the primary end-point.  Overall, non-inferiority of ceftobiprole was reported 
for NP (75), although in sub-group analyses, a trend favouring ceftazidime/linezolid was 
consistently observed in VAP patients.  In particular, younger patients (< 45yrs), and those 
with high CG CLCR (≥ 150ml/min) demonstrated numerically worse clinical cure rates with 
ceftobiprole (75).   
 
Finally, a recent prospective single-centre observational study has demonstrated an 
association between ARC (defined by a 24-hr CLCR > 130ml/min/1.73m2), and therapeutic 
failure (defined by a poor clinical response and the need for an alternative antibiotic) in 
critically ill patients receiving anti-infective therapy (104).  Of interest, this observation was 
most evident in those receiving non-carbapenem beta-lactams.  
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3.7 Implications of ARC for Dosing Beta-lactams in the Critically Ill 
 
These data serve to underline the importance of ARC in achieving adequate beta-lactam 
exposure in the critically ill, and raises important questions as to the optimal dosing 
strategy in this setting.  Given the time-dependent kill characteristics of this class of agents 
and the increased CL documented in the critically ill, maintaining sufficient drug 
concentrations through out the dosing interval remains challenging.  More frequent, 
extended or continuous dosing must be considered.   
 
PK-PD data supports administration by extended or continuous infusion (23, 85, 174-180), 
although a clear clinical benefit remains uncertain.  Lodise and colleagues examined the 
role of extended infusions of piperacillin-tazobactam in a retrospective cohort of critically ill 
patients with Pseudomonas aeruginosa infection.  Extended infusions were associated 
with a significant improvement in 14-day survival in those patients with higher illness 
severity (181).  Similar retrospective analyses have been performed in patients with 
ventilator associated pneumonia due to gram-negative bacilli, with continuous infusions of 
meropenem (182), ceftazidime (183), and piperacillin-tazobactam (184), all associated 
with improved rates of clinical cure, particularly with more difficult to treat organisms.  In a 
small prospective study, Roberts et al. also reported a clinical advantage to continuous 
infusion of ceftriaxone, when patients received four or more days of therapy (174). 
 
Confounding these results was a systematic review and meta-analysis performed in 2009, 
which reported no significant clinical advantage to continuous infusion of beta-lactams in 
hospitalized patients (185).  More recently, Falagas and colleagues repeated this analysis 
focusing on piperacillin/tazobactam and carbapenem administration.  Overall, lower 
mortality was demonstrated with extended or continuous infusions, although only 3 of 14 
included studies were randomized controlled trials (186).  Contrasting findings were 
recently reported from a single-centre before and after study, in which extended infusions 
of beta-lactams offered no advantage over intermittent dosing (187). 
 
In the largest prospective study to date, a multicentre double-blind randomized controlled 
trial of continuous infusion of beta-lactams reported improved fT≥MIC, and clinical cure, in 
critically ill patients with severe sepsis (188).  No significant difference was noted in ICU-
free days or survival to hospital discharge (188), although further studies are ongoing. 
 31 
 
Use of continuous or extended infusions in patients manifesting ARC represents an 
attractive approach, although to date there are no prospective data comparing dosing 
regimens in this setting.  However, a recent observational study by Carlier et al. suggests 
that despite the use of such strategies, elevated CLCR remains strongly associated with 
sub-optimal beta-lactam drug exposure (189).  This in combination with the inferior clinical 
outcomes demonstrated in patients manifesting ARC (104), indicates that higher daily 
doses are also likely to be required.  This is supported by dosing simulations reported for 
doripenem (173), meropenem (190, 191), cefepime (192), and piperacillin-tazobactam 
(193), in which adjustments in total dose, in addition to use of extended or continuous 
infusions are required.  
 
3.8 Conclusions 
 
Beta-lactams are commonly used empirically in the ICU.  They are time-dependent agents, 
such that effective bacterial killing is reliant on achieving drug concentrations in excess of 
the MIC for prolonged periods of the dosing interval.  They are predominantly renally 
eliminated. Many prior publications have demonstrated either elevated beta-lactam drug 
CL or marked inter-patient variability in the ICU, often in parallel with augmented CLCR.  
Failure to achieve the required PK-PD targets (at least 50% fT≥MIC) has been associated 
with inferior clinical outcomes (169), while treatment failure has also been noted in those 
manifesting ARC in a mixed ICU cohort (104).  ARC may have also confounded results 
from clinical trials of new or emerging antibacterial agents, potentially slowing the 
progression of these drugs into wider clinical practice (194).  Although use of extended or 
continuous infusions of beta-lactams appears attractive in the critically ill, outcome data 
are currently lacking, with additional studies suggesting an increase in total daily dose may 
be required (189).  Additional data concerning the prevalence of ARC in the critically ill, 
and improved methods to identify patients at risk of sub-therapeutic exposure are required 
to plan further studies in this area. 
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PART TWO – CLINICAL STUDIES
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Chapter 4 
 
Sub-therapeutic Initial Beta-lactam Concentrations in Select Critically Ill Patients: 
Association Between ARC and Low Trough Drug Concentrations 
 
4.1 Chapter Overview 
 
This chapter presents the findings from a single centre observational study of trough beta-
lactam plasma concentrations in patients receiving empirical therapy in the ICU.  The 
association between sub-optimal drug exposure and CLCR is explored, in order to assist in 
identifying future patients manifesting ARC.   
 
Text, figures, and tables from the published manuscript (as outlined in Chapter 1) are 
reproduced here. The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
 
4.2 Introduction 
 
Sepsis continues to be a major cause of morbidity and mortality in the critically ill (1), with 
leading international guidelines stressing the importance of appropriate antibacterial 
administration (2).  In this respect, optimising antibacterial exposure must be considered a 
clinical imperative, particularly with the expanding body of literature demonstrating a 
survival benefit with early, appropriate chemotherapy (6).   
 
To maximise the efficacy of antibacterials, prescribers must not only consider the likely 
causative organism, but also the PK-PD implications of the underlying disease state, and 
ancillary interventions provided (135).  Some consideration of the pathophysiology of 
critical illness and in its' influence on antibacterial handling and efficacy is essential, 
particularly as many dosing regimens have been derived outside of this setting.  In this 
manner, personalizing drug prescription is paramount to improving the chances of clinical 
success, and reducing the opportunity for selection of drug resistant strains (131). 
 
The beta-lactams are arguably the most commonly prescribed class of antibacterials in the 
critically ill (132).  They are primarily hydrophilic in nature, with a low Vd, and 
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predominantly renally excreted.  Bacterial killing is considered time-dependent, such that 
the duration the free (or unbound) drug concentration remains above the MIC of the 
infecting organism, is considered the primary PK-PD index of efficacy (fT≥MIC) (138).  
Ideally this should be 90-100% of the dosing interval, with maximal bacterial killing 
achieved at concentrations 4-5 x MIC (139-141, 195). 
 
Changes in organ function in the critically ill will considerably impact the probability of 
achieving such targets with beta-lactam dosing.  In particular, extra-vascular volume 
expansion with fluid loading and capillary leak may alter the Vd (135), while changes in 
renal function can significantly influence drug CL (71). In order to avoid drug accumulation 
and potential toxicity, dose reduction in the setting of renal dysfunction tends to be the 
primary concern for many clinicians, although increasing drug exposure in response to 
augmented drug elimination is seldom considered (12).  This largely stems from a paucity 
of data concerning changes in drug CL in the critically ill, the limited sensitivity of plasma 
CR concentrations to identify augmented renal function, and the lack of routine TDM of 
beta-lactams in clinical practice.   
 
Recently however, we have demonstrated that such measurements are feasible for a 
range of beta-lactams as part of a wider TDM program (196).  Utilising these data, the aim 
of this study was to identify clinically significant risk factors, with particular emphasis on 
renal function that may promote sub-therapeutic beta-lactam trough concentrations, as a 
maker of sub-optimal drug exposure. 
 
4.3 Materials and Methods 
 
4.3.1 Study Population 
Our institution operates a 30 bed tertiary level ICU that acts a major referral centre for the 
wider region.  The only major patient groups not represented include; paediatrics, cardiac 
surgical patients, and solid organ transplant recipients.  From February 2009, beta-lactam 
TDM has been available to tailor drug prescription, with utilisation of this service at the 
discretion of the treating physician and/or clinical pharmacist (196).  In a smaller sub-
group, where plasma CR concentrations alone have been considered a poor index of renal 
function, CLCR collections have been obtained concurrently.  These measures are typically 
obtained in patients considered 'at risk' of augmented drug CL; such as those admitted 
post-operatively, with sepsis or after major trauma (12), and without significant 
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derangement in plasma CR concentrations.  This involves an 8-hour urine collection via an 
indwelling catheter, with determination of the plasma CR concentration at a point mid-way.  
This service is provided as a part of routine clinical care, and as such, informed consent 
was not considered necessary by our institutional review board (Royal Brisbane and 
Women’s Hospital, Human Research Ethics Committee, GC2008/054). 
 
4.3.2 Sampling 
Blood samples were collected for TDM of the following beta-lactam antibacterials; 
ampicillin, dicloxacillin, penicillin, flucloxacillin, piperacillin, cefalothin, cefazolin, 
ceftriaxone, ceftazidime, cefepime, meropenem, and ertapenem.  As initial dosing at our 
institution employs intermittent regimens, samples were drawn immediately prior to re-
dosing, after at least four prior doses had been administered, thereby ensuring that all 
samples were obtained at 'steady-state', and limiting the impact of distribution kinetics.  
Sampling occurred over the same time-period as the 8-hour CLCR.  Empirical dose 
selection was at the discretion of the treating clinician, although consistent with the product 
information and in-line with local protocols. Continuous infusion is not employed 
empirically, but is considered if the subsequent trough level is sub-therapeutic, and the 
maximum recommended daily dose is already being prescribed.  Total blood 
concentrations of each antibacterial were determined, with the unbound fraction being 
calculated using data from previously published studies (196). 
 
4.3.3 Beta-lactam assay 
Beta-lactam antibacterial levels were measured using a validated high performance liquid 
chromatography (HPLC) assay method, details of which have previously been published 
(197).  In brief, the assay requires 200 µL of plasma and the sample preparation involves 
protein precipitation with acetonitrile and removal of lipid-soluble components by 
chloroform wash.  The results of the assay are reported typically within 12 hours of 
sampling.  The calibration curves for all the beta-lactam antibacterials were linear over the 
concentration ranges of 1 to 500 mg/L with correlation coefficients (r2) = 0.998.  Within-run 
precision (n=10) across three levels was = 3.1% CV. Inter-run precision (n=10) was = 
6.9% CV and the limit of quantification was 1mg/L. 
 
4.3.4 Therapeutic Drug Monitoring Targets and Susceptibility Data 
Although specific PD targets for beta-lactam dosing are the subject of debate, recent 
clinical data supports maintenance of longer fT≥MIC in the critically ill (ideally 100% of the 
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dosing interval) (168, 181).  Furthermore, given that bactericidal activity is reported to be 
maximal at 4-5 x MIC of the known or suspected pathogen (140, 195), this represents a 
logical target trough plasma concentration to ensure adequate tissue penetration, clinical 
cure, and limited opportunity for drug resistance.  Given the controversy concerning 
appropriate targets for antibacterial therapy, we elected to analyse the results obtained in 
terms of a conservative 100% fT≥MIC as well as a more ‘aggressive’ 100% fT≥4 x MIC.  
 
Where possible, beta-lactam concentrations were compared with susceptibility data of 
known or suspected pathogens, with breakpoints identified from the local antibiogram.  
Where local data were not available, the highest MIC in the susceptible range was 
selected as the dosing target from breakpoints published by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
(http://www.eucast.org/clinical_breakpoints).  The MIC (either known or presumed) 
employed in dose modification, was also categorised as ‘low’, ‘moderate’, or ‘high’, on the 
basis of the EUCAST distinctions.  In those patients where no organism was isolated, if 
treatment was commenced within 48hrs of admission, infection was presumed to be 
secondary to a community acquired pathogen.  Alternatively, a health-care or hospital 
acquired infection was presumed in those starting treatment > 48hours after admission. 
 
4.3.5 Statistical Analysis 
Continuous data are presented as the mean (SD).  Categorical data are presented as 
counts and/or percentages.  Sub-therapeutic unbound trough concentrations were defined 
as < MIC and < 4 x MIC respectively.  Comparisons between groups utilised an 
Independent Student T-test test for continuous data, and a Chi-square or Fishers Exact 
test for categorical data, where analysis assumptions were met.  Following identification of 
important covariates in univariate testing (p<0.15), a multivariate logistic regression model 
(single step, forced entry) was constructed to determine the primary determinants of sub-
therapeutic trough concentrations.  CLCR as the primary covariate of interest, was entered 
as a linear (continuous) variable.  Goodness of fit of the model was assessed by the 
Hosmer-Lemeshow statistic.  A receiver operator characteristic (ROC) curve was 
constructed utilising the largest sub-group receiving the same antibacterial, to examine 
threshold CLCR values.  All analyses employed IBM SPSS Statistics version 19 (Chicago, 
IL), and a p-value < 0.05 was considered as statistical significance. 
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4.4 Results 
 
Fifty-two concurrent trough beta-lactam concentrations and CLCR measures, from forty-
eight patients (four patients had beta-lactam concentrations determined twice due to a 
change in antibacterial agent), were used in analysis.  Demographic details, including a 
breakdown of the antibacterial agents employed, and suspected or known pathogens, are 
presented in table 4.1.  Admission diagnosis was classified as primarily neurological (eg. 
subarachnoid haemorrhage), post-operative, sepsis, or trauma.  As demonstrated, 
piperacillin was the most frequent beta-lactam employed (48%), while empirical cover and 
Staphylococcus spp. were the most common indications for antibacterial therapy (62%). 
The mean (SD) recorded CLCR was 134 (90) ml/min/1.73m2, with > 90% of plasma CR 
concentrations being < 120 µmol/l (1.4mg/dl).  
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Table 4.1 Demographic Data for Those Patients (n=48) Receiving Beta-lactam 
Therapeutic Drug Monitoring in the Intensive Care Unit 
 
Variable  
Male / Female, n (%) 34 (70.8) / 14 (29.2) 
Age, yrs, mean (SD) 52.9 (20.9) 
ICU LOS, days, mean (SD) 14.6 (11.2) 
APACHE II, mean (SD) 20.3 (6.8) 
SAPS II, mean (SD) 39.6 (16.1) 
Height, cm, mean (SD) 171.4 (11.2) 
Weight, kg, mean (SD) 85.4 (22.2) 
Admission Diagnosis, n (%): 
- Neurological 
- Post-operative 
- Sepsis 
- Trauma 
 
9 (18.8) 
15 (31.3) 
11 (22.9) 
13 (27.1) 
Beta-lactam  (n=52), n (%): 
- Penicillin 
- Fluclox/Dicloxacillin 
- Cefazolin 
- Ceftriaxone 
- Piperacillin 
- Meropenem 
 
2 (3.8) 
11 (21.2) 
1 (1.9) 
4 (7.7) 
25 (48.1) 
9 (17.3) 
Time to TDM Sampling from Admission (n=52), days, mean 
(SD) 
6.5 (6.1) 
Pathogen, (n=55)*, n (%): 
- Empirical cover 
- Staphylococcus Species 
- Enterobacteriaceae 
- Pseudomonas Species 
- Acinetobacter Species 
- Haemophilus influenzae 
- Streptococcus Species 
 
17 (30.9) 
17 (30.9) 
16 (29.1) 
2 (3.6) 
1 (1.8) 
1 (1.8) 
1 (1.8) 
Plasma CR concentration (n=52), µmol/L, mean (SD) 80 (42) 
Measured CLCR (n=52), ml/min/1.73m2, mean (SD) 134 (90) 
 
* > 1 potential pathogen isolated in three cases 
APACHE - Acute Physiology and Chronic Health Evaluation, SAPS - Simplified Acute 
Physiology Score, ICU LOS - Intensive Care Unit Length of Stay, CLCR - Creatinine 
Clearance, CR – Creatinine, TDM - Therapeutic Drug Monitoring 
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The majority of patients were being mechanically ventilated on the day of study (85%), 
although only 25% were receiving vasopressors.  The most common site of infection 
(presumed or confirmed) was the respiratory tract (52%).  The mean (SD) fluid balance 
over the course of the measured CLCR was -35 (1145) ml.   Tables 4.2 and 4.3 
demonstrate the differences in demographic and therapy related variables between those 
with sub-therapeutic and therapeutic concentrations (target; MIC and 4 x MIC 
respectively).  In only 58% (n=30) of instances was the trough drug concentration ≥ MIC, 
falling significantly to 31% (n=16) when using 4 x MIC as the target. 
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Table 4.2 Comparison of Demographic, Therapeutic and Infection Related Variables Between Those with Unbound Trough 
Concentrations < MIC, and ≥ MIC 
 
Variable Drug Concentration < MIC (n=22) Drug Concentration ≥ MIC (n=30) p-value 
Male / Female, n (%) 15 (68.2) / 7 (31.8) 22 (73.3) / 8 (26.7) 0.685 
Age, yrs, mean (SD) 40.1 (19.6) 60.3 (18.1) <0.001 
APACHE II, mean (SD) 18.8 (6.6) 21.3 (6.8) 0.182 
SAPS II, mean (SD) 36.6 (16.8) 41.8 (15.2) 0.249 
Measured CLCR, ml/min/1.73m2, mean (SD) 188 (101) 95 (56) <0.001 
Known / Suspected Source, n (%): 
- Skin/Soft Tissue/Bone 
- Respiratory Tract 
- Abdomen 
- Bacteraemia 
- Central Nervous System 
- Urinary Tract 
 
3 (13.6) 
13 (59.1) 
1 (4.5) 
3 (13.6) 
2 (9.1) 
0 (0) 
 
4 (13.3) 
14 (46.7) 
5 (16.7) 
3 (10.0) 
3 (10.0) 
1 (3.3) 
 
1.000 
0.376 
0.226 
0.689 
1.000 
1.000 
Mechanical ventilation, n (%) 18 (81.8) 26 (86.7) 0.708 
Fluid Balance, ml, mean (SD) 108 (1119) -140 (1172) 0.446 
Vasopressor, n (%) 4 (18.2) 9 (30.0) 0.331 
β-lactam, n (%): 
- Fluclox/Dicloxacillin 
- Piperacillin 
- Meropenem 
- Other 
 
6 (27.3) 
10 (45.5) 
4 (18.2) 
2 (9.1) 
 
5 (16.7) 
15 (50.0) 
5 (16.7) 
5 (16.7) 
 
0.495 
0.746 
1.000 
0.685 
Target MIC, n (%): 
- Low 
- Moderate 
- High 
 
5 (22.7) 
3 (13.6) 
14 (63.6) 
 
12 (40.0) 
8 (26.7) 
10 (33.3) 
 
0.190 
0.319 
0.030 
Nil Organism identified, n (%) 4 (18.2) 13 (43.3) 0.056 
ICU mortality, n (%) 1 (4.5) 2 (6.7) 1.000 
APACHE - Acute Physiology and Chronic Health Evaluation, SAPS - Simplified Acute Physiology Score, ICU - Intensive Care Unit, CLCR 
- Creatinine Clearance 
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Table 4.3 Comparison of Demographic, Therapeutic, and Infection Related Variables Between Those with Unbound Trough 
Concentrations < 4 x MIC, and ≥ 4 x MIC 
 
Variable Drug Concentration < 4 x MIC (n=36) Drug Concentration ≥ 4 x MIC (n=16) p-value 
Male / Female, n (%) 28 (77.8) / 8 (22.2) 9 (56.3) / 7 (43.8) 0.184 
Age, yrs, mean (SD) 45.8 (20.2) 65.1 (16.9) 0.002 
APACHE II, mean (SD) 19.4 (6.3) 22.2 (7.6) 0.173 
SAPS II, mean (SD) 36.9 (15.1) 45.9 (16.5) 0.059 
Measured CLCR, ml/min/1.73m2, mean (SD) 165 (91) 64 (28) < 0.001 
Known / Suspected Source, n (%): 
- Skin / Soft Tissue / Bone 
- Respiratory Tract 
- Abdomen 
- Bacteraemia 
- Central Nervous System 
- Urinary Tract 
 
4 (11.1) 
22 (61.1) 
2 (5.6) 
5 (13.9) 
3 (8.3) 
0 (0) 
 
3 (18.8) 
5 (31.3) 
4 (25.0) 
1 (6.3) 
2 (12.5) 
1 (6.3) 
 
0.662 
0.047 
0.064 
0.653 
0.637 
0.308 
Mechanical ventilation, n (%) 29 (80.6) 15 (93.8) 0.409 
Fluid Balance, ml, mean (SD) -17 (1117) -75 (1242) 0.869 
Vasopressor, n (%) 7 (19.4) 6 (37.5) 0.184 
β-lactam, n (%): 
- Fluclox/Dicloxacillin 
- Piperacillin 
- Meropenem 
- Other 
 
9 (25.0) 
17 (47.2) 
5 (13.9) 
5 (13.9) 
 
2 (12.5) 
8 (50.0) 
4 (25.0) 
2 (12.5) 
 
0.468 
0.853 
0.431 
1.000 
Target MIC, n (%): 
- Low 
- Moderate 
- High 
 
9 (25.0) 
7 (19.4) 
20 (55.6) 
 
8 (50.0) 
4 (25.0) 
4 (25.0) 
 
0.076 
0.719 
0.041 
Nil Organism identified, n (%) 9 (25.0) 8 (50.0) 0.076 
ICU mortality, n (%) 1 (2.8) 2 (12.5) 0.221 
APACHE - Acute Physiology and Chronic Health Evaluation, SAPS - Simplified Acute Physiology Score, ICU LOS - Intensive Care Unit 
Length of Stay, CLCR - Creatinine Clearance
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As observed, there was a statistically significant difference in the value of the measured 
CLCR between groups.  In this respect, in instances where the trough concentration was < 
MIC, 82% had a CLCR ≥ 130ml/min/1.73m2 (p<0.001).  Where the trough concentration 
was < 4 x MIC, 72% had a CLCR ≥ 130ml/min/1.73m2 (p<0.001).  Those with trough 
concentrations < MIC and < 4 x MIC were also noted to be significantly younger, with 
higher MIC targets for suspected or known pathogens.  There was also a greater 
incidence of respiratory tract infections in those with concentrations < 4 x MIC.  There was 
no significant difference noted in gender, ICU mortality, beta-lactam employed, mechanical 
ventilation, vasopressor use, or fluid balance between groups.  Figure 4.1 graphically 
depicts the trough drug concentration to MIC ratio as a function of the measured CLCR.   
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Figure 4.1 Trough Drug Concentration / MIC Ratio (Log10 scale) as a Function of 
CLCR 
 
 
 
Caption: Plot of trough drug concentration to MIC ratio as a function of CLCR.  A value > 1 
indicates a trough concentration > MIC of the known or suspected pathogen.  A trend-line 
has been fitted with an R2 value of 0.53.  MIC - minimum inhibitory concentration. 
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Using a cut-off p-value < 0.15, variables were identified for inclusion in a multivariate 
logistic regression analysis, using a target concentration of MIC and 4 x MIC respectively.  
The results of this analysis are presented in Table 4.4.  As demonstrated, CLCR was 
identified as being a statistically significant contributor to the likelihood of obtaining a 
therapeutic concentration  (target ≥ MIC OR: 0.986 (0.973-0.999), p=0.037; target ≥ 4 x 
MIC OR: 0.944 (0.902-0.989), p=0.015).  In this respect, maintaining all other variables 
constant in the model, a 25 ml/min/1.73m2 increase in the measured CLCR (from that 
observed), is associated with a mean 60% reduction in the probability of obtaining a trough 
concentration ≥ 4 x MIC. 
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Table 4.4 Results of Single Step Forced Entry Logistic Regression Modelling, Using 
a Target Concentration ≥ MIC and ≥ 4 x MIC 
 
Logistic Regression Model – Target Concentration = MIC 
Variable Odds Ratio (95% CI) p-value 
Age 1.044 (0.999-1.091) 0.056 
CLCR 0.986 (0.973-0.999) 0.037 
High MIC 2.205 (0.464-10.47) 0.320 
Nil Organism 0.281 (0.040-1.971) 0.202 
Logistic Regression Model – Target Concentration = 4 x MIC 
Variable Odds Ratio (95% CI) p-value 
Age 0.992 (0.925-1.064) 0.820 
SAPS II 1.042 (0.953-1.139) 0.372 
CLCR 0.944 (0.902-0.989) 0.015 
Respiratory source 35.96 (0.974-1328) 0.052 
Intra-abdominal 
source 
0.698 (0.013-37.40) 0.860 
Low MIC 3.306 (0.125-87.76) 0.475 
High MIC 2.575 (0.067-98.38) 0.611 
Nil Organism 0.158 (0.005-4.666) 0.285 
 
CLCR - Creatinine Clearance, APACHE - Acute Physiology and Chronic Health Evaluation, 
SAPS - Simplified Acute Physiology Score, MIC - Minimum Inhibitory Concentration 
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We further investigated statistical relationships in our dataset by performing a sub-group 
analysis on those patients receiving piperacillin for a known or suspected Pseudomonas 
aeruginosa infection (n=25, EUCAST MIC = 16mg/L).  The ROC curve constructed to 
further examine the utility of CLCR measures to accurately predict sub-therapeutic drug 
concentrations (< MIC) is presented in Figure 4.2.  This demonstrates very good 
discrimination, with an area under the curve of 0.87 (p=0.002), and a 77% sensitivity, and 
83% specificity for CLCR values ≥ 110ml/min/1.73m2. 
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Figure 4.2 Receiver Operating Characteristic (ROC) Curve for CLCR vs Trough 
Concentration ≥ 16mg/l in 25 Patients Receiving Piperacillin 
 
 
Caption: The area under the curve is 0.87.  A CLCR ≥ 110ml/min/1.73m2 displays a 
sensitivity of 77% and specificity of 83% for predicting a trough piperacillin concentration < 
16mg/l.  A diagonal reference line is also provided. 
 
 48 
4.5 Discussion 
 
These data demonstrate that in select critically ill patients receiving beta-lactam therapy, 
there is a strong association between augmented CLCR and sub-therapeutic unbound 
plasma trough concentrations.  Although such an observation is predictable, based on the 
established PK characteristics of these agents, this work is unique in contemporary 
literature, given the number of agents employed, and the strength of the relationship 
demonstrated in both univariate and multivariate analysis.  This highlights the concern that 
in many critically ill patients (largely those with seemingly 'normal' renal function), standard 
dosing is likely to provide inadequate beta-lactam exposure, potentially predisposing to 
treatment failure or the selection of drug resistant strains.  
 
Previous authors have demonstrated that CLCR is a key covariate in determining drug CL 
for a range of beta-lactams in the critically ill (23, 28, 30-33, 102, 117, 145, 146, 149, 150).  
In particular, Lipman et al. have demonstrated a near linear relationship between 
measured CLCR and cefepime/cefpirome elimination (31, 32), while more recently Conil 
and colleagues have shown an inverse relationship between trough piperacillin 
concentrations and 24-hour measured CLCR (26).  Such work confirms the significant 
relationship between CLCR and beta-lactam elimination, although the present study 
extends this finding to a broader range of agents commonly employed in this setting. 
 
Although a significant proportion of critically ill patients will develop renal dysfunction 
during their ICU stay (17), an increasingly recognised observation in this population is that 
of elevated CLCR values.  This phenomenon has been recently termed ARC, and defines 
the enhanced renal elimination of circulating solute, such as waste products or 
pharmaceuticals (71).  Although a relatively new term, many authors are describing this 
finding in a variety of subsets of critically ill patients (59, 84, 88, 92), and was a feature in 
over 50% of the cohort included in this analysis (mean CLCR = 134ml/min/1.73m2). 
 
Specifically, Minville and colleagues have very recently described augmented CLCR in a 
cohort of stable polytrauma victims (88), while similar findings have been observed in 
those receiving directed therapy for traumatic brain injury (92).  Brown and colleagues also 
report CLCR reaching a peak of 190ml/min/1.73m2 in traumatised post-operative patients 
(84), while more recent research has demonstrated that younger, trauma and post-
operative admissions, with lower illness severity scores, are more likely to manifest higher 
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CLCR on admission (59).  These findings are in keeping with our cohort, and provide some 
indication of sub-groups where beta-lactam TDM or regular CLCR measurement may be 
useful in optimising drug exposure. 
 
The physiological processes driving such changes in beta-lactam PK largely stem from the 
underlying inflammatory state, and invasive interventions provided.  In this respect, many 
critically ill patients will manifest SIRS (15), characterised by a low systemic vascular 
resistance and high CO (62).  In experimental models of gram-negative sepsis, this 
'hyperdynamic' circulation has been associated with increases in blood flow to major 
organs, including RBF (63).  This in turn results in greater delivery of solute to the kidney, 
and is likely to contribute to the higher CL observed in septic patients without renal 
dysfunction. 
 
Such changes can be further exacerbated by the application of vasoactive medications 
(69), and large volume fluid resuscitation (68), both of which are routinely employed in 
septic patients, usually as part of goal-directed therapy (2).  Similarly, aggressive 
haemodynamic targets are often employed in managing subarachnoid haemorrhage, 
particularly in attempts to ensure adequate cerebral perfusion, and prevent delayed 
cerebral ischaemia (110).  Although we could not demonstrate a difference in the 
application of vasopressor agents between groups, this study was not powered for such an 
observation.  Other 'at-risk' groups demonstrating similar changes in cardiovascular 
physiology include pregnancy (64), and burns victims (111). 
 
Our findings raise the possibility that a significant proportion of critically ill patients will 
receive inadequate beta-lactam exposure, despite the application of 'standard' empiric 
dosing regimens.  In addition, without easily defined and repeatable measures to guide 
therapy (such as blood pressure when titrating anti-hypertensives), recognizing this 
scenario can be problematic.  Although our data does not demonstrate a difference in ICU 
mortality, this study is significantly under-powered for such an observation.  This is not 
surprising given the number of potential confounders, although separate research has 
demonstrated improved clinical cure and bacterial eradication with 100% fT≥MIC for beta-
lactam antibacterials (168).   
 
Further clinical investigation is clearly required.  Specifically, the use of extended interval 
or continuous infusion strategies (to ensure higher beta-lactam concentrations over longer 
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intervals) has a sound PK-PD rationale (135), although outcome data continues to be 
scarce (185).  Controlled trial data is perhaps flawed in this setting however, as the 
substantial changes in organ function encountered in the critically ill are rarely considered.  
The role of such dosing regimens in the setting of ARC remains un-tested.           
 
The significance of the likely pathogen is also demonstrated in our analysis.  In this 
respect, a higher MIC target was observed in those with sub-therapeutic concentrations in 
univariate analysis, although this was not significant in multivariate modelling.  It still 
remains a logical conclusion however, that when targeting therapy towards more resistant 
pathogens (with higher MICs'), sub-therapeutic drug concentrations are likely to be more 
common.  This is further demonstrated by our ROC analysis utilising piperacillin trough 
levels, which suggests that even relatively normal CLCR values (110ml/min/1.73m2) can 
predict sub-therapeutic drug concentrations when targeting more resistant pathogens.  
Importantly, dosing studies in the 'non-critically ill' are perhaps unlikely to enrol patients 
with CLCR values significantly above this threshold, thereby validating current dosing 
regimens outside of the ICU.  However, given the demonstrable changes in organ function 
with critical illness, such thresholds clearly require further assessment in a larger critically 
ill population. 
  
This study has a number of potential limitations.  Firstly, we have single data points only 
for analysis, and as such our findings do not attempt to describe the changes in beta-
lactam PK throughout the ICU stay.  In this respect, it is anticipated that there could be 
significant intra-individual variability due to the dynamic nature of critical illness.  
Furthermore, as we only have a single plasma concentration, it is not possible to 
determine drug CL.  Secondly, we have chosen to employ 8-hour CLCR measures, as 
compared with more traditional 24-hour collections.  This represents the preferred practice 
at our institution, and previous authors have shown equivalence when using such 
measures (45).  Thirdly, our data represents a relatively small select cohort from a single 
centre, and as such, may lack application in a wider setting.  Finally, we have measured 
total drug concentrations, with correction for protein binding based on published literature.  
As protein binding is complex in critical illness, such assumptions may not be correct, 
although assays for free drug concentrations are not readily available currently. 
 
 
 
 51 
4.6 Conclusions 
 
In conclusion, this study has demonstrated a strong association between elevated CLCR 
measures and sub-therapeutic trough concentrations for a range of beta-lactams in 
critically ill patients, regardless of whether a target of MIC or 4 x MIC is employed.  
Multivariate modelling confirms CLCR as a significant covariate for predicting low trough 
concentrations, despite differences in illness severity, age, and MIC.  Given the strong 
possibility that many critically ill patients receive inadequate beta-lactam exposure with 
standard dosing, we recommend the routine application of CLCR measurement in the 
critically ill where ARC is suspected, to either guide the application of beta-lactam TDM 
where available, or the application of higher empirical dosing. 
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Chapter 5 
 
ARC in Septic and Traumatized Patients with Normal Plasma Creatinine 
Concentrations: Identifying At-risk Patients  
 
5.1 Chapter Overview 
 
This chapter outlines the results of a prospective observational study of demographic and 
physiological risk factors for ARC in traumatized and septic patients receiving empirical 
beta-lactam therapy.  In addition, the relationship between cardiac index (CI) and CLCR is 
explored, in order to further elucidate the potential mechanisms underpinning ARC in 
these patients. 
 
Text, figures, and tables from the published manuscript (as outlined in Chapter 1) are 
reproduced here. The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
 
5.2 Introduction 
 
Accurate pharmaceutical prescription remains uniquely challenging in the critically ill. Many 
dosing schedules are simply extrapolated from data derived from healthy volunteers or 
ambulatory patients, without consideration of the pathophysiology (11) or clinical 
heterogeneity, often encountered in this setting. Capillary leak, fluid loading, decreased 
protein binding, use of vasoactive medications and altered excretory organ function, will 
significantly distort the 'normal' PK profile of many agents (135). Most concerning is the 
potential effects on antibacterial drug exposure, given the wealth of data demonstrating 
improved outcomes with early appropriate therapy (4-6). Although infrequently considered, 
such issues may not only confound the successful individual use of many 
pharmaceuticals, but also the planning, methodology and interpretation of clinical trials in 
this population (194). 
  
A key PK variable of interest is drug CL, with previous data demonstrating notably 
elevated values in subsets of critically ill patients (71). This phenomenon has recently 
been termed ARC (198) and may significantly impact the successful application of many 
 53 
renally eliminated agents by promoting sub-therapeutic drug exposure (18, 198). Although 
specific data concerning drug CL in critical illness remains sparse, elevated urinary CLCR, 
as a marker of ARC, has been documented in sepsis (61), VAP (101), TBI (92), burns 
(44), multitrauma (88), and post-operatively (84). Furthermore, elevated CLCR has been 
closely linked with sub-therapeutic beta-lactam antibacterial trough concentrations (26, 
199) in addition to being significantly correlated with renal drug elimination (71). 
 
Identification of patients manifesting ARC remains clinically challenging, principally as 
many agents (most notably antibacterials) manifest 'silent' PD indices, making under-
dosing substantially less visible (12). Although various mathematical estimates of 
glomerular filtration are widely applied (40, 41), each was primarily designed for use 
outside of the ICU, making application in this setting flawed (46, 200) and of little value in 
guiding therapy. While a measured CLCR has greater utility (54), a defined urinary 
collection period is required, thereby limiting application to initial dose selection. Improved 
methods to identify patients with ARC using simple bedside assessment are urgently 
required. 
 
The physiological alterations promoting ARC remain poorly understood. In large animal 
models of gram-negative sepsis, elevated CO, low systemic vascular resistance, and 
increased major organ blood flow have been demonstrated (63). Application of aggressive 
fluid resuscitation (201) and vasopressor support (69) further augments this process, 
leading to substantial changes in renal function. Many parallels can be drawn with 
pregnancy, where similar cardiovascular changes are associated with augmented RBF 
and glomerular filtration (65). As such, in the absence of established AKI, the innate 
hemodynamic response to critical illness, coupled with common clinical interventions, may 
promote increased solute delivery to the kidneys and subsequent augmented renal 
elimination. 
  
In this respect, assessment of CO offers a logical, pragmatic and physiologically sound 
method of rapidly assessing patients for the presence of ARC. To our knowledge, there 
has been little data reported on this application, representing a new, unique, indication for 
cardiovascular monitoring. Importantly, although CO assessment has historically employed 
invasive techniques (such as pulmonary artery catheterization), a variety of new devices 
are making continuous CO measurement accessible, feasible and safe (202). The aims of 
this pilot prospective observational study were, therefore, to: a) describe the prevalence of 
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ARC in a cohort of septic and traumatized critically ill patients receiving beta-lactam 
therapy; b) correlate CLCR and cardiac function in these patients; and c) examine 
demographic, physiological and illness severity characteristics that may help to identify 
patients manifesting ARC. 
 
5.3 Materials and Methods 
 
5.3.1 Study Population 
Patients were enrolled consecutively as part of a wider open label study examining beta-
lactam antibacterial PK in critical illness, the methodology of which has been published 
elsewhere (203). In brief, patients were eligible for enrolment if they were: a) 18 to 80 
years of age; and b) receiving piperacillin-tazobactam for treatment of presumed or 
confirmed nosocomial infection, while manifesting SIRS (15), or were receiving cefazolin 
as prophylaxis following multitrauma. This, therefore, represents a convenience sample of 
multitrauma and septic critically ill patients admitted to our institution. This manuscript 
reports a separate, independent analysis, focusing on ARC. The study protocol was 
approved by our institutional human research ethics committee (HREC 2007/188) and 
informed consent was obtained from either the patient or their substitute decision maker in 
all cases. 
 
5.3.2 Study Protocol 
An in-depth physiological and PK investigation was performed over a single six-hour 
dosing interval following antibacterial infusion (203). Pulse contour analysis, utilizing the 
Vigileo® system (software version 1.10), connected to an existing intra-arterial catheter via 
a Flo Trac® (Edwards Lifesciences, Irvine, CA, USA) sensor, was employed as the primary 
method of measuring CO. Demographic data including patient age, gender, body weight 
and height were inputted, following which the sensor was levelled to the phlebostatic axis 
and 'zeroed' to atmospheric pressure. The system provides continuous CO data utilizing 
the heart rate and an index of stroke volume (obtained from the arterial pressure 
waveform), which is automatically averaged and updated. CI (L/min/m2) is then calculated 
as the CO (L/min) divided by the body surface area (BSA) (m2). Three CI measurements 
were recorded at 0, 180, and 300 minutes, after which the mean value was calculated for 
use in subsequent analysis.  
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CLCR was measured as the primary method of determining kidney function. All urine was 
collected via an indwelling catheter over three two-hour time periods (0 to 120, 120 to 240, 
and 240 to 360 minutes, respectively), following which urinary volume and CR 
concentration were determined by laboratory analysis. CR measurement in plasma and 
urine utilized automated analyzers employing a modified Jaffe (alkaline picrate) technique, 
representing an isotope dilution mass spectrometry (IDMS) traceable assay. Plasma CR 
concentrations measured on the day of investigation were used to calculate each CLCR 
(normalized to a BSA of 1.73m2), after which the mean value was used in further analysis. 
  
Additional data, including the requirement for mechanical ventilation, vasopressor support, 
modified sequential organ failure assessment (SOFA) score (excluding the neurological 
component) and 24-hour fluid balance, were also recorded on the day of drug 
administration. Admission acute physiology and chronic health evaluation (APACHE) II 
score, in addition to ICU and in-hospital clinical outcomes, were also recorded. Given that 
changes in cardiovascular physiology are unlikely to promote enhanced renal elimination 
in the setting of evolving AKI, patients with a plasma CR concentration greater than the 
upper limit of the reported reference range (>110 µmol/L) were excluded from further 
analysis. ARC was defined as a CLCR ≥130ml/min/1.73m2, given previous data 
demonstrating an association with sub-therapeutic beta-lactam concentrations, when using 
standard doses (199). 
 
5.3.3 Statistics  
Continuous data are presented as the mean (SD) or median [IQR]. Categorical data are 
presented as counts (%). Correlation was assessed by means of a scatter graph and 
Pearson correlation coefficient (r). Comparisons between groups utilized an Independent 
Student T-test or Mann-Whitney U test for continuous data, and a Chi-square or Fishers 
Exact test for categorical data, where analysis assumptions were met. A backward 
conditional logistic regression model was developed to describe risk factors for ARC in 
multivariate analysis. Covariates were identified if the associated P-value was <0.15 in 
univariate testing, and the Hosmer-Lemeshow statistic was used to assess goodness of fit. 
Receiver operator characteristic (ROC) curves were constructed to examine the accuracy 
of any variable to predict ARC. A P-value <0.05 was considered as indicating statistical 
significance, and all analyses were performed using SPSS version 19 (Chicago, IL, USA). 
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5.4 Results 
 
Eighty patients were enrolled in the open label PK study, fifty meeting the criteria for 
sepsis, and the remaining thirty admitted post multitrauma. One patient was excluded from 
further analysis as no CI measurements were available, while a further eight patients were 
excluded due to a plasma CR concentration >110 µmol/L on the day of study. Laboratory, 
demographic, illness severity and outcome data for the remaining seventy-one patients 
(sepsis n = 43, trauma n = 28) are presented in Table 5.1. As expected, young male 
patients dominated the trauma group, although illness severity scores were similar 
between diagnostic categories. Data collection occurred a median of 1.60 [1.20 to 2.13] 
days post admission in the trauma sub-group, compared with 4.11 [1.68 to 6.83] days in 
sepsis (P <0.001). Crude ICU (4.2%) and in-hospital (8.5%) mortality were remarkably low. 
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Table 5.1 Laboratory, Demographic and Illness-severity Data of All Patients (n = 71) 
 
Variable All patients 
(n = 71) 
Trauma 
(n = 28) 
Sepsis 
(n = 43) 
P-valuea 
Age, years, mean (SD) 42.4 (16.6) 36.4 (13.9) 46.3 (17.1) 0.013 
Male gender, number (%)  45 (63.4) 23 (82.1) 22 (51.2) 0.008 
BSA, m2, mean (SD) 1.98 (0.26) 2.01 (0.25) 1.96 (0.27) 0.415 
APACHE II score, mean (SD) 17.9 (7.15) 16.1 (7.68) 19.0 (6.62) 0.096 
Modified SOFA score, median [IQR] 3 [2-5] 3.5 [2-5] 3 [2-5] 0.659 
Use of Vasopressors, number (%) 20 (28.2) 11 (39.3) 9 (20.9) 0.093 
Mechanical ventilation, number (%) 66 (93.0) 26 (92.9) 40 (93.0) 1.000 
24hour Fluid balance, ml, mean 
(SD) 
656 (1,886) 1,209 (1903) 295 (1,806) 0.045 
Plasma CR, µmol/L, mean (SD) 66.1 (18.1) 62.7 (13.2) 68.4 (20.5) 0.157 
CI, L/min/m2, mean (SD) 4.20 (1.10) 4.30 (0.86) 4.13 (1.23) 0.507 
CLCR, ml/min/1.73m2, mean (SD) 135 (51.8) 166 (42.5) 114 (47.2) <0.001 
Augmented renal clearance, n (%) 41 (57.7) 24 (85.7) 17 (39.5) < 0.001 
ICU length of stay, days, mean (SD) 16.0 (11.1) 13.3 (10.2) 17.8 (11.4) 0.090 
ICU mortality, number (%) 3 (4.20) 1 (3.6) 2 (4.7) 1.000 
Hospital mortality, number (%) 6 (8.50) 3 (10.7) 3 (7.0) 0.674 
 
aComparison between sub-groups. APAHCE II, Acute Physiology and Chronic Health 
Evaluation; BSA, body surface area; CI, cardiac index; CLCR, creatinine clearance; CR, 
creatinine concentration; SOFA, Sequential Organ Failure Assessment. 
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Overall, 57.7% of the cohort manifested ARC (CLCR ≥130ml/min/1.73m2), although higher 
CLCR values were noted in traumatized patients (166 (42.5) versus 114 (47.2) 
ml/min/1.73m2, P <0.001), leading to a greater prevalence in this group (85.7% versus 
39.5%, P <0.001). The range of CI and CLCR measures observed in each diagnostic sub-
group are presented in Figure 5.1.  In all patients (n = 71), a weak, statistically significant 
correlation was evident between CI and CLCR (r = 0.346, P = 0.003), although this was 
primarily due to the relationship observed in septic patients (r = 0.508, P = 0.001), as no 
correlation (r = -0.012, P = 0.951) was evident in trauma patients (see Figure 5.2). 
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Figure 5.1 Box Plot of CI (L/min/m2) and CLCR (ml/min/1.73m2) in Trauma and Septic 
Patients 
 
 
 
Caption: Box plot (median, interquartile range, maximum and minimum) of cardiac index, 
L/min/m2 (A) and creatinine clearance, ml/min/1.73m2 (B) in trauma (n = 28) and septic (n 
= 43) patients. Higher CLCR values were demonstrated in those admitted post trauma (P 
<0.001). 
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Figure 5.2 Correlation of CI (L/min/m2) and CLCR (ml/min/1.73m2) 
 
 
 
Caption: Scatter graphs of cardiac index (L/min/m2) and creatinine clearance 
(ml/min/1.73m2) in all patients (A), septic patients (B) and trauma patients (C). The 
Pearson correlation coefficient (r) for all patients was r = 0.346 (P = 0.003), septic patients 
r = 0.508 (P = 0.001), and trauma patients r = -0.012 (P = 0.951). 
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Differences in demographic, illness severity, physiological and laboratory data on the basis 
of ARC status are provided in Table 5.2. As illustrated, those manifesting ARC tended to 
be younger (P <0.001), male (P = 0.012), with lower APACHE II (P = 0.008) and modified 
SOFA scores (P = 0.013) and higher cardiac indices (P = 0.013). The range of values 
recorded for age, CI, CLCR and modified SOFA score are presented graphically in Figure 
5.3. 
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Table 5.2 Demographic, Diagnostic and Treatment-related Data in Those With and 
Without ARC 
 
Variable ARC (n = 41) No ARC (n = 30) P-value 
Age, years, mean (SD) 34.1 (11.7) 53.7 (15.5) <0.001 
Male gender, number (%) 31 (75.6) 14 (46.7) 0.012 
BSA, m2, mean (SD) 1.98 (0.25) 1.99 (0.28) 0.850 
APACHE II score, mean (SD) 16.0 (6.33) 20.4 (7.49) 0.008 
Modified SOFA score, median [IQR] 3 [2-4] 4 [3-6] 0.013 
Use of vasopressors, number (%) 9 (22.0) 11 (36.7) 0.173 
Mechanical ventilation, number (%) 39 (95.1) 27 (90.0) 0.644 
24hr Fluid balance, ml, mean (SD) 428 (2011) 967 (1684) 0.237 
CI, L/min/m2, mean (SD) 4.47 (1.01) 3.80 (1.12) 0.013 
CLCR, ml/min/1.73m2, mean (SD) 170 (32.9) 86.8 (29.5) <0.001 
Category 
   Trauma, number (%) 
   Sepsis, number (%) 
 
24 (58.5) 
17 (41.5) 
 
4 (13.3) 
26 (86.7) 
 
<0.001 
<0.001 
 
APACHE II, Acute Physiology and Chronic Health Evaluation score; BSA, body surface 
area; CI, cardiac index; CLCR, creatinine clearance; SOFA, Sequential Organ Failure 
Assessment. 
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Figure 5.3 Box Plot of Age (years), CI (L/min/m2), CLCR (ml/min/1.73m2) and Modified 
SOFA Score in Patients With and Without ARC 
 
 
 
Caption: Box plot (median, interquartile range, maximum and minimum) of age, years (A), 
cardiac index, L/min/m2 (B), creatinine clearance, ml/min/1.73m2 (C) and modified SOFA 
score (D), in those with (n = 41) and without (n = 30) augmented renal clearance. Younger 
age (P <0.001), higher cardiac indices (P = 0.013) and lower modified SOFA scores (P= 
0.013) were observed in those manifesting augmented renal clearance. 
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Linear variables associated with ARC were then dichotomized to facilitate multivariate 
logistic regression. Cut-points were identified from visual inspection of the data (Figure 
5.3). Specifically, age ≤50 years, CI ≥3.5 L/min/m2 and modified SOFA score ≤4, along 
with gender and diagnostic sub-group, were entered as categorical variables into a 
backward conditional regression model. APACHE II scores were not included, as these 
are co-linear with age and SOFA, and poorly validated in trauma. This analysis identified 
age ≤50 years (adjusted odds ratio (OR) 28.6, 95% CI 4.4 to 187.2), trauma (adjusted OR 
16.1, 95% CI 3.0 to 87.7) and modified SOFA score ≤4 (adjusted OR 5.1, 95% CI 1.0 to 
25.0) as statistically significant risk factors for ARC. The r2 value was 0.59, and the 
Hosmer-Lemeshow statistic had a significance value of P = 0.834, suggesting acceptable 
goodness of fit. There was no improvement in model performance when continuous 
variables were utilized. 
 
To further illustrate the relative significance of these covariates, a weighted scoring system 
was constructed based on the adjusted ORs and their proportions to each other. Age ≤50 
years was assigned six points, admission post-trauma three points and modified SOFA 
score ≤4 one point. Scores were then summated for each patient, with higher totals 
strongly associated (P <0.001) with ARC (see Figure 5.4). This model was also compared 
with CI measurement as a predictor of ARC status using ROC analysis (see Figure 5.5). 
CI values alone demonstrate an area under the curve (AUC) of 0.67 (95% CI 0.54 to 0.81, 
P = 0.013), whereas the combined ARC score has improved accuracy, with an AUC of 
0.89 (95% CI 0.80 to 0.97, P <0.001). Separate ROC curves were also constructed 
utilizing CI values in each diagnostic sub-group (figures not displayed). In those 
manifesting trauma, CI was less discriminating, with an AUC of 0.57 (95% CI 0.31 to 084, 
P = 0.646), although this variable performed better in sepsis, AUC 0.72 (95% CI 0.57 to 
0.87, P = 0.015).  
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Figure 5.4 Proportion of Patients Manifesting ARC with Increasing ARC Risk Scores 
 
 
 
Caption: Summated risk scores were grouped into three categories (0 to 3, 4 to 6, 7 to 10) 
and the proportion of patients manifesting augmented renal clearance determined in each. 
Higher scores were strongly associated with a greater prevalence of augmented renal 
clearance (P <0.001). 
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Figure 5.5 Receiver Operating Characteristic (ROC) curve of CI (L/min/m2) and ARC 
Risk Score in Predicting ARC 
 
 
 
Caption: ROC curve of cardiac index, L/min/m2 (dashed line) and ARC risk score (solid 
line). Cardiac index demonstrates an AUC of 0.67 (95% CI 0.54 to 0.81, P = 0.013), 
whereas the ARC risk score has improved accuracy, with an AUC of 0.89 (95% CI 0.80 to 
0.97, P <0.001). A diagonal reference line (AUC = 0.5) is also provided. 
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5.5 Discussion 
 
This pilot investigation, in the context of a larger study examining beta-lactam antibacterial 
PK in the critically ill (203), has explored the relationship between CI and CLCR in a cohort 
of septic and traumatized patients with normal plasma CR concentrations. Overall, ARC 
was present in more than 50%, similar to a previous report in critically ill patients receiving 
anti-infective therapy (104). A greater prevalence of ARC was noted in those suffering 
multitrauma (85.7%). In univariate analysis, a statistically significant association between 
higher CI and ARC (P = 0.013) was observed, while in multivariate modelling, age (≤50 
years), diagnostic category (trauma) and modified SOFA score (≤4) were identified as 
significant risk factors for ARC. 
  
These findings principally suggest that the underlying disease process and physiological 
reserve, more than any specific cardiovascular parameter, are implicated in the 
development of ARC. This is highly clinically relevant, given the potential for significant 
sub-therapeutic drug exposure when employing 'standard' doses in such patients. 
Relevant examples include increased clinical failure (168) or drug resistance (131) with 
beta-lactam antibacterial therapy or sub-optimal venous thromboembolism prophylaxis in 
those receiving low molecular weight heparin (204). 
 
Multitrauma has already been identified as a significant risk factor for ARC (18, 88, 92) and 
this is further confirmed by our findings. The absence of any correlation between CI and 
CLCR in trauma is likely related to the higher CLCR measures observed in this group, the 
narrow range of recorded cardiac indices (see Figure 5.1) and the smaller sample size. 
Furthermore, recruitment of renal reserve (73), typically seen in states characterized by 
protein loading (205), may potentially augment glomerular filtration in this setting, 
independent of changes in CI.  
 
Importantly, the high prevalence of ARC observed in the trauma sub-group, despite the 
limited value of CI measurement as a discretionary variable, has considerable potential 
ramifications for both future study design (194) and daily prescribing practice. Specifically, 
this finding reminds the clinician that a 'one size fits all' approach to drug dosing in critical 
illness, is flawed and requires adjustment for a number of variables, least of which is 
diagnostic category. The recent poor results from clinical trials of emerging antibacterial 
agents in VAP (194) further illustrate this concept. Selecting a single dosing regimen for all 
 68 
study participants is unlikely to accommodate the range of clinical and physiological 
characteristics encountered.  
 
The lower prevalence of ARC (39.5%) and greater variability in CLCR and CI in the septic 
sub-group (Figure 5.1) reflects the heterogeneity of this syndrome and the wider spectrum 
of age and underlying co-morbid disease. Such variables significantly impact the available 
physiological reserve and, as such, the likelihood of manifesting augmented CL. This is 
evidenced by the strong overall association between ARC, lower modified SOFA scores 
and age, findings which are consistent with previous literature (59). Identification of 
additional drivers of ARC in septic patients is not possible with the current dataset, 
although this is likely to reflect the interaction between the innate inflammatory response 
and available organ reserve. 
 
Previous data examining the relationship between CI and renal solute elimination in critical 
illness are limited. Specifically, Brown et al. sequentially assessed CLCR in fifty relatively 
young critically ill post-operative trauma and non-trauma patients while simultaneously 
measuring CI via a pulmonary artery catheter (PAC) (84). After exclusion of those 
receiving inotropes or diuretics and those with sepsis or renal failure, a modest correlation 
was established between CI and CLCR (r = 0.63, P <0.01) (84). Our study extends these 
findings, with data distinct from a peri-operative setting and suggests a modest correlation 
between CI and CLCR in critically ill septic patients (r = 0.508, P = 0.001). 
 
The influence of common critical care interventions on cardiovascular and renal function 
remains to be accurately determined. Specifically, although improvements in CLCR 
following intravenous fluid administration (68, 201) and use of vasopressor agents (69, 70) 
have been noted in large animal models, we did not observe any statistically significant 
difference in either the requirement for vasopressors (P = 0.173) or 24-hour fluid balance 
(P = 0.237) in those manifesting ARC. Importantly, these data could be misleading, as 
they represent information obtained around the time of drug dosing only and, therefore, fail 
to consider any prior interventions. 
 
Minimally invasive pulse contour CO analysis was employed in this study primarily due to 
ease of application and decreasing use of PACs in routine clinical practice (206). Although 
mixed results have been reported in prior validation studies (207), particularly with the 
earlier software (208), later iterations have improved the accuracy of the device (209), with 
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an acceptable percentage error (207) and concordance rate (210) in comparison to PAC 
thermodilution. Aortic valve abnormalities are still likely to cause discrepancy (211) through 
distortion of the pulse contour, although they were not actively screened for in our 
analysis. Importantly, despite the growing use of pulse contour CO analysis in clinical 
practice, its use in general intensive care remains controversial (212) and must be 
recognized as a limiting factor in this analysis.  
 
Despite the perceived inaccuracies of any specific device(s), our findings indicate a 
potential new, unique, direction for minimally invasive CI monitoring in critically ill septic 
patients. The modest correlation observed between CI and CLCR, in addition to the ROC 
analysis, suggests that elevated values may be viewed as a clinical 'trigger' in patients 
without AKI, to re-consider the dosing strategy in use, particularly in relation to 
antibacterial therapy. While additional prospective studies utilizing drug PK data are 
urgently required, clinical trials examining the efficacy of new agents in this setting must be 
cognisant of these findings (194). Importantly, our data is limited temporally, such that we 
do not report changes in CI and CLCR during the ICU stay. As critical illness represents a 
highly dynamic state, ongoing CI measurement may be even more useful in tailoring drug 
prescription over time. 
 
We have not included specific drug PK data in these analyses for the following reasons: a) 
routine measurement of drug levels (beta-lactam or otherwise) is infrequent; b) CI and 
CLCR assessment are much more accessible in clinical practice; and c) CLCR (allowing 
identification of ARC) was the primary end-point of interest. In addition, ARC may influence 
drug handling for many different pharmaceuticals, as CLCR is recognized as a key PK 
covariate for renally eliminated agents (26, 198, 199). It is acknowledged that CLCR is not a 
'gold standard' measure of glomerular filtration (such as inulin CL), albeit tubular CR 
secretion is unlikely to influence the result at higher filtration rates (213). Two-hour urinary 
collections were employed, as prior research has reported acceptable accuracy compared 
with longer time-periods (43). The implications of the proposed ARC scoring system are 
also acknowledged, with the current findings being primarily speculative. Separate, large, 
multicentre validation studies are required, in order to establish its external validity, and 
assess any potential clinical utility. 
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5.6 Conclusions 
 
To our knowledge, this is the first study to correlate CI and CLCR in a range of critically ill 
patients, in addition to investigating the application of pulse contour CO monitoring as a 
means of identifying augmented renal solute elimination. Our findings suggest that 
diagnostic category, illness severity, age and organ function are likely to significantly 
influence the probability of developing ARC and should be more regularly considered in 
future study design and daily prescribing practice. Specifically, these factors may be useful 
in identifying patients at risk of altered drug handling in critical illness. While additional PK 
data are required, these results provide a robust basis on which to undertake larger clinical 
investigation, specifically focusing on the development of improved drug dosing algorithms 
in the critically ill. 
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Chapter 6 
 
ARC in the ICU: Results of a Multicentre Observational Study of Renal Function in 
Critically Ill Patients with Normal Plasma Creatinine Concentrations 
 
6.1 Chapter Overview 
 
This chapter presents the results from an international multicentre observational study of 
CLCR in recently admitted critically ill patients with normal plasma CR concentrations.  The 
overall prevalence of ARC is determined during the first seven days in ICU, in addition to 
providing data on temporal trends. 
 
Text, figures, and tables from the published manuscript (as outlined in Chapter 1) are 
reproduced here. The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
 
6.2 Introduction 
 
Accurate assessment of organ function in the critically ill remains uniquely challenging.  
Such patients routinely manifest an inflammatory response, which in combination with 
invasive interventions, results in physiology that is infrequently encountered in other 
settings (214).  Regular clinical examination and use of select biomarkers dominate 
modern critical care practice, being primarily employed to identify and monitor evolving 
organ dysfunction.  Enhanced or augmented organ performance is often of less concern, 
based on the premise that this is unlikely to lead to adverse outcomes.   
 
However, changes in renal function, and therefore drug handling can significantly distort 
the normal PK profile of many commonly prescribed agents (71, 198).  As a consequence, 
the clinician may adjust the dosing regime.  Usually, progressive AKI, often recognised by 
a rising plasma CR concentration, will impair the elimination of renally cleared agents, 
leading to drug accumulation.  Consequently dose reduction is generally appropriate to 
avoid drug toxicity. 
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The converse, dose escalation in the presence of augmented renal drug elimination, is 
infrequently reported in clinical practice (194).  This largely results from the lack of 
'visibility' of this phenomenon, due to the poor discrimination of plasma CR concentrations, 
when reported within the 'normal' reference range (12).  There is, however, increasing 
evidence supporting the presence of ARC in critically ill patients (215).  ARC is defined as 
the enhanced renal elimination of circulating solute (18).  Specifically, elevated CLCR, has 
been reported in burns (44), TBI (92), polytrauma (88), sepsis (61), VAP (101), and 
general intensive care practice (59, 84). 
 
While there is a paucity of specific data detailing renal drug CL in the critically ill, CLCR is a 
routinely used surrogate, representing a key covariate describing renal drug elimination 
(71).  Mathematical estimates of CLCR have been proposed, however these were 
principally designed for use in an ambulatory or ward-based setting, and are inaccurate in 
the critically ill (46, 200).  As such, a directly measured urinary CLCR is the most accurate 
and reproducible measure of renal function routinely available (54).   
 
Currently little data exists that describes the epidemiology of ARC, particularly in respect to 
its’ prevalence, and natural history.  The impact of ARC on drug PK is not only relevant for 
daily practice, but also the implementation and interpretation of clinical trials of new or 
emerging pharmaceuticals (194).  As such, there is significant uncertainty regarding the 
design of robust investigations that account for this phenomenon.  The aims of this 
multicentre prospective observational study were therefore to examine the prevalence and 
natural history of ARC in a cohort of critically ill patients with normal plasma CR 
concentrations, with a view to informing future clinical study and current prescribing 
practice. 
 
6.3 Materials and Methods 
 
6.3.1 Setting 
This multicentre observational study was undertaken in four, tertiary-level, university 
affiliated, ICUs in Australia, Singapore, Hong Kong and Portugal.  Ethical approval was 
obtained from the institutional review board of each participating site, with written informed 
consent obtained from either the patient or their nominated substitute decision-maker.  The 
lead site was the Royal Brisbane and Women’s Hospital, Australia, with ethical approval 
granted by the Human Research Ethics Committee (HREC/09/QRBW/192). 
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6.3.2 Study Population 
Study participants had to have an expected ICU LOS > 24 hours, no evidence of absolute 
renal impairment (admission plasma CR < 120 µmol/L), and no history of prior RRT or 
CKD.  Patients were excluded if: a) either invasive haemodynamic monitoring (principally 
an intra-arterial cannula) or an indwelling urinary catheter (IDC) were not employed as part 
of standard management; b) they were < 18 years of age; c) they were pregnant; d) 
rhabdomyolysis was clinically suspected or the admission plasma creatinine kinase was > 
5000 IU/L; or e) they were in the 'risk' category or greater for AKI, as defined by the RIFLE 
criteria (216).  Convenience sampling was employed at each participating site.  Patients 
undergoing an operative procedure within 24 hours prior to admission were classified as 
‘surgical’.  Planned post-operative admissions were considered ‘elective’.  
 
6.3.3 Interventions 
Demographic and outcome data, including age, gender, anthropometric measures, 
admission diagnosis, APACHE II scores, ICU and hospital LOS, and ICU mortality were 
recorded prospectively.  Modified (excluding the neurological and renal components) 
SOFA scores, physiological variables, ventilation parameters, 24-hour fluid balance, 
vasopressor / inotrope administration, diuretic use, and antibacterial administration were 
recorded daily.  Data collection commenced within 48 hours of ICU admission, and was 
discontinued at: a) ICU discharge; b) death; c) development of severe renal impairment 
(CLCR < 30ml/min/1.73m2); d) institution of RRT; e) removal of invasive monitoring or IDC; 
f) withdrawal of informed consent; or g) day 28, whichever came first. 
 
An 8-hour CLCR was the primary method of measuring renal function.  Urine was collected 
via the IDC between midnight and 0800hrs daily, following which urinary volume and CR 
concentration were determined by laboratory analysis.  Concurrent plasma CR 
concentrations were obtained, following which CLCR was calculated utilising the standard 
formula.  CR measurement in plasma and urine utilised automated analysers employing a 
modified Jaffe (alkaline picrate) technique, representing an IDMS traceable assay.    As 
per convention, CLCR values were subsequently normalised to a BSA of 1.73m2.  ARC was 
defined as an 8-hour CLCR ≥ 130ml/min/1.73m2, given the association with sub-therapeutic 
antibacterial concentrations, when using standard doses (199). 
 
 
 74 
6.3.4 Statistical Analysis 
Continuous data are presented as the mean (95% CI).  Where continuous data were non-
normal, a log transformation was applied; all summary statistics were calculated on the log 
scale, and back transformed for ease of interpretation. When a log transform was not 
appropriate, data are presented as median [IQR]. Categorical data are presented as 
counts (%).  Non-paired analysis of continuous data utilised an independent Students t-
test for two groups, or one-way ANOVA for multiple groups.  When data exhibited non-
normality and could not be transformed, a Mann-Whitney U or Kruskal-Wallis H test was 
used alternatively.  Paired comparisons employed a paired Students t-test.  Independent 
associations between categorical data were explored by Chi-square test or Fishers Exact 
test, where appropriate. To model changes in CLCR over time, a mixed-effects model with 
a random intercept and random slope was constructed.  These models are desirable in 
situations where data is missing not at random (due to patients being discharged from the 
ICU).   As there are limited baseline data concerning ARC in critical illness, no specific 
power analysis was possible.  Apriori a sample size > 250 patients was deemed sufficient 
for exploratory analysis.   No assumptions were made for missing data and proportions 
were adjusted for the number of patients with available data.  A two-sided P-value < 0.05 
was considered as statistical significance, and all analyses were performed using SPSS 
version 21 (IBM Corporation, Armonk, New York). 
 
6.4 Results 
 
6.4.1 Demographic Data 
During the study period, 932 patients were admitted to participating ICUs, of which 281 
patients were recruited into the study, contributing 1660 individual CLCR measures.  
Demographic, admission and illness severity data are presented in Table 6.1.  The cohort 
was relatively young (54.4 (52.5-56.4) years), with most requiring admission to ICU on an 
emergent basis, with or without an antecedent operation. Routine admissions were scarce 
(<10%).  Illness severity scores were moderately low, despite the non-elective nature of 
the cohort.  Data collection commenced on day 1 [1-2], with patients remaining in the ICU 
for a median of 4 [2-10] days.  As determined by protocol, admission plasma CR 
concentrations were within the ‘normal’ range (mean 72 (69-75) µmol/L). ICU mortality was 
8.5%. 
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Table 6.1 – Demographic, Admission, and Illness severity Data 
 
Variable  
Age, years, mean (95% CI) 54.4 (52.5-56.4) 
Gender, male, n (%) 178 (63.3) 
Weight, kg, mean (95% CI) 72.4 (70.1-74.6) 
Height, m, mean (95% CI) 1.66 (1.65-1.68) 
BMI, kg/m2, mean (95% CI) 26.0 (25.3-26.6) 
BSA, m2, mean (95% CI) 1.80 (1.77-1.83) 
APACHE II score, mean (95% CI) 16.0 (15.2-16.7) 
Modified SOFA score (max), median [IQR] 3 [2-6] 
Mechanical ventilation (at any point), n (%) 206 (73.8) 
Vasopressor / inotropes (at any point), n (%) 111 (39.5) 
Participating site, n (%) 
! Australia 
! Singapore 
! Hong Kong 
! Portugal 
 
116 (41.3) 
81 (28.8) 
59 (21.0) 
25 (8.9) 
Admission category, n (%) 
! Elective 
! Emergency 
! Surgical emergency 
! Trauma 
 
26 (9.3) 
93 (33.1) 
126 (44.8) 
36 (12.8) 
 
ICU Day of enrolment, median [IQR] 1 [1-2] 
Plasma CR concentration (Day 1), µmol/L, mean (95% CI) 72 (69-75) 
CR excretion rate, mg/kg/day, (Day 1), mean (95% CI) 19.2 (17.8-20.5) 
CLCR, ml/min/1.73m2 (Day 1), mean (95% CI) 108 (102-115) 
ICU length of stay, days, median [IQR] 4 [2-10] 
ICU Mortality, n (%) 24 (8.5) 
 
APACHE – acute physiology and chronic health evaluation, BMI – body mass index, BSA 
– body surface area, CLCR – creatinine clearance, CI – confidence interval, CR – 
creatinine, ICU – intensive care unit, IQR – interquartile range, SOFA – sequential organ 
failure assessment 
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6.4.2 Prevalence of ARC 
Overall, 65.1% (n=183) of the cohort manifested ARC on at-least one occasion during the 
first seven study days.  On study day 1, ARC was evident in 108 patients (prevalence = 
38.4%), with the majority of new cases occurring on study day 2 (n=41), and day 3 (n=13).  
The number of evaluable patients fell to 231 on study day 2, with the prevalence of ARC 
increasing to 49.4% (n=114).  Of the fifty patients not completing a second CLCR, 64% 
(n=32) did not manifest ARC.  Figure 6.1 demonstrates the prevalence of ARC, as a 
fraction of the patients remaining in the study, through to day 7.  From day 2, the 
prevalence of ARC remained relatively constant (~50%) with the highest prevalence 
(54.5%, n=67) recorded on study day 5.  43.4% of patients remaining in the ICU, who did 
not manifest ARC on day 1, went on to do so at least once in the subsequent six days.  
34.9% of patients never displayed ARC on any CLCR measure in the first seven days.  Of 
those patients manifesting ARC, the majority (74%) did so on ≥ 50% of their CLCR 
measures. 
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Figure 6.1 Daily Prevalence of ARC to Study Day 7 
 
 
 
Caption: Percentage of patients with ARC (solid bars), compared to no ARC (open bars), 
on each study day.  The total number (n) of patients remaining in the study, and those 
manifesting ARC are provided 
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6.4.3 Characteristics of patients displaying ARC 
Comparison of admission, demographic, and illness severity data between groups (ARC 
vs no ARC) are presented in Table 6.2.  Differences in physiological and treatment 
variables on study days 1, 4, and 7 are provided in Appendix A (Supplemental Digital 
Content).  Patients manifesting ARC (at any point in the first seven study days) tended to 
be younger, male, multitrauma victims, receiving mechanical ventilation.  On study day 1, 
the absence of ARC was associated with higher modified SOFA scores (P=0.007), the 
application of vasopressor or inotropic support (P=0.015), and a lower 24-hr urine output 
(P=0.004).   Frusemide use was more common in those not manifesting ARC.  Differences 
in the minimum mean arterial pressure (study day 1), and body temperatures (study day 4) 
were also observed, although these deviations are unlikely to be clinically meaningful.  No 
difference was observed in the provision of enteral nutrition between groups.  Significantly 
lower plasma CR concentrations (P<0.01), and high CR excretion rates (P<0.001) were 
consistently noted in those manifesting ARC (Appendix A, Supplemental Digital Content).   
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Table 6.2 Demographic, Therapeutic, and Illness severity Data in Those With and 
Without ARC at Any Time During the First Seven Study Days 
 
Variable ARC (n=183) No ARC (n=98) P-value 
Age, years, mean (95% CI) 49.1 (46.8-51.4) 64.4 (61.6-67.2) <0.001 
Gender, Male, n (%) 124 (67.8) 54 (55.1) 0.036 
Weight, kg, mean (95% CI) 73.3 (70.6-76.0) 70.6 (66.6-74.7) 0.266 
Height, m, mean (95% CI) 1.67 (1.66-1.69) 1.65 (1.63-1.67) 0.077 
BMI, kg/m2, mean (95% CI) 26.0 (25.3-26.8) 25.8 (24.5-27.1) 0.750 
BSA, m2, mean (95% CI) 1.82 (1.78-1.85) 1.77 (1.72-1.81) 0.106 
APACHE II, mean (95% CI) 15.7 (14.7-16.6) 16.6 (15.3-17.8) 0.265 
Modified SOFA score (max), median [IQR] 3 [2-6] 3 [2-6] 0.711 
Mechanical ventilation (at any point), n (%) 150 (82.4) 56 (57.7) <0.001 
Vasopressor / inotropes (at any point), n (%) 76 (41.5) 35 (35.7) 0.342 
Norepinephrine (at any point), n (%) 66 (36.1) 30 (30.6) 0.358 
Dopamine (at any point), n (%) 14 (7.7) 5 (5.1) 0.417 
Admission category, n (%) 
! Elective 
! Emergency 
! Surgical Emergency 
! Trauma 
 
13 (7.1) 
54 (29.5) 
86 (47.0) 
30 (16.4) 
 
13 (13.3) 
39 (39.8) 
40 (40.8) 
6 (6.1) 
 
0.089 
0.081 
0.321 
0.014 
ICU length of stay, days, median [IQR] 5 [3-11] 3 [2-6] <0.001 
ICU mortality, n (%) 14 (7.7) 10 (10.2) 0.465 
 
APACHE – acute physiology and chronic health evaluation, ARC – augmented renal 
clearance, BMI – body mass index, BSA – body surface area, CI – confidence interval, 
ICU – intensive care unit, IQR – interquartile range, SOFA – sequential organ failure 
assessment  
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6.4.4 Natural history of ARC & Comparison between admission types 
Figure 6.2 displays mean CLCR as a function of admission type to study day 7.  In the 
overall cohort, a significant rise is noted on study day 2 (Day 2 - 121 (113-129), Day 1 - 
108 (102-115) ml/min/1.73m2, P=0.001).  Significant differences in demographics, 
anthropometric measures, illness severity, and interventions exist between diagnostic 
groups (Table 6.3).  In addition, CLCR varies both between, and within the groups.  Of note, 
CLCR on study day 2 rises significantly in trauma (P=0.013) and surgical emergency 
admissions (P=0.015), although no significant difference was identified in elective cases 
(P=0.916) or emergency admissions (P=0.121).  Sustained increases in CLCR appear to 
occur in trauma victims and surgical emergency admissions primarily (Figure 6.2). 
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Figure 6.2 Daily CLCR Measures by Admission Type to Study Day 7 
 
 
 
Caption: Mean CLCR in elective ( ), emergency ( ), surgical emergency ( ), and trauma  
( ) patients to study day 7.  The dashed line represents the cut-off for ARC 
(130ml/min/1.73m2).   The number of patients of each admission type remaining in the 
study per day is provided. 
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Table 6.3 Comparison of Demographics, Anthropometric Measures, Illness severity, and Interventions Between Admission 
Types 
 
Variable Elective Emergency Surgical Emergency Trauma P-value 
Age, years, mean (95% CI) 58.5 (53.8-63.3) 56.3 (53.0-59.6) 56.2 (53.4-59.0) 40.7 (34.5-46.9) <0.001 
Gender, Male, n (%) 15 (57.7) 50 (53.8) 79 (62.7) 34 (94.4) <0.001 
Weight, kg, mean (95% CI) 73.7 (68.3-79.1) 72.7 (67.8-77.6) 69.8 (67.2-72.4) 79.5 (72.7-86.2) 0.059 
Height, m, mean (95% CI) 1.68 (1.64-1.72) 1.65 (1.63-1.67) 1.66 (1.64-1.67) 1.72 (1.69-1.75) 0.001 
BMI, kg/m2, mean (95% CI) 26.1 (24.4-27.8) 26.5 (25.0-28.0) 25.3 (24.5-26.1) 26.8 (24.7-28.9) 0.344 
BSA, m2, mean (95% CI) 1.83 (1.76-1.90) 1.78 (1.73-1.84) 1.77 (1.73-1.81) 1.92 (1.84-1.99) 0.008 
APACHE II, mean (95% CI) 13.4 (11.4-15.4) 17.0 (15.6-18.4) 16.3 (15.2-17.4) 14.2 (12.2-16.1) 0.017 
Modified SOFA score (max), median [IQR] 3 [1.5-5.5] 4 [2-6] 3 [2-5] 4 [3-6] 0.014 
Vasopressor / inotrope (at any point), n (%) 7 (26.9) 46 (49.5) 45 (35.7) 13 (36.1) 0.089 
Mechanical ventilation (at any point), n (%) 7 (26.9) 72 (78.3) 99 (78.6) 28 (80.0) <0.001 
ICU length of stay, days, median [IQR] 3.5 [2-4.5] 4 [3-12] 5 [2-9] 4.5 [2-11.5] 0.239 
 
APACHE – acute physiology and chronic health evaluation, BMI – body mass index, BSA – body surface area, CI – confidence 
interval, CLCR – creatinine clearance, IQR – interquartile range, SOFA – sequential organ failure assessment 
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Variations in CLCR as a function of ARC status on study day 1, are presented in Figure 6.3.  
Significant differences exist between groups on each study day, although greater within 
group variability is noted in those without ARC initially.  Specifically, a significant increase 
in CLCR is noted on study day 2 in those not previously manifesting ARC (P<0.001), which 
is not the case in those with documented augmented CL already.  However, the presence 
of ARC initially is associated with a sustained elevation of CLCR, over the first seven study 
days (Figure 6.3).   
 
A mixed-effects model was generated to account for variable ICU LOS.  Modelling 
occurred from study day 2, in order to mitigate the influence of factors outside ICU.  
Significant covariates included; hospital location, age, ARC status on day 1, daily modified 
SOFA scores, and frusemide administration.  Vasopressor use was not included given the 
strong correlation with modified SOFA scores, while gender, mechanical ventilation, 24-hr 
fluid balance and admission type were not predictive of daily CLCR. As illustrated (Figure 
6.3), ARC status on stay day 1 significantly predicts CLCR from day 2 to day 7, with values 
being markedly lower in those without ARC initially (P=0.019).  Changes in modified daily 
SOFA scores are only significant in those without ARC, whereby increasing scores 
promote lower CLCR values (P<0.001).  Age was highly significant, with patients’ ≥ 65 
years having log CRCL values on average 0.46 units lower than those < 40 years 
(P<0.001).  Hospital location was included as an adjusting variable in order to account for 
differences in case-mix.  Of note, frusemide administration was associated with lower 
CLCR values (P<0.001). 
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Figure 6.3 Mixed Effects Model Comparing Those With and Without ARC on Study 
Day 1 
 
 
 
Caption: Mean CLCR (grey lines), and results from the model (black lines).  The solid lines 
represent those without ARC on study day 1, and the dotted lines, those with ARC on 
study day 1. 
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6.5 Discussion 
 
This paper reports the findings of a multicentre observational study examining the 
frequency of ARC in critically ill patients with normal plasma renal indices on admission.  
Major observations include a high prevalence overall, with ~65% of patients manifesting 
ARC on at least one occasion in the first seven study days.  ARC on day 1 is also strongly 
associated with higher clearances over the subsequent six days, a finding that is not 
simply related to ongoing fluid loading.  Although plasma CR concentrations were 
consistently lower in those manifesting ARC, the sustained elevation in CLCR and CR 
excretion rates, and the lack of any significant difference in 24-hour fluid balance, strongly 
supports this assertion. 
 
These data suggest that a significant proportion of patients will manifest sustained 
augmented renal solute elimination over the first week in ICU, a consideration not 
immediately obvious to the clinician or prescriber.  Importantly, ARC will significantly 
impact drug PK for a variety of renally eliminated pharmaceuticals (such as low molecular 
weight heparins, aminoglycosides, glycopeptides, and beta-lactams (198)), leading to sub-
therapeutic concentrations and potentially adverse clinical outcomes (104, 168, 204). 
 
Brown et al. reported similar data in their work examining CR, osmolar, and free water CL 
in fifty critically ill post-operative patients (84).  In those patients admitted to the surgical 
ICU with trauma, CLCR values were elevated on day 1 (mean 140ml/min/1.73m2), peaked 
on day 4 (mean 190ml/min/1.73m2), and returned to initial levels by day 7.  A strong 
inverse relationship was also demonstrated between age and CLCR, as measured on the 
second post-operative day (84).   Similar observations have been reported in more 
contemporary research (59, 88, 92, 215), while the present study confirms these findings 
in a larger, multicentre dataset.  
 
The mechanisms driving such variation in renal function in the critically ill remain poorly 
understood.  Increased major organ blood flow has been demonstrated in large animal 
models of gram-negative sepsis (63), similar to changes observed in human pregnancy 
(65), which may promote enhanced renal solute elimination.  Recent clinical investigation 
however has demonstrated at best, only a weak correlation between pulse contour derived 
CI and CLCR in critical illness (215).  Of note, the high prevalence of ARC in this patient 
group suggests this might represent the ‘expected’ response to systemic inflammation, as 
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an indicator of accessible physiological reserve.  Whether the absence of ARC can be 
used as a useful diagnostic or prognostic indicator represents an important area for future 
clinical investigation.    
 
The true biological influence of trauma and surgery in the pathogenesis of ARC remains 
uncertain, given the confounding influence of age (217).  Specifically, age was identified as 
the most significant covariate in predicting the development of ARC in mixed-effects 
modeling, suggesting that the high prevalence in trauma, may simply be a reflection of the 
underlying demographic.  As illustrated, the trauma sub-group was almost exclusively 
young men, with greater body size, who were frequently ventilated.  As such, systemic 
inflammation coupled with a greater physiological reserve may account for the higher 
clearances observed, rather than any unique mechanism.  While an increase in glomerular 
filtration in response to protein loading may also be implicated (73, 205), no difference in 
the provision of enteral nutrition was noted between patients with and without ARC.   
 
Of note is the significant increase in CLCR between day 1 and 2, which appears to drive 
some of the with-in subject variability, particularly in those not manifesting ARC initially.  
Interpreting this finding is complex, given the number of patients not completing a second 
CLCR, and the potential impact of pre-ICU care.  Relatively poor renal function despite 
normal plasma CR concentrations on admission to the ICU has been previously reported 
(39), and may suggest the presence of ‘occult’ AKI, in parallel with a greater disease 
burden.   This is reflected in the higher modified SOFA scores, greater vasopressor 
requirements, and lower urine outputs in patients without ARC on day 1.  In those 
remaining in the study, renal function appears to improve, possibly associated with ICU 
intervention, or disease evolution.   
 
Identifying a specific pattern of intra-patient variation, particularly in relation to ICU 
intervention, remains complex.  Vasopressor administration increases RBF and glomerular 
filtration in large animal models (218), although the relationship in critical illness is much 
more dynamic.  The inverse association between vasopressor administration and CLCR on 
day 1 illustrates this.  Of interest, the majority of participants received norepinephrine, such 
that exploring the influence of differing vasoactive agents is limited in the current dataset.  
The true clinical significance of mechanical ventilation is also uncertain, and likely reflects 
the ubiquitous nature of this intervention and longer LOS in ARC patients.  The association 
between frusemide administration and lower CLCR is also unclear; although this may 
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represent clinician directed diuretic therapy in the context of worsening azotaemia, or 
overly aggressive attempts at fluid diuresis. 
   
6.6 Limitations 
 
In order to maximize data efficiency, a mixed effects model was generated to infer results, 
despite participants contributing an unequal number of CLCR measures.  This represents a 
well-recognized statistical technique uniquely suited to dealing with missing information, 
and strengthens the overall study findings.  Four separate institutions contributed data, 
significantly improving the generalizability and external validity of our findings.  We 
recognize however that the prevalence of ARC will vary significantly with case-mix, and in 
this manner, assessment of CLCR in individual institutions is highly recommended.   
 
8-hour collections were employed as the primary outcome measure, as prior research has 
suggested this time-period provides the best balance between feasibility and accuracy 
(45).  In addition, the observed CR excretion rates are within the range reported for the 
general populous (219).  We acknowledge that CLCR is not a ‘gold standard’ measure of 
glomerular filtration (such as inulin CL), although tubular CR secretion is unlikely to 
confound the results at higher filtration rates (213).  Of note, we have not collected data on 
patient ethnicity, which represents an unexplored variable in this analysis.   
 
The prevalence of ARC reported is consistent with recent data (104), although the 
exclusion of patients unlikely to remain in the ICU for > 24hrs, and those with established 
or evolving AKI, has resulted in a select study population.  This is reflected in the moderate 
overall APACHE II score and ICU mortality, although the majority of patients were 
mechanically ventilated, and ~40% received vasopressor or inotrope therapy.  As such, 
although the prevalence of ARC may be lower in the wider ICU population, this analysis 
provides a unique longitudinal view of CLCR in a significant fraction of critically ill patients.   
We do not report on specific PK end-points, therapeutic outcomes, or antibiotic resistance 
patterns, as such data were beyond the aims of this study.  In addition, while ARC was 
associated with a longer ICU LOS, it should be recognized that this study was not 
designed to assess any specific clinical outcomes. 
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6.7 Conclusions  
 
The findings from this prospective, multicentre, observational study suggest a substantial 
group of patients that will manifest significantly elevated renal solute elimination over the 
first seven days in ICU, not overtly obvious to the clinician.  In addition, the observation of 
relatively low CLCR in some patients reinforces the concept that an assessment of ‘renal 
function’, as opposed to simply identifying ‘kidney injury’, is necessary.  Recognition of 
patients at risk of ARC allows the targeted use of CLCR measurement (not routine in most 
units), to monitor changes in renal function. Future studies should focus on expanding 
current knowledge regarding the implications for accurate dosing of renally eliminated 
pharmaceuticals in patients with ARC.  In addition, given the high prevalence of ARC in 
this study (65.1%), further investigation to assess the potential impact on individual clinical 
outcomes is warranted. 
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Chapter 7 
 
A Comparison of CKD-EPI Estimated Glomerular Filtration Rate and Measured CLCR 
in Recently Admitted Critically Ill Patients with Normal Plasma Creatinine 
Concentrations 
 
7.1 Chapter Overview 
 
This chapter explores the utility of mathematical estimates of glomerular filtration to 
accurately reflect measured CLCR in recently admitted critically ill patients with normal 
plasma CR concentrations.  Bias and precision are determined in the context of previously 
discussed ARC thresholds. 
 
Text, figures, and tables from the published manuscript (as outlined in Chapter 1) are 
reproduced here. The layout has been adjusted to fit the overall style of the thesis.  The 
references are found alongside those for the other chapters, at the conclusion of the main 
body. 
 
7.2 Background 
 
Accurate assessment of renal function is a priority in the management of critically ill 
patients. Clinicians regularly utilize such information to help guide drug dosing, optimize 
fluid, acid–base, and electrolyte management, tailor nutritional requirements, and assess 
the need for RRT. Rising plasma CR concentrations often trigger clinical interventions, 
including dose reduction of renally eliminated agents. In contrast, plasma CR 
concentrations within the reported reference range appear to be less useful. Normal 
values in the critically ill have been associated with both augmented CLCR (215), and 
occult AKI (39). 
 
Driven primarily by a desire to more effectively monitor and screen for CKD, formulae 
using simple demographic variables have been developed to estimate the glomerular 
filtration rate (eGFR). The most commonly applied include the MDRD (41), and newer 
CKD-EPI (42) equations. Their application is based principally on large cohort studies that 
effectively stratify patients in terms of long-term clinical risk (220, 221). This has led to 
recommendations for widespread laboratory reporting of eGFR (222, 223). 
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While these initiatives represent key developments in improving the quality of care for 
patients with CKD, some clinicians have expressed concern about the ubiquitous 
application of eGFR, particularly in dose modification (224). Use of formulae to help guide 
drug dosing represents an attractive approach, although an ability to trigger both dose 
reduction and escalation is required. Currently there is a paucity of data examining 
whether eGFR could be used in place of conventional measures for such a purpose, 
particularly in the critical care environment. The aim of this study was therefore to compare 
CKD-EPI eGFR with measured urinary CLCR, in a cohort of recently admitted critically ill 
patients with normal plasma CR concentrations. 
 
7.3 Methods 
 
7.3.1 Setting 
This study was performed in a tertiary level, university affiliated, metropolitan ICU, over a 
two-month period. Enrolment utilized convenience sampling. Ethical approval was 
obtained from the institutional Human Research Ethics Committee (HREC/09/QRBW/192), 
with written informed consent obtained from either the patient or their nominated substitute 
decision-maker. 
 
7.3.2 Study population 
Study participants had to have an anticipated ICU LOS > 24 hours, a plasma CR 
concentration < 121 µmol/L, and no history of prior RRT or CKD. Patients were excluded 
if: a) either invasive haemodynamic monitoring or an IDC were not employed as part of 
standard management; b) they were < 18 years of age; c) they were pregnant; d) 
rhabomyolysis was clinically suspected or the admission plasma creatinine kinase was > 
5000 IU/L; or e) they were in the ‘risk’ category or greater for AKI, as defined by the RIFLE 
criteria (216). Patients undergoing an operative procedure within 24 hours prior to 
admission were classified as ‘surgical’. Planned post-operative admissions were 
considered ‘elective’. 
 
7.3.3 Interventions 
Demographic and illness severity characteristics, including; age, gender, anthropometric 
measures, diagnosis, and APACHE II scores were recorded on admission. Modified 
(excluding the neurological component) SOFA scores, ventilation parameters, 24-hour 
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fluid balance, vasopressor administration, and diuretic use, were recorded prospectively at 
the time of CLCR assessment. ICU and hospital LOS, and ICU mortality were determined 
for all patients. Data capture occurred within 48 hours of admission to the ICU, as 
determined by staff availability and admission time. 
 
An 8-hour measured CLCR was obtained using the following method. Urine was collected 
via the IDC between midnight and 0800 hrs, following which urinary volume and CR 
concentration were determined by laboratory analysis. Concurrent plasma CR 
concentrations were obtained at a point mid-way through the urinary collection, following 
which CLCR was calculated using the formula listed below. CR measurement in plasma 
and urine utilised automated analysers employing a modified Jaffe (alkaline picrate) 
technique, representing an isotope dilution mass spectrometry (IDMS) traceable assay. 
 
As per convention, CLCR values were normalised to a BSA of 1.73 m2. The abbreviated 
175 MDRD (175 eGFR), CKD-EPI (CKD-EPI eGFR), and CG CLCR equations were used 
to calculate estimates for comparison, as outlined below. ARC was defined as a measured 
8-hr CLCR ≥ 130 ml/min/1.73 m2, given the association with sub-therapeutic drug 
concentrations, when using standard doses of renally eliminated antibiotics (199, 225). 
 
7.3.4 List of Equations Employed 
BSA = 0.007184 × (Ht) 0.725 × (Wt) 0.425 
CLCR = (UCR × UVol/PCR × 480) × 1.73/BSA 
CG CLCR = [(140 – age) × Wt × (1.23 if male, 1.04 if female)]/PCR × 1.73/BSA 
175 eGFR = 175 × (PCR × 0.0113) -1.154 × age -0.203 (× 0.742 if female) 
CKD-EPI eGFR 
Females, PCR ≤ 62 = 144 × (PCR × 0.0113/0.7) -0.329 × 0.993 age 
Females, PCR > 62 =144 × (PCR × 0.0113/0.7) -1.209 × 0.993 age 
Males, PCR ≤ 80 = 141 × (PCR × 0.0113/0.9) -0.411 × 0.993 age 
Males, PCR > 80 =141 × (PCR × 0.0113/0.9)-1.209 × 0.993 age 
 
Where CLCR = 8-hr Creatinine Clearance (ml/min/1.73 m2), UCR = Urinary Creatinine 
Concentration (µmol/L), UVol = Urinary volume (ml), PCR = Plasma Creatinine 
Concentration (µmol/L), BSA = Body Surface Area (m2), Ht = Height (cm), Wt = Weight 
(kg), CG CLCR = Cockcroft-Gault Creatinine Clearance (ml/min/1.73 m2), 175 eGFR = 
Abbreviated Modification of Diet in Renal Disease 175 formula (ml/min/1.73 m2), and CKD-
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EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration Equation (ml/min/1.73 
m2), age (in years). 
 
7.3.5 Statistical analysis 
Continuous data are presented as the mean (SD) or median [IQR] depending on 
adherence to a normal distribution. Normality was assessed by visual inspection, and a 
one-sample Kolmogorov-Smirnov test. Categorical data are presented as counts (%). 
Correlations were assessed using a Pearson correlation coefficient (r). Precision and bias 
were examined using a Bland-Altman plot, with the bias representing the mean difference 
between each variable, and precision being one SD from the mean. Comparison of 
continuous data utilized a paired Students T-test. A two-sided P-value < 0.05 was 
considered as statistical significance, and all analyses were performed using SPSS 
version 21 (IBM Corporation, Armonk, New York) and PRISM version 5 (GraphPad 
Software Inc, La Jolla, California). 
 
7.4 Results 
 
One hundred and ten patients (n = 110) were included in the study, with all participants 
completing an 8-hr CLCR. Demographic, admission, illness severity and outcome data are 
presented in Table 7.1. As illustrated, approximately two-thirds of the cohort was male, the 
patients were relatively young (50.9 (16.9) years), greater than 50% received invasive 
mechanical ventilation, and about one-third required vasopressor support. Less than 15% 
were elective cases, with the majority manifesting systemic inflammation, with or without 
undergoing prior surgery. As per protocol, plasma CR concentrations were within the 
normal reference range (68.5 (21.8) µmol/L), and did not change significantly in the 
following 24 hrs (P = 0.157), where data were available. The mean 8-hr CLCR was 125 
(45.1) ml/min/1.73 m2, 48.2% (n = 53) manifested ARC, and 10 (9.1%) had a CLCR < 60 
ml/min/1.73 m2. 
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Table 7.1 Demographic, Illness severity and Treatment Data 
 
Variable N = 110 
Age, years, mean (SD) 50.9 (16.9) 
Gender, male/female, n (%) 70 (63.6)/40 (36.4) 
Height, m, mean (SD) 1.71 (0.09) 
Weight, kg, mean (SD) 80.9 (22.4) 
Body surface area, m2, mean (SD) 1.92 (0.24) 
APACHE II, mean (SD) 16.1 (6.20) 
Modified SOFA, median [IQR] 3 [2-5] 
Admission type, n (%)  
 - Elective 15 (13.6) 
 - Emergency 33 (30.0) 
 - Surgical Emergency 37 (33.6) 
 - Trauma 25 (22.7) 
Mechanical ventilation, n (%) (n = 108) 63 (57.3) 
Intravenous Contrast administration, n (%) (n = 109) 30 (27.3) 
Frusemide administration, n (%) 13 (11.8) 
Mannitol administration, n (%) 4 (3.6) 
Vasopressors, n (%) 33 (30.0) 
Systemic Inflammatory Response Syndrome, n (%) 95 (86.4) 
Plasma CR concentration, µmol/L, mean (SD) 68.5 (21.8) 
Plasma CR concentration + 24 hrs, µmol/L, mean (SD) (n = 80) 63.0 (19.6) 
ICU length of stay, days, median [IQR] 4 [2-10] 
ICU mortality, n (%) 11 (10) 
 
APACHE-Acute physiology and chronic health evaluation, ICU-Intensive care unit, SOFA-
sequential organ failure assessment. 
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A comparison of measured 8-hr CLCR and 175 eGFR, CG CLCR, and CKD-EPI eGFR in all 
patients, and each diagnostic category separately, are presented in Table 7.2. Scatter 
graphs using all data points are provided in Figure 7.1. Equivalent Bland-Altman plots are 
presented in Figure 7.2. Across all groups, the observed bias is greatest with the CKD-EPI 
equation. A significant proportional error is also apparent, with higher average values 
significantly correlated with a larger positive bias (Figure 2C, r = 0.705, P < 0.001). This 
was not evident with either the 175 eGFR (r = 0.102, P = 0.289), or CG CLCR (r = 0.103, P 
= 0.285) formulae. 
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Table 7.2 Comparison, Correlation, Bias and Precision Between Measured 8-hr CLCR 
and Mathematical Estimates in All Patients, and Each Diagnostic Sub-group 
 
 Mean (SD) r (P-value) Bias +/− precision 
All Patients (n = 110) 
CLCR, ml/min/1.73 m2 125 (45.1)   
175 eGFR, ml/min/1.73 m2 110 (41.6)* 0.600 (<0.001) 15.6 +/− 38.9 
CG CLCR, ml/min/1.73 m2 119 (41.7) 0.638 (<0.001) 6.23 +/− 37.1 
CKD-EPI eGFR, ml/min/1.73 m2 101 (23.7)* 0.720 (<0.001) 24.4 +/− 32.5 
Elective Admissions (n = 15) 
CLCR, ml/min/1.73 m2 118 (27.2)   
175 eGFR, ml/min/1.73 m2 115 (51.2) 0.325 (0.237) 2.77 +/− 49.5 
CG CLCR, ml/min/1.73 m2 119 (44.1) 0.531 (0.042) −1.04 +/− 37.5 
CKD-EPI eGFR, ml/min/1.73 m2 101 (20.0)** 0.488 (0.065) 17.2 +/− 24.7 
Emergency Admission (n = 33) 
CLCR, ml/min/1.73 m2 113 (50.0)   
175 eGFR, ml/min/1.73 m2 114 (47.9) 0.624 (<0.001) −0.77 +/− 42.5 
CG CLCR, ml/min/1.73 m2 123 (49.1) 0.599 (<0.001) −10.4 +/− 44.3 
CKD-EPI eGFR, ml/min/1.73 m2 99 (27.6)** 0.692 (<0.001) 13.8 +/− 36.8 
Surgical Emergency Admission (n = 37) 
CLCR, ml/min/1.73 m2 125 (46.4)   
175 eGFR, ml/min/1.73 m2 101 (37.2)* 0.741 (<0.001) 23.7 +/− 31.3 
CG CLCR, ml/min/1.73 m2 108 (37.5)** 0.753 (<0.001) 16.4 +/− 30.6 
CKD-EPI eGFR, ml/min/1.73 m2 95 (23.7)* 0.779 (<0.001) 29.5 +/− 31.6 
Trauma Admission (n = 25) 
CLCR, ml/min/1.73 m2 146 (39.5)   
175 eGFR, ml/min/1.73 m2 114 (32.0)* 0.745 (<0.001) 32.7 +/− 26.5 
CG CLCR, ml/min/1.73 m2 129 (33.8)** 0.757 (<0.001) 17.4 +/− 26.1 
CKD-EPI eGFR, ml/min/1.73 m2 111 (17.4)* 0.772 (<0.001) 35.2 +/− 28.4 
 
* P < 0.001, when compared to CLCR ** P < 0.05, when compared to CLCR. 
CLCR = 8-hr Creatinine Clearance, CG CLCR = Cockcroft-Gault Creatinine Clearance, 175 
eGFR = Abbreviated Modification of Diet in Renal Disease 175 formula, CKD-EPI eGFR = 
Chronic Kidney Disease Epidemiology Collaboration Equation, r = Pearson correlation 
coefficient. 
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Figure 7.1 Scatter Graphs of CLCR Versus Mathematical Estimates in All Patients 
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Caption: CLCR on the x-axis compared with 175 eGFR (panel A), CG CLCR (panel B), and 
CKD-EPI eGFR (panel C), on the y-axis. CLCR = 8-hr Creatinine Clearance, 175 eGFR = 
Abbreviated Modification of Diet in Renal Disease 175 formula, CG CLCR = Cockcroft-
Gault Creatinine Clearance, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology 
Collaboration Equation 
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Figure 7.2 Bland-Altman Plots of CLCR Versus Mathematical Estimates in All Patients 
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Caption: Comparison of the difference between CLCR and 175 eGFR (panel A), CG CLCR 
(panel B), and CKD-EPI eGFR (panel C) on the y-axis, versus the average value obtained 
on the x-axis. CLCR = 8-hr Creatinine Clearance, 175 eGFR = Abbreviated Modification of 
Diet in Renal Disease 175 formula, CG CLCR = Cockcroft-Gault Creatinine Clearance, 
CKD-EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration Equation.  
 98 
8-hr CLCR values were used to categorize patients into four groups; < 90, 90–119, 120–
149, and ≥ 150 ml/min/1.73 m2. Comparisons with each mathematical estimate are 
presented in Table 7.3 and Figure 7.3. As illustrated, CKD-EPI eGFR was generally higher 
than CLCR in the lower range (< 90 ml/min/1.73 m2), although the opposite was observed 
at higher values. Correlation was generally poor in each group (Table 7.3). In those 
patients with a calculated CKD-EPI eGFR between 60–119 ml/min/1.73 m2 (n = 77), 8-hr 
CLCR values were significantly higher (118 (38.3) vs 96 (16.6) ml/min/1.73 m2, P < 0.001), 
41.6% (n = 32) displayed ARC, and 7.8% (n = 6) had a CLCR < 60 ml/min/1.73 m2. 
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Table 7.3 Correlation, Bias and Precision Across Different Ranges of CLCR 
 
 r (P-value) Bias +/− precision (ml/min/1.73 m2) 
CLCR < 90 ml/min/1.73 m2 (n = 28) 
175 eGFR 0.223 (0.253) −12.6 +/− 35.2 
CG CLCR 0.278 (0.152) −15.9 +/− 37.2 
CKD-EPI eGFR 0.351 (0.067) −11.1 +/− 23.2 
CLCR 90–119 ml/min/1.73 m2 (n = 23) 
175 eGFR 0.065 (0.767) 10.5 +/− 44.4 
CG CLCR 0.066 (0.763) −0.93 +/− 43.9 
CKD-EPI eGFR −0.067 (0.760) 14.8 +/− 22.8 
CLCR 120–149 ml/min/1.73 m2 (n = 23) 
175 eGFR 0.047 (0.832) 22.7 +/− 26.1 
CG CLCR 0.369 (0.083) 6.62 +/− 23.9 
CKD-EPI eGFR 0.347 (0.104) 29.2 +/− 10.8 
CLCR ≥ 150 ml/min/1.73 m2 (n = 36) 
175 eGFR 0.427 (0.009) 36.1 +/− 31.3 
CG CLCR 0.399 (0.016) 27.8 +/− 27.2 
CKD-EPI eGFR 0.460 (0.005) 55.0 +/− 20.9 
 
CLCR = 8-hr Creatinine Clearance, CG CLCR = Cockcroft-Gault Creatinine Clearance, 175 
eGFR = Abbreviated Modification of Diet in Renal Disease 175 formula, CKD-EPI eGFR = 
Chronic Kidney Disease Epidemiology Collaboration Equation, r = Pearson correlation 
coefficient. 
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Figure 7.3 Comparison of CLCR with Mathematical Estimates Over Different Ranges 
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Caption: CLCR compared with 175 eGFR, CG CLCR, and CKD-EPI eGFR over different 
ranges. CLCR < 90 (open), 90–119 (solid), 120–149 (lines), and ≥ 150 (dots) ml/min/1.73 
m2. * P < 0.05, ** P < 0.001. CLCR = 8-hr Creatinine Clearance, 175 eGFR = Abbreviated 
Modification of Diet in Renal Disease 175 formula, CG CLCR = Cockcroft-Gault Creatinine 
Clearance, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration 
Equation. 
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7.5 Discussion 
 
To our knowledge, this is the first report of CKD-EPI eGFR performance in a cohort of 
Australian patients recently admitted to the ICU. These data demonstrate significant 
disparity between CKD-EPI eGFR and measured CLCR in patients with normal plasma CR 
concentrations. Despite an overall reasonable correlation, bias and precision were 
unacceptable across a range of values. This highlights that clinicians must carefully 
consider which estimate of renal function they use in clinical decision-making, as these 
may be very dissimilar. A modest fraction of study participants displayed CLCR measures 
significantly higher than might be expected, a finding that requires further evaluation. 
 
Albeit the CKD-EPI equation is relatively new in Australian practice, ours is not the only 
study to explore the use of eGFR formulae in the critically ill. Martin and colleagues 
examined the utility of MDRD eGFR and CG CLCR in comparison to 8-hr CLCR in a cohort 
of mainly traumatised patients (46). CLCR measures were markedly elevated, with 
significant bias reported with both equations. In ~350 recently admitted patients, Herrera-
Gutierrez et al. demonstrated significant bias when comparing CG CLCR to measured 
values (43). This was particularly evident in patients with elevated CLCR (≥ 100 ml/min/1.73 
m2), where CG estimates were markedly lower. Other studies in surgical intensive care 
(45), and burns injury (44), have reported similar observations. 
 
Hoste and colleagues examined the relationship between 1-hr CLCR, CG CLCR, and MDRD 
eGFR in twenty-eight adult patients recently admitted to the ICU (39). Here, 25% had a 1-
hr CLCR < 60 ml/min/1.73 m2, despite a normal plasma CR concentration. Even with a 
lower range of CLCR measures, neither equation was considered specific enough for 
clinical use (39). In our study, fewer patients manifest this level of renal impairment (n = 
10, 9.1%), limiting any definitive conclusions. However, these patients often (n = 6, 60%) 
had a normal or near-normal calculated CKD-EPI eGFR (60–119 ml/min/1.73 m2). 
 
Baptista and colleagues were the first to explore the role of eGFR in the setting of ARC, 
comparing CG CLCR and MDRD eGFR with measured CLCR in eighty-six critically ill 
patients (200). Calculated values were significantly less than measured CLCR, with 
considerable bias and imprecision. In a retrospective analysis of 390 patients with ARC 
admitted to a single centre, Grootaert and colleagues similarly reported poor agreement 
between CG CLCR, MDRD eGFR and 24-hr measured CLCR (226). 
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Confounding these analyses however, is often the lack of an exogenous marker of GFR. 
Despite this, markedly elevated renal drug elimination has been noted in many sub-groups 
of critically ill patients (71), in parallel with higher CLCR (61). Furthermore, recent research 
suggests elevated CLCR measures (> 130 ml/min/1.73 m2) are associated with sub-
therapeutic drug concentrations (199, 225) and worse clinical outcomes (104), in critically 
ill patients receiving antimicrobial therapy. While the implications of this phenomenon 
require substantial validation, the observation that ~40% of patients with a normal or near-
normal CKD-EPI eGFR (60–119 ml/min/1.73 m2) actually manifest ARC, suggests such 
thresholds are not simply transferrable to different estimates of renal function. 
 
This realization is consistent with these formulae being developed outside of an ICU 
environment; generating results that fail to consider the unique characteristics of critical 
illness (18, 214). Of note, bias appeared to be greatest in emergent surgical and trauma 
admissions (Table 7.2), sub-groups where ARC has been previously well documented (84, 
88). Recent data from Shimamoto et al. suggests systemic inflammation is a key factor, 
with increasing SIRS criteria associated with elevated renal vancomycin CL (74). This has 
important ramifications for clinical practice, where use of variable estimates of renal 
function may result in disparate conclusions (12, 227), potentially leading to inadequate 
drug dosing (228). 
 
We wish to acknowledge the following limitations. This paper reports the findings from a 
single-centre only, and therefore may not be representative of case-mix at other 
institutions. Despite this, the majority of study participants manifested SIRS; over half 
received invasive mechanical ventilation; and 30% required vasoactive support. Illness 
severity scores were moderate, and consistent with tertiary level ICU practice. Our 
inclusion criteria were designed to select a cohort of patients with normal plasma CR 
concentrations, as assessing renal function in the context of drug dosing remains 
challenging in this group. In addition, the CKD-EPI equation is reported to have improved 
accuracy compared to older eGFR estimates (229), particularly in patients with normal or 
near-normal renal function (230). 
 
We have employed 8-hr urinary collections, as recommended by prior research (45). This 
method is not a gold standard measure of GFR, such that tubular CR secretion, and errors 
in measurement may have confounded our results. Without employing an exogenous 
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filtration maker (such as inulin), it is impossible to determine which estimate is closer to the 
‘true’ filtration rate. As such, use of endogenous CLCR may have resulted in systematically 
higher values. Despite this, CLCR remains a common modifier of drug dosing in clinical 
practice, with recent data suggesting important PK (199, 225), and clinical (104) 
implications. Unfortunately no readily accessible, pragmatic, error free measure of GFR is 
currently available. This analysis principally serves to remind the clinician of the inherent 
discrepancy between estimates of GFR in the ICU. 
 
7.6 Conclusion 
 
In conclusion, this study has examined CKD-EPI eGFR in comparison to 8-hr measured 
CLCR in a cohort of recently admitted critically ill patients with normal plasma CR 
concentrations. Our results suggest poor agreement between these techniques in this 
population. Whether this represents a true limitation of CKD-EPI eGFR, or an intuitive 
discrepancy based on the problems with endogenous CLCR, remains uncertain. 
Notwithstanding this, until additional data are available on the utility of CKD-EPI eGFR for 
drug dose adjustment, particularly in identifying ARC, we would recommend clinicians 
consider using CLCR for this purpose. 
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PART THREE - DISCUSSION
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Chapter 8 
 
Discussion, Key Findings, and Future Directions 
 
8.1 Discussion 
 
The critical care environment is often defined by logistic, administrative, and human 
resources factors.  In this respect, ‘critical illness’ is a highly non-specific term, reflecting a 
diverse range of patients, and pathophysiology.  Interventions are generally applied to this 
group in an unmalleable fashion, such that individual patient characteristics are less 
emphasised in therapeutic guidelines (3).  A relevant example is blood pressure 
management in septic shock, where pre-existing physiology or comorbidity is infrequently 
considered.  Even more pertinent is drug administration, where dose adjustment is only 
practiced in the setting of drug eliminating organ dysfunction, or with an easily ‘titrate-able’ 
end-point.  Outside of these scenarios, a ‘one dose fits all’ approach is generally applied. 
 
This represents a logistically attractive solution, such that protocols and procedures can be 
developed to support clinical practice, particularly ‘out-of-hours’.  However, this ignores the 
clinical heterogeneity confounding critical care practice, such that patients vary 
significantly in terms of their presenting illness, associated interventions, and organ 
function. Systemic inflammation, endothelial dysfunction, haemodynamic instability, 
intravenous fluid loading, use of vasoactive medications, and organ dysfunction, will 
greatly impact the clinical course for many patients.  Importantly these factors will distort 
the PK profile of many pharmaceuticals used in this setting.  Consequently doses 
determined from non-critically ill cohorts are unlikely to reliably reproduce the same drug 
exposure, potentially resulting in inferior clinical outcomes. 
 
This scenario has perhaps no greater implications than for antibacterial application in the 
critically ill.  This class of pharmaceuticals are prescribed ubiquitously in the ICU, often in 
the setting of diagnostic uncertainty, and without any immediate clinical feedback to guide 
dosing.  Failure to provide timely and effective chemotherapy has also been strongly 
associated with inferior clinical outcomes (4-7), highlighting the clinical imperative to 
optimise drug exposure.  For beta-lactams, this involves maintaining drug concentrations 
above the MIC of the likely pathogen for sufficient periods of the dosing interval (168).  In 
the critically ill, this remains a challenging task, primarily related to the complex interaction 
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between patient physiology, drug PK, and microbial susceptibility.  This triad of ‘man, 
molecule and microbe’ means that a single ‘standard’ dose is unlikely to be sufficient for 
many patients, such that clinicians must individualise drug prescription much more 
frequently. 
 
This thesis has primarily focused on alterations in renal physiology, thought to underpin 
some of the variability in beta-lactam PK observed in the critically ill.  These data highlight 
a number of important findings.  Many of the patients included in these studies did 
manifest CLCR measures significantly higher than has been reported in the general 
population (19), reinforcing that ARC is more than simply an academic construct.  
Specifically, in the multicentre dataset ~65% manifest at least one episode of ARC in the 
first seven study days, indicating that clinicians are likely to encounter this phenomenon on 
a regular basis.  In addition, the presence of ARC on day one was an important predictor 
of elevated CLCR over the remaining week (231), implying that an early assessment of 
renal function is warranted when antibacterial dosing is being considered.   
 
The association between elevated CLCR and low beta-lactam trough concentrations, as 
demonstrated in the analysis of our TDM data, underlines the PK-PD implications of these 
findings.  Sub-therapeutic concentrations (Cmin < MIC) were identified in ~40% of study 
participants, while CLCR was a significant predictor of insufficient levels in multivariate 
modelling.  While this finding is somewhat expected, given the established renal route of 
elimination for these agents, the identification of a useful CLCR threshold will allow for 
further research in this area.  In addition, although beta-lactam TDM is the gold standard in 
dose adjustment, this service is infrequently available in clinical practice. As such CLCR 
measures are likely to be much more readily available, acting as a trigger for dose 
escalation or alternative methods of administration where appropriate. 
 
Our study findings have also further identified which patients are at greatest risk of ARC.  
The significance of age as a defining factor is a constant finding.  Younger patients, often 
admitted post major trauma, appear to constitute a major at-risk group.  While 
chronological decline in renal function is well described, ARC appears to be more than 
simply a reflection of ‘young kidneys’.  Rather it is driven by the interplay between 
physiological reserve (which is greatest in younger patients without major comorbidity), 
and systemic inflammation.  The lack of associated organ dysfunction (as manifest by 
lower SOFA scores), indicates ARC is unlikely to be encountered with greater illness 
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severity.  While the development of AKI has clear prognostic implications in the ICU, it 
remains to be determined whether the absence of ARC (as the expected renal response) 
has any additional implications. 
 
While it was hypothesised that cardiovascular alterations would drive ARC in many 
patients, this remains largely an assertion.  No correlation was identified between CI and 
CLCR in our trauma population.  This is likely a consequence of the narrow range of cardiac 
indices and generally higher CLCR measures observed in this group.  In septic patients, a 
moderate correlation was demonstrated, a reflection of the greater heterogeneity 
associated with this syndrome.  In ROC analysis, CI was less discriminating than the 
combination of age, trauma status, and SOFA score, reinforcing that intrinsic changes in 
kidney function (with inflammation) may have a greater role in ARC.  In this context, CI and 
CLCR may rise in parallel, a reflection of organ reserve, although increased major organ 
blood flow may not be sole driver of increased clearances.  The ‘ARC Risk Score’ 
developed from this analysis also provides a useful tool to guide current prescription and 
future research, although validation in a much larger cohort is required.   
 
The clinical imperative to consider renal function, as opposed to identifying kidney injury 
has also been highlighted by this research.  In this respect, plasma CR concentrations 
alone were not representative of renal function in many study participants, providing little 
useful data when adjusting drug doses.  Mathematical estimates of renal function, based 
primarily on these values have become commonplace in hospital practice.  However there 
application to critical care practice, particularly drug dose modification, has been 
questioned (224), in that these estimates should not only trigger dose reduction, but also 
escalation.  Our analyses support these concerns, demonstrating that these equations 
have poor utility in identifying ARC, with significant bias and imprecision compared to CLCR 
measures.  This is primarily a reflection of these formulae being developed from cohorts of 
non-critically ill patients, where significant acute systemic inflammation is likely to be 
absent. 
 
8.2 Limitations 
 
These data suffer from certain limitations that must be considered in the interpretation and 
application of this thesis.  The use of CLCR as the primary method of measuring renal 
function does not represent a gold-standard assessment of GFR.  Creatinine undergoes 
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both filtration and tubular secretion, such that CLCR may systematically over-estimate the 
patients true GFR.  While this represents a source of significant bias in patients with 
declining renal function, the implications at higher filtration rates are less certain (232).  In 
addition, serial measurements are reported to be accurate in following changes in GFR 
over time (213).  The application of this measure is based on the following considerations; 
a) exogenous markers of GFR are infrequently available in clinical practice, such that 
extrapolation to daily dosing decisions is limited; b) CLCR represents a more useful 
measure of renal function than plasma CR concentrations alone; c) a wealth of PK data 
has identified CLCR as a key covariate in predicting antibacterial renal drug elimination; and 
d) CLCR is a widely available, repeatable, and inexpensive intervention that can be applied 
on a global scale.   In addition, although quantifying the true GFR would be ideal, the 
validity of any absolute figure is perhaps less important, than identifying patients likely to 
manifest sub-therapeutic drug exposure with standard dosing.  As such, elevated CLCR 
can be used as a marker of likely augmented beta-lactam drug clearance, prompting the 
institution of TDM, or empirically higher doses, where the agent has a favourable 
therapeutic index. 
 
Some of these data are drawn from selected cohorts of critically ill patients, such that 
application to the wider ICU population remains uncertain.  In particular, the analysis of 
beta-lactam TDM trough concentrations in comparison to 8-hr measured CLCR (199), may 
suffer from selection bias, due to the enrolment of patients likely to manifest distorted PK.  
Although this may have influenced the prevalence of sub-therapeutic concentrations (Cmin 
< MIC), the robust association with elevated CLCR remains a highly applicable finding.  The 
use of EUCAST breakpoints (where no causative organism was identified) to inform the 
adequacy of drug exposure could have also introduced additional bias.  Importantly, our 
data are consistent with large international point prevalence studies, where approximately 
30% of infected critically ill patients are culture negative (233).  Use of these breakpoints 
allows consideration of a ‘worst case scenario’, although in some patients this degree of 
drug exposure may not be clinically necessary.  This represents a valid concern, but as 
such susceptibility data are infrequently available at the time of commencing antibacterial 
therapy, these analyses remain highly informative.  As such, until further information is 
available to tailor ongoing therapy, the clinician should aim to ‘cover’ all potential causative 
organisms.  Equally the impact of sub-optimal drug exposures on resistance patterns 
remains uncertain, further reinforcing the need to employ robust initial dosing strategies. 
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The descriptive analyses presented in this thesis have focused on identifying patients at-
risk of ARC. Measured CLCR has been used as a surrogate of beta-lactam renal clearance, 
given prior data reinforcing its’ utility in this context (see Chapters 2 and 3).  However, it 
must be reinforced that alterations in beta-lactam renal elimination are only a single 
component in this complex clinical interaction.  Anthropometric irregularities (e.g. morbid 
obesity), changes in protein binding, altered volume of distribution, and use of 
extracorporeal modalities will also significantly impact antibacterial PK.  As such, this 
research has focused on the impact of augmented renal function, although this must be 
considered in the context of any additional factors that will influence drug exposure.  
Recent data from the Defining Antibiotic Levels in Intensive (DALI) care unit patients study 
(169) demonstrated that treatment failure was three times more likely when fT≥MIC was < 
50%.  However, the required drug levels for therapeutic success are unlikely to be 
constant across all patient groups, or even potentially within the same patient over time.  
Indeed, in cases where the patient is receiving prophylaxis against infection, or a less 
virulent organism has been identified, more modest degrees of drug exposure may only be 
necessary.  Although this is a crucial area for additional research, data from this thesis 
suggests that ARC will none the less have important implications. 
 
The clinical ramifications of this phenomenon are also currently limited.  Although there is 
an increasing literature base examining this area of critical care practice, a robust link 
between ARC, sub-therapeutic beta-lactam exposure, and inferior clinical outcomes 
remains to be established.  This thesis highlights that ARC is likely to occur in younger 
patients, with lower illness severity scores, such that any effect on mortality is likely to be 
very small, and difficult to detect.  Indeed, ICU mortality in those patients displaying ARC 
on at least one occasion in the multicentre study was 7.7%, compared to 10.2% in those 
that never manifest ARC (231).  This implies that a significantly larger sample would be 
required to achieve a statistically robust result.  More appropriate end-points could include 
treatment failure, microbiological resistance patterns, ICU and hospital LOS, in addition to 
health economic outcomes.  Of note, the observation that ARC may be associated with a 
survival advantage represents an intriguing area for ongoing study.  In particular, elevated 
CLCR may in fact represent a maker of adequate physiological reserve, whereby the host is 
able to generate supra-normal organ function in the setting of systemic infection.  As such, 
the absence of infection related organ dysfunction might have equally important prognostic 
implications, although temporal associations with antibiotic drug exposure require 
significant additional research.        
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8.3 Key Findings 
 
Summary findings from this research are listed below: 
 
• ARC is associated with low beta-lactam trough concentrations in critically ill patients 
receiving standard doses 
• Younger age and admission post-trauma are important risk factors 
• ARC is associated with less severe organ dysfunction 
• CLCR is moderately correlated with CI in critically ill septic patients 
• ARC is prevalent in recently admitted patients with normal plasma CR 
concentrations 
• ARC on day one is highly predictive of elevated CLCR over the first week in ICU 
• There is poor agreement between measured CLCR and mathematical estimates in 
critically ill patients with normal plasma CR concentrations 
• ARC has important ramifications for beta-lactam dosing, that require further study 
 
8.4 Future Directions 
 
The clinical and dosing implications of these findings require additional investigation.  
Specifically, prospective clinical studies examining the impact of varying dosing strategies 
(such as extended or continuous infusion) in the setting of ARC are needed. These should 
be powered to identify significant differences in both PK-PD and clinical endpoints.  The 
combination of ARC and borderline bacterial susceptibility represents a key area for future 
research, as it is this sub-group where treatment failure is of greater concern.  Importantly 
the ICU represents common area for intermediate pathogens. 
 
Wider dissemination of these data is also required.  The idea of a ‘one dose fits all’ 
approach to beta-lactam antibacterial application in the ICU is fundamentally flawed.  
Prescribers must be encouraged to consider their dosing decisions in the context of the 
likely pathogens, but also the patients underlying physiology.  Individualising or tailoring 
drug prescription represents a key goal in translating this research to the bedside.  For 
drug developers and pharmaceutical companies, greater emphasis must be placed on 
considering these issues prior to large-scale clinical investigation of new or emerging 
agents.  This will ensure that poor efficacy is not simply a reflection of inadequate dosing, 
such that these agents can enter wider clinical practice successfully. 
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Finally the implications of ARC on microbiological resistance patterns deserve attention.  
This represents a global problem in both developed and developing nations.  Responsible, 
directed, and adequate antibacterial dosing represents a key strategy in ensuring 
therapeutic longevity for many agents.  This must be considered a priority in clinical 
practice and critical research programmes.  How ARC is implicated in this process 
represents an important area for future study.   
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Appendix A – Physiological and treatment variables in those with and without ARC on study day 1, day 4, and day 7. 
 
 Study Day 1 (n=281) Study Day 4 (n=143) Study Day 7 (n=93) 
Variable ARC No ARC ARC No ARC ARC No ARC 
Mod SOFA score, median [IQR] 2 [1-4] 3 [2-5.5] 2 [1-4] 2 [1-5] 2 [1-5] 3 [1-3] 
Max MAP, mmHg, mean (95% 
CI) 
105 (102-107) 104 (102-106) 110 (106-114) 109 (105-113) 107 (104-113) 110 (106-114) 
Min MAP, mmHg, mean (95% CI) 74 (72-76) 70 (69-72) 77 (74-80) 75 (72-78) 81 (78-85) 79 (75-83) 
Max CVP, mmHg, mean (95% 
CI) 
14 (13-16) 14 (13-15) 15 (13-16) 15 (14-17) 14 (12-15) 14 (13-16) 
Min CVP, mmHg, mean (95% CI) 6 (5-6) 6 (5-6) 5 (4-6) 6 (5-8) 5 (4-7) 5 (4-7) 
Max HR, /min, mean (95% CI) 99 (95-103) 103 (100-106) 100 (96-105) 103 (96-110) 101 (95-106) 105 (98-111) 
Min HR, /min, mean (95% CI) 70 (66-73) 74 (71-76) 74 (70-78) 76 (72-80) 75 (70-79) 78 (73-83) 
Max RR, /min, mean (95% CI) 22 (21-23) 24 (22-25) 25 (24-27) 24 (22-26) 28 (26-31) 27 (24-29) 
Min RR, /min, mean (95% CI) 13 (12-13) 13 (13-14) 15 (14-16) 15 (14-17) 15 (14-17) 15 (14-17) 
Max Temp, oC, mean (95% CI) 37.8 (37.7-38.0) 37.9 (37.7-38.0) 38.4 (38.2-38.5) 38.0 (37.8-38.2) 38.5 (38.3-38.8) 38.2 (37.9-38.4) 
Min Temp, oC, mean (95% CI) 36.4 (36.1-36.7) 36.2 (36.1-36.4) 37.1 (36.9-37.3) 36.7 (36.6-36.9) 37.1 (36.9-37.3) 36.9 (36.6-37.2) 
WCC, x 109/L, mean (95% CI) 12.3 (10.8-13.7) 13.6 (11.1-16.1) 10.5 (9.24-11.8) 10.6 (9.43-11.8) 12.0 (10.8-13.3) 11.4 (10.2-12.6) 
Mechanical Ventilation, n (%) 78 (72.9) 121 (70.3) 55 (74.3) 47 (69.1) 27 (62.8) 39 (78.0) 
Any vasopressors / inotrope, n 
(%) 
25 (23.1) 64 (37.0) 16 (21.6) 17 (24.6) 13 (30.2) 7 (14.0) 
Norepinephrine administration, n 
(%) 
19 (17.6) 57 (32.9) 12 (16.2) 15 (21.7) 9 (20.9) 6 (12.0) 
Dopamine administration, n (%) 7 (6.5) 9 (5.2) 5 (6.8) 3 (4.3) 3 (7.0) 1 (2.0) 
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Receiving enteral nutrition, n (%) 62 (57.4) 99 (57.2) 53 (71.6) 53 (76.8) 34 (79.1) 42 (84.0) 
Frusemide administration, n (%) 10 (9.3) 30 (17.5) 12 (16.2) 25 (36.8) 11 (26.2) 20 (40.0) 
Mannitol administration, n (%) 13 (12.0) 14 (8.1) 5 (6.8) 5 (7.5) 1 (2.4) 0 (0.0) 
Antibiotic administration, n (%) 80 (74.1) 141 (82.0) 46 (62.2) 56 (82.4) 32 (74.4) 38 (76.0) 
IV contrast administration, n (%) 21 (19.6) 33 (19.3) 3 (4.2) 1 (1.5) 2 (4.9) 1 (2.0) 
24-hr UO, ml, mean (95% CI) 2206 (1934-
2478) 
1776 (1616-
1935) 
2763 (2460-
3066) 
2461 (2181-
2742) 
3392 (2761-
4024) 
2722 (2339-3104) 
Plasma CR concentration, 
µmol/L, mean (95% CI) 
60 (57-63) 79 (75-83) 55 (52-59) 73 (67-80) 55 (50-60) 66 (60-73) 
CR excretion rate, mg/kg/day, 
mean (95% CI) 
25.0 (22.0-28.0) 15.5 (14.7-16.4) 23.3 (21.5-25.1) 15.2 (14.0-16.4) 22.0 (20.0-23.9) 14.9 (13.6-16.2) 
CLCR, ml/min/1.73m2, mean (95% 
CI) 
172 (164-181) 81 (76-85) 178 (168-188) 88 (81-95) 169 (159-180) 95 (88-103) 
24-hr Total fluid balance, ml, 
mean (95% CI) 
722 (424-1019) 1042 (803-1281) 264 (-13-541) 231 (-84-509) -338 (-790-114) -201 (-533-132) 
ARC – augmented renal clearance, CI – confidence interval, CR – creatinine, CLCR – creatinine clearance, CVP – central venous 
pressure, HR – heart rate, IQR – interquartile range, MAP – mean arterial pressure, RR – respiratory rate, SOFA – sequential organ 
failure assessment, UO – urine output, WCC – white cell count (in blood) 
 
 
